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Monoclonal antibodies (mAb) for treating various cancers and 
autoimmune diseases are the top-selling class of biologics. A plasmid vector 
was designed to express the light chain (LC), heavy chain (HC) and selection 
marker genes required for generating stable mAb producing Chinese hamster 
ovary (CHO) cells together on a single transcript by linking the genes using 
internal ribosome entry site (IRES) elements. Compared to traditional co-
transfection and multi-promoter single vector systems, the IRES tricistronic 
vector generated fewer non-expressing cells and gave higher mAb 
productivity (chapter 3). We observed that only clones from the IRES 
tricistronic system exhibited similar LC:HC ratios. The strict control of LC 
and HC relative amounts by linking the genes on one transcript was important 
as LC:HC ratio has been shown to be important to mAb expression in 
transient, clonal and in-silico modelling experiments.  
Another DNA element which is able to link multiple genes is the 2A 
peptide coupled to a furin cleavage site (F2A). F2A was expected to give 
balanced ratios of the two linked genes while when using IRES, the gene 
upstream of IRES would always be in excess compared to the downstream 
gene. F2A could possibly be used to express LC and HC peptides in equal 
amounts to study LC:HC ratio in stable cell lines. We compared a series of 
vectors generated using IRES and F2A for expressing mAb (chapter 4). F2A 
was not appropriate for expressing mAb as there was presence of fusion 
proteins, eg. LC-F2A-HC or HC-F2A-LC, that arose due to failure of the 2A 
peptide processing or furin cleavage. Extra 2A peptide amino acid residues 
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also possibly affected signal peptide cleavage. Use of F2A to control LC:HC 
ratio for further studies would require further optimization of the system. 
We next proceeded with studying the effect of LC:HC ratio on stable 
mAb expression using variations of the IRES tricistronic vector described in 
chapter 3 to generate CHO cell lines with LC:HC ratios of 3.4, 1.2, 1.1 and 0.3 
(chapter 5). The LC:HC ratio of 3.4 was the best for both mAb expression 
level and quality. At the ratio of 0.3, mAb expression level was low, 
aggregated easily, had undesired highly matured glycans and was less stable. 
In chapter 6, we observed that the aggregates could be dissociated in reducing 
and denaturing conditions, revealing possible disulfide and hydrophobic 
bonding between the molecules. Cell engineering by over-expressing BiP 
chaperone could reduce the amount of unwanted products. Re-transfection of 
the cells having excess HC with more LC greatly improved mAb products 
secreted and the cells started to only produce IgG monomers. 
The IRES tricistronic vector presented in this thesis presents an 
attractive and flexible alternative to existing vector systems. The vector and its 
variants were also used for the first report of controlled LC:HC in stably 
transfected mAb expressing CHO cells to study its effects on mAb expression 
and quality. Possible solutions to remedy cells expressing mAb with high 
aggregation due to poor control of LC:HC ratio giving excess HC were also 
presented.         
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 Introduction Chapter 1:
 





Monoclonal antibodies (mAb) are the top selling class of biologics 
with an annually growing market demand. The highly specific mAbs are used 
to treat various cancers, battle transplant rejections and fight autoimmune 
diseases by recognition of cell surface antigens or secreted activating factors. 
In contrast to small molecule drugs like paracetamol which are produced by 
chemical synthesis, mAbs are complex protein molecules requiring the use of 
live cellular machinery in a recombinant protein production process. 
Recombinant protein production involves transferring foreign genes encoding 
proteins not normally produced by the target cell into the cell to allow its 
expression by the cell. Mammalian cells like the Chinese hamster ovary 
(CHO) cells are commonly used for their ability to perform the required 
protein modifications for product safety and efficacy. DNA plasmid vectors 
are used to transfer the required genes into the cell and its design is critical to 
ensuring good mAb production. It is required that the cells are producing 
mAbs at a high level for maximal production efficiency and the product 
having the required critical product quality attributes, like molecular weight, 
aggregation level, glycosylation, stability, charge and antigen binding, for 
safety and efficacy. It is not uncommon to screen thousands of clones before 
the final candidate clone is selected. The process is labor intensive and time 
consuming if expensive automated systems are not available. One reason for 
the need to screen clones is due to problems associated with the commonly 
used vector systems.  
The most commonly produced mAbs are multimeric immunoglobulin 
G (IgG) molecules assembled from two heavy chain (HC) peptides and two 
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light chain (LC) peptides and is the product of interest in this report. Three 
exogenous genes, HC, LC and a selection marker, are expressed when 
producing mAb using CHO cells. Gene expression requires a basic expression 
cassette consisting of a promoter, the gene of interest and a polyadenylation 
signal and each of the three genes are in separate expression cassettes on most 
plasmid vectors (further discussed in section 2.5). Issues like vector 
fragmentation causing false positives (Ng et al. 2010), transcriptional 
interference due to multiple promoters in close proximity (Eszterhas et al. 
2002) and poor control of LC:HC ratios (Chusainow et al. 2009; Lee et al. 
2009) can plague mAb cell line generation processes using these vectors. As 
LC and HC peptides are translated separately before assembly, their relative 
amounts could potentially affect mAb titer and quality attributes. As such 
there are conflicting reports which either encourage the expression of more 
HC as it is the rate-limiting reagent (Dorai et al. 2006) or discourage excess 
HC as it slows down assembly (Gonzalez et al. 2002). There is still no 
consensus LC:HC ratio which is best for both mAb expression level and 
quality. To date, there has been no studies where LC:HC ratio is effectively 
controlled in all cells of a stably transfected CHO cell lines. In this thesis, a 
novel vector for generating mAb producing CHO cells would be designed to 
address the issues faced when using the existing vectors.  
It is possible to link all the three genes (LC, HC and selection marker) 
together using internal ribosome entry site (IRES) element from the 
encephalomyocarditis virus (EMCV) or 2A peptide from the food-and-mouth-
disease virus (FMDV) to express the multiple required genes using a single 
promoter in one mRNA transcript. Using such vectors should minimize the 
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occurrence of non-expressing clones due to vector fragmentation and provide 
better control of LC:HC ratio. An IRES-based vector system which can 
achieve high mAb product titers in CHO cells is currently not available. In the 
only available report of an IRES vector for mAb expression, the expression 
levels obtained was more than two magnitudes below the desired levels and 
the experiments were also not performed in CHO cells (Mielke et al. 2000). 
While 2A peptides shown to generate mAb expression similar to that of co-
transfection, 2A’s have been reported to have cleavage errors and proper 
evaluation is still required for our application. 
 
1.2 Hypothesis 
It is hypothesized that a vector with the LC, HC and selection marker 
genes linked on a single transcript using IRES can be designed to generate 




1.3 Aim and Objectives 
The main aim of this thesis was to design a novel vector to improve the 
process of generating mAb producing CHO cell lines. The designed vector 
should be able to generate CHO cell lines capable of producing high amounts 
of mAb product (above 20 pcd) with low levels of aggregates and consistent 
glycosylation profiles. The vector should be able to help control LC:HC ratio 
at a similar level in all transfected cells to assist in achieving the targets. The 
following objectives were designed to explore and evaluate the above 
hypothesis. 
 
Objective 1: Evaluate a vector design which expresses LC, HC and 
selection marker genes on a single transcript using IRES elements for 
controlling LC:HC ratio. Optimize the selection marker to obtain high 
mAb producing CHO cell lines. 
 
Objective 2: Compare the use of 2A peptide with IRES for expressing 
mAb in CHO cells.    
 
Objective 3: Investigate the effect of different LC:HC ratios on stable 
mAb production in CHO cells to ensure optimized gene arrangement on 




 Literature review Chapter 2:
 
This chapter describes the uses and market for monoclonal antibodies (mAb). 
It also reviews the recent developments made towards generating mAb 
producing mammalian cell lines. 
 
Parts of the following were first published in “Ho, S. C. L., Tong, Y. W. and 
Yang, Y. (2013). "Generation of monoclonal antibody-producing mammalian 
cell lines." Pharmaceutical Bioprocessing 1(1): 71-87”. 
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2.1 Monoclonal antibodies for therapy 
Immunoglobulins (Ig) are produced by B cells as cell-surface receptors 
for disease and foreign antigens. Upon antigen stimulation, the B cells 
differentiate to plasma cells, which now secrete soluble effector molecules 
known as antibodies (Baumal and Scharff 1973). Each antibody is made up of 
light chain (LC) and heavy chain (HC) peptides which can both be separated 
into variable and constant regions. There are five main antibody isotypes, IgA, 
IgD, IgE, IgG and IgM that differ in the heavy chain constant regions. IgG is 
the simplest form, composed of two identical LC peptides and two identical 
HC peptides linked by disulfide bonds to form a “Y” shaped structure (Fig. 
2.1). The paratope at the tip of the variable region on Fab fragment is 
responsible for the highly specific antigen recognition and binding and the Fc 
fragment commonly elicits the effector functions.      
Recombinant therapeutic antibodies are copies of the antibody 
generated by a single, selected B cell candidate and are referred to as 
monoclonal antibodies (mAb). IgG is the dominant form of marketed 
therapeutic mAbs (Reichert 2012). Early attempts at mAb therapy were foiled 
by low protein amounts and highly immunogenic rodent sera cocktails (Gura 
2002). These issues were addressed later by the development of hybridoma 
technology to generate larger amounts of product (Kohler and Milstein 1975) 
and antibody humanization to reduce the immunogenic segments (Jones et al. 
1986) . Fully human mAbs can now be generated with the recent inventions of 
phage display (Winter et al. 1994) and transgenic mice (Lonberg et al. 1994; 
Wagner et al. 1994; Fishwild et al. 1996). The improvement in efficacy and 
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safety brought about by the aforementioned technologies has seen mAbs 
develop into the best-selling class of biologics. 
 
Figure 2.1 Structure of an IgG antibody molecule. Each IgG is a multimeric 
protein molecule composed of two identical light chains with MW ~25 kDa 
(white ovals) and two identical heavy chains with MW ~50 kDa (grey ovals). 
Each peptide chain has variable (V) and constant (C) regions. The paratope 
end is responsible for antigen binding while the Fc fragment composed of CH2 
and CH3 domains are required for effector functions. The solid black line 
between CH1 and CH2 domains is the hinge region. Dotted lines represent 
disulfide bonds and the white squares on the CH2 domain represent the N-
glycosylation oligosaccharide residues. 
  
Therapeutic mAbs function by binding to cell surface receptors or 
cytokines to either disrupt signal pathways or elicit immunogenic reactions 
like antibody dependent cell-mediated cytotoxicity (ADCC) and complement 
dependent cytotoxicity (CDC). Bevacizumab (Trade name: Avastin
®
) 
approved for the treatment of various tumors including metastatic colorectal 
cancer, an example of a cytokine binder, is an anti-vascular endothelial growth 
factor (VEGF) antibody. VEGF is an angiogenic factor which is promotes 
formation of vessels in tumors (Ferrara 2004). Bevacizumab binds to the 
VEGF released by the tumor cells to render the factors inactive to the VEGF 
receptors and aid in inhibiting tumor growth (Ferrara et al. 2004). Tumor 
9 
 
necrosis factor (TNF) is up-regulated in autoimmune diseases, including 
rheumatoid arthritis, psoriasis and Crohn’s disease, resulting in uncontrolled 
inflammation and tissue destruction due to formation of osteoclasts (Brennan 
et al. 1989; Pfeilschifter et al. 1989; Tracey et al. 2008). Adalimumab 
(Humira
®
) is an antagonist which binds to TNF when administered to prevent 
activation of the TNF receptor and alleviate the symptoms (Chan and Carter 
2010). Some mAbs can function through multiple mechanisms of action. 
Trastuzumab (Herceptin
®
) recognizes the human epidermal growth factor 
receptor 2 (HER2), a tyrosine kinase receptor, is most commonly used for 
treating HER2 positive metastatic breast cancer patients.  HER2 receptor 
binding inhibits downstream phosphatidylinositol-3 kinase (PI3K) and Akt 
signaling leading to cell cyle arrest of the tumor cells (Yakes et al. 2002). The 
Fc fragment on the constant region also activates ADCC by engaging the Fcγ 
receptors on effector immune cells like natural killer cells (Barok et al. 2007).  
 
2.2 MAb market and production 
 The market for mAbs saw 8.3% growth and $18.5 billion in sales for 
2010, followed by similarly robust 10.1% growth and $20.3 billion of sales in 
2011 in the US (Aggarwal 2011; Aggarwal 2012). The highly specific 
targeting capability of mAbs is now used to treat various cancers, battle 
transplant rejections and fight autoimmune diseases. 28 mAb products are 
approved for the market and over 350 are at various stages of clinical testing 
(Reichert 2012). Five full IgG mAb products that are currently listed as 











. As the market continues to mature, two 
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new trends are also forming. Biotech companies are starting to target the 
smaller markets of orphan diseases as seen by the record number of 
biopharmaceuticals approved for such indications (Kling 2012). Biosimilars of 
existing blockbuster products are also being developed and gaining approval 
outside of the US (Kling 2012; Reichert 2012). The increasing demand for 
existing mAbs and rapid innovation in mAb therapeutics has stimulated a 
parallel improvement in mammalian cell culture technologies used to produce 
a majority of the products. Faster and more efficient cell line development 
technologies for mAb production are now of utmost importance.  
 MAb production in mammalian cells can be performed either in 
transient or stable transfections. Transient transfections allow quick generation 
of small amounts of product for use during early stages of drug discovery 
(Pham et al. 2006). There are several review articles available for information 
on large-scale transient transfections of mammalian cells (Pham et al. 2006; 
Geisse 2009; Geisse and Voedisch 2012). Stably transfected cell lines are 
more widely used in large scale industrial production. Cell lines used for 
manufacturing are from a single cell clone in order to get high amounts of 
consistent product. The cell line development process (Fig. 2.2) starts from 
transfection of a mammalian cell line with plasmid vectors carrying the light 
chain (LC) gene, heavy chain (HC) gene, and a selection marker gene (Birch 
and Racher 2006). The plasmid vector comes in various designs, optimized for 
mAb production. Several cell types can be used but mammalian cells are the 
main workhorse for producing the safest and most effective mAb products. 
Plasmid delivery can be performed using calcium-phosphate precipitation, 
electroporation, lipofection and polymer-mediated techniques (Norton and 
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Pachuk 2003). After transfection, positive transfectants are selected by their 
drug resistance or growth advantage. If an amplifiable selection marker is 
used, gene amplification can be carried out to increase gene copies, leading to 
increase in product expression. Single clones are then chosen for scale up and 
characterization of product quality and long-term expression. The following 
sections will look at existing and upcoming materials and methods for 
generating stably transfected mammalian cell lines. 
 
Figure 2.2 Generating a monoclonal antibody producing cell line. 
Mammalian cells are first transfected with plasmids carrying the light chain, 
heavy chain and selection marker genes. Drug selection is then carried out to 
select for positive transfectants. An initial round of screening is carried out to 
identify high producers. Selected clones are scaled up to collect sufficient 
mAb for characterization of product quality before production cell lines are 
selected for large scale production. 
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2.3 Mammalian cells for producing mAb 
 A survey of the mAbs currently approved by US or EU for the market 
shows a heavy reliance on mammalian cells for production. Of the 28 
products, 12 are produced in Chinese hamster ovary (CHO) cells, 12 are 
produced in murine lymphoid cell lines NS0 or Sp2/0 and two  are from 
hybridomas (Reichert 2012). E. coli microbial systems are only used for 
producing two antigen binding fragments products. Mammalian cell types 
have become dominant for manufacturing due to their abilities to produce high 
amounts of mAb with consistent quality and to adapt well to culturing in large 
scale suspension bioreactors (Butler 2005; Birch and Racher 2006; Costa et al. 
2010). Another reason for the dominance is the capabilities to perform the 
required protein folding, assembly and post-translational modifications such as 
glycosylation (Walsh and Jefferis 2006; Jenkins 2007; Hossler et al. 2009). 
The mAb produced would be biochemically similar to human forms for 
increased product efficacy and safety (Matasci et al. 2009). 
2.3.1 Chinese hamster ovary cells  
 Chinese hamster ovary (CHO) cells were first isolated in 1958 and 
they quickly gained recognition for ease of culture and fast generation times 
(Tjio and Puck 1958). Pathogenic human virus like HIV, influenza and polio 
do not replicate in CHO cells, greatly increasing safety of the mAb produced 
and simplifying the downstream purification process (Jayapal et al. 2007). The 
ease of genetic modification is another advantage of using CHO cells for mAb 
production (Jayapal et al. 2007). CHO cells have proven track record of 
producing safe, biocompatible and bioactive mAbs, enabling products from 
these cells to gain regulatory approval more easily (Butler and Meneses-
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Acosta 2012; Kim et al. 2012). They will remain as the most widely used 
mammalian cells for therapeutic protein production in the near future as 
evidenced by the continued usage of the cells for producing new mAb 
therapeutics (Bronson et al. 2012; Reichert 2012). The recently assembled 
genomic sequence of the ancestral CHO-K1 cell line will increase 
understanding of these cells and their popularity (Xu et al. 2011). 
2.3.2 Murine lymphoid cells  
 Murine lymphoid cells (NS0 and SP2/0) originate from differentiated 
B cells, which have the innate ability to produce large amounts of 
immunoglobulin, making them good candidates for manufacturing mAbs. 
Although there are currently a similar number of approved products from 
CHO cells and murine lymphoid cells, CHO derived cells are becoming the 
preferred hosts. Four of the six products approved before the year 2000 were 
from NS0 or Sp2/0 cells while two were from CHO. This changed in favor of 
CHO cells for products approved since 2010 where four were from CHO and 
only one from NS0. One reason for moving away from these cells is that 
glycoproteins from NS0 and Sp2/0 can have residues which are immunogenic 
and have reduced in-vivo half-life (Baker et al. 2001; Brooks 2004; Durocher 
and Butler 2009).       
2.3.3 Human cells 
 To ensure mAbs produced do not carry any antigenic carbohydrate 
groups, cells from a human source can be used for production (Butler 2005). 
Possible candidates include the human embryonic kidney derived HEK293 
cell line, immortalized human amnioctyes from CEVEC  and human 
embryonic retinoblast derived Per.C6 cell line from Crucell (Swiech et al. 
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2012). HEK293 and amniocytes are reported to be better suited for transient 
protein production (Pham et al. 2006; Fischer et al. 2012). Per.C6 is currently 
the most promising candidate. This cell line can reach cell densities ten folds 
higher than CHO cells and been reported to produce up to 8 g L
-1
 of protein in 
fed-batch reactors (Kuczewski et al. 2011; Swiech et al. 2012). Several Per.C6 
based products are currently undergoing clinical trials. Regulatory concerns 
exist regarding use of human based cell lines for production due to their lack 
of resistance against adventitious agents (Swiech et al. 2012). 
 
2.4 Host cell engineering 
 Mammalian cell culture performance can be improved by genetic 
engineering of either enzymatic or regulatory activities. Modifications to the 
cell phenotype can be achieved through traditional recombinant DNA 
techniques to over-express target genes or to knockdown/knockout target 
genes by using more recent cell engineering techniques like RNA interference 
(RNAi) and zinc-finger nucleases (Wu 2009; Krämer et al. 2010; Lim et al. 
2010; Liu et al. 2010; Dietmair et al. 2011).  
2.4.1 Apoptosis 
 Apoptosis is a form of programmed cell death which occurs during 
high stress conditions in dense and productive mAb producing mammalian 
cell cultures (Singh et al. 1994). Delaying the onset of apoptosis would benefit 
culture health and lifespan, making genes involved in the pathway interesting 
cell engineering targets (Arden and Betenbaugh 2006; Wong et al. 2006). One 
approach is to over-express anti-apoptotic genes, like those in the Bcl-2 
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family, which had been shown to improve cell viability and increase mAb 
production (Tey et al. 2000; Chiang and Sisk 2005; Majors et al. 2009; 
Carlage et al. 2012). Another approach involves down-regulating pro-
apoptosis genes like Bax and Bak by RNAi (Lim et al. 2006) or deleting the 
genes using zinc-finger nucleases (ZFN) (Cost et al. 2010). Deleting the genes 
inhibited activation of downstream caspases in the presence of apoptotic 
stimuli, improving cell viability and increased mAb expression by up to five 
folds (Cost et al. 2010).     
2.4.2 mAb folding and secretion 
 mAb folding is a intricate process which is mediated by a series of 
chaperones and foldases (Feige et al. 2010; Braakman and Bulleid 2011) and 
is a possible bottleneck for mammalian cells producing high levels of the 
recombinant mAb (Dinnis and James 2005). Over-expression of protein 
disulfide isomerase (PDI), a foldase which catalyzes formation of disulfide 
bond, only saw moderate increases in mAb expression of CHO cells (Borth et 
al. 2005; Mohan et al. 2007) or no effect (Hayes et al. 2010). BiP, a protein in 
the folding pathway which helps retain incompletely folded proteins by 
binding to exposed hydrophobic regions, caused a drop in mAb expression 
when over-expressed either alone or in tandem with PDI (Borth et al. 2005). 
The unfolded protein response (UPR) is a cellular reaction to increased 
demand of the cells folding capacity by regulating the expression of a number 
of chaperones and foldases (Schröder and Kaufman 2005). XBP-1 plays a 
major role in the UPR but its over-expression generated no effects on mAb 
expressing CHO cells (Ku et al. 2008). The limited success of these attempts 
shows that engineering of the mAb folding pathway alone is likely not the 
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ideal approach to improve mAb expression level. Cell engineering studies of 
chaperones have mainly focused on the expression level and it is still unclear 
how it could affect product qualities like aggregation. 
2.4.3 Glycosylation 
 mAb glycosylation is important for the product’s pharmacokinetics, 
pharmacodistribution, stability, receptor binding and effector functions 
(Werner et al. 2007). Despite its importance, there is no consensus for the 
“correct” mAb glycosylation due to inherent heterogeneity of the process and 
differences in activity (Higgins 2010). It is still of great interest to both 
research and industry to generate mAbs with specific glycoforms to improve 
efficacy and safety. Although mAb glycosylation can vary through control of 
culture conditions (Wong et al. 2005; Butler 2006), genetic approaches can be 
more efficient (Omasa et al. 2010). Many mAbs function through eliciting 
antibody dependent cell cytotoxicity (ADCC) and significant improvements 
were seen in ADCC activity for fucose deficient IgG1 mAbs (Shields et al. 
2002).  Knockout of the α-1,6 fucosyltransferase (FUT8) gene has been 
achieved by homologous recombination (Yamane-Ohnuki et al. 2004) and 
ZFN deletion (Malphettes et al. 2010). Afucosylated Rituxan
®
 exhibited 100-
fold improvements in ADCC activity (Yamane-Ohnuki et al. 2004). It has also 
been demonstrated that normal mAb producing cells can generate afucosylated 
product through siRNA knockdown of FUT8 and GDP mannose 4,6-
dehydratase (GMD) (Imai-Nishiya et al. 2007). Fucose modification is 
currently the most successful method to improve mAb efficacy and the first 
glyco-modified afucosylated mAb produced from engineered CHO cells was 
recently approved in Japan in March 2012 (Beck and Reichert 2012). This 
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approval will pave the way for more glycosylation optimized biobetters 
produced from modified CHO cells. 
2.4.4 MicroRNA 
 Engineering of singular targets in complex mammalian pathways have 
yielded limited or mixed results (Dietmair et al. 2011). MicroRNAs (miRNA) 
are non-coding double-stranded RNA molecules able to globally modify gene 
expression levels to affect entire pathways (Müller et al. 2008). Use of miRNA 
in CHO cells is a recent cell engineering technique first reported in 2007 
(Gammell et al. 2007). The number of identified CHO miRNAs has increased 
exponentially since that report (Hackl et al. 2011; Johnson et al. 2011; 
Hammond et al. 2012). Although more studies still need to be done using mAb 
producing cell lines to verify the usefulness of miRNAs, existing reports are 
promising. Over-expression of cgr-miR-7 produced effects similar to 
temperature-shifting with arrested growth and increased specific productivity 
(Barron et al. 2011) and miRNAs in the cgr-miR-17-92 cluster was beneficial 
to cell growth (Jadhav et al. 2012).  
 Despite all the promise of cell engineering, none of the cell lines 
reported with improved growth or productivity have been used in industrial 
mAb production. Approval of glyco-modified mAb from an engineered CHO 
cell line and with over 10 others under testing, we would likely see an increase 
in such products in future (Beck and Reichert 2012). Increased knowledge of 
CHO genome (Omasa et al. 2009; Hammond et al. 2011; Xu et al. 2011), 
transcriptome (Becker et al. 2011; Hackl et al. 2011) and  proteome (Baycin-
Hizal et al. 2012) would allow better understanding of the complex 
interactions taking place for better cell engineering approaches. Construction 
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of dynamic computational models have worked well in production microbial 
cells and this extra information would eventually allow similar 
implementations in mammalian cells (Dietmair et al. 2011; Dietmair et al. 
2012; Nolan and Lee 2012). 
2.4.5 Targeted gene modification using programmable nucleases 
Targeted and controlled gene modification is desirable for both cell 
line generation and cell engineering of CHO cells. Transfected plasmids can 
be targeted into sites which are active and resistant to epigenetic silencing to 
obtain high and sustained mAb expression (Zhou et al. 2010). Specific gene 
knockouts can also be carried out at higher efficiency compared to traditional 
homologous recombination techniques to generate novel CHO cell variants 
(Yamane-Ohnuki et al. 2004; Fan et al. 2012). 
  Programmable nucleases can be used to cleave the target cell’s 
chromosome at pre-determined, specific sites to engage the endogenous DNA 
repair system for modification. Available programmable nucleases include 
zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases 
(TALENs) and the recently reported RNA-guided engineered nucleases based 
on the clustered regularly interspaced short palindromic repeat (CRISPR)-
CRISPR associated (Cas) bacterial adaptive immune system (Kim and Kim 
2014). The nucleases produce double-strand breaks (DSB) which can enhance 
homologous recombination efficiency for gene insertion from an exogenous 
template by more than two orders of magnitude (Rouet et al. 1994). DSBs can 
also activate a non-homologous end joining (NHEJ) repair mechanism which 




Zinc finger proteins are eukaryotic DNA binding proteins of ~30 
amino acids with conserved Cys2-His2 residues coordinating a zinc atom and 
each finger is able to recognize and bind three specific base pairs. Activity of 
the fingers are modular and can be linked together to recognize specific 
sequences. At least three fingers are needed for sufficient binding specificity 
and affinity (Fig. 2.7A) (Gersbach et al. 2014). A FokI cleavage domain is 
fused to the zinc finger chain to generate the sequence specific ZFN to 
generate DSBs (Bibikova et al. 2002). TALE proteins are 33-35 amino acid 
domains originating from the plant-pathogenic bacteria Xanthomonas which 
recognize singular DNA base pairs. Binding specificity is determined by 




 position. Similar to zinc 
finger proteins, TALE proteins are highly modular and can linked together to 
recognize specific DNA sequences in the chromosome. Fusing of a FokI 
domain similar produces TALENs for targeted DSBs (Fig. 2.7B). TALENs 
generally exhibit higher specificity compared to ZFNs due to their one 
domain-one base pair system. Greater optimization and engineering is required 
to reduce off-targets for ZFNs. One advantage ZFN has is the smaller size of 
the coding sequence required, ~1 kbp less than that required for TALEN. 
CRISPR-Cas RNA guided systems are the adaptive immune system of 
bacteria to provide protection from foreign DNA and the newest tools for 
targeted modification. The system requires two main components, the Cas9 
enzyme and a guide RNA (gRNA) (Fig. 2.7C). Major advantages of the 
CRISPR-Cas system compared to ZFN and TALEN include: the Cas9 
nuclease is the same regardless of target and no protein engineering is 
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required; ease of designing and producing the gRNAs; possible to have 
multiple targets by simply using a mixture of gRNAs (Carroll 2014). 
To date, there are only reports of ZFN being used to generate novel 
CHO cell hosts. The first report involved use of ZFN to knockout the FUT8 
gene to generate novel CHO lines which produce defucosylated antibodies as 
mentioned in section 2.4.3 (Malphettes et al. 2010). Another group generated 
GS knock-out CHO cell lines for better selection efficiency (Fan et al. 2012). 
The CRISPR-Cas system development for CHO cell biotechnology is 
currently being carried out by Sigma-Aldrich as they hold the propriety rights 
to use of the system for CHO (personal communication). Issues with 
intellectual property for the more recent TALEN and CRISPR-Cas system 
could explain why their use is still not widespread in the industry.  
 
Figure 2.3 Programmable nucleases for targeted genome editing. (A) 
Zinc-finger nuclease, (B) transcription activator-like effector nucleases. 
The triangles in (A) and (B) represent the binding domains of ZFN and 
TALEN. Each different shading indicates different specificity. 
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2.5 Vector design 
2.5.1 Co-expression of LC and HC genes 
 Complex interactions occur between LC and HC during folding and 
assembly of an IgG mAb. The LC: HC peptide ratio plays an important role in 
the kinetics of mAb formation (Gonzalez et al. 2002). Excess LC has been 
suggested to be beneficial for higher mAb expression levels (Gonzalez et al. 
2002; Schlatter et al. 2005; Yang et al. 2009). There was also a study which 
correlated mAb expression to the amount of available HC, suggesting that HC 
is the limiting reagent and higher HC expression is beneficial (Dorai et al. 
2006; Jiang et al. 2006; Fallot et al. 2009). It is also still unclear if equimolar 
amounts of LC and HC is optimal (Jostock et al. 2010). There is a report that 
at LC:HC mRNA ratios above 1.5 results in minimal product aggregation 
levels (Lee et al. 2009). As LC: HC ratio could affect mAb assembly, it has 
been suggested that mAb glycosylation could vary with ratio as well (Schlatter 
et al. 2005). It is of interest to express these mAb subunits at optimal 
stoichiometric ratios for better mAb production. LC and HC genes are 
traditionally introduced by co-transfecting on two separate vectors (Kim et al. 
2001; Chusainow et al. 2009) or transfecting a single larger vector carrying all 
the required genes (Bebbington et al. 1992; Jun et al. 2005).  LC and HC 
peptide ratios can be varied under transient conditions when co-transfecting 
the genes on separate vectors by changing the relative amounts of each 
plasmid (Fig. 2.3A) (Lee et al. 1999; Schlatter et al. 2005). Controlling ratio 
by this method in stable transfections is inefficient as in the random 
integration process, gene copies and the site of integrated cannot be controlled 
(Trill et al. 1995; Fussenegger et al. 1999; Mielke et al. 2000). Single vectors 
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should provide better control of the ratio as all genes are integrated in the same 
site (Fig. 2.3B). One possible issue that could arise with having multiple 
promoters in close proximity is the resulting transcriptional interference 
(Eszterhas et al. 2002). This interference suppresses gene expression to 
different degrees depending on the site of integration. Suppression of a 
downstream gene in a tandem pair of expression cassettes was suspected to be 
due to obstruction of the downstream promoter region by the polymerase II 
complex coming from the upstream gene. Formation of the promoter complex 
on the first promoter might also inhibit formation of a second promoter 













Figure 2.4 Different vector designs for expression of light chain (LC) and 
heavy chain (HC) for mAb production. (A) Co-transfection on two separate 
vectors. (B) Single vector with separate expression cassettes for each gene. (C) 
Single vector, single promoter vector with genes linked together on one 
expression unit. The linker element used can be an internal ribosome entry site 
(IRES)element, a furin-2A peptide (F2A) sequence or intein sequences. CMV: 
human cytomegalovirus immediate-early gene promoter, SV40: simian virus 
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40 promoter, LC: Light chain gene, HC: Heavy chain gene, SM: Selection 
marker, pA: Polyadenylation signal. 
  
Single promoter, single vector systems for expressing LC and HC have 
the stricter control on LC: HC ratio (Fig. 2.3C). Typical eukaryotic mRNA 
translation is dependent upon 5’-cap mediated ribosome binding, following by 
scanning to identify the AUG start codon for initiation (Kozak 1989). An 
internal ribosome entry site (IRES) element when placed between two genes 
mediates cap-independent translation initiation of the second gene (Pelletier 
and Sonenberg 1988). IRES elements from the Encephalomyocarditis 
(EMCV) virus are known to be strong initiators and among the most 
commonly used (Borman et al. 1997). IRESes form complex secondary 
structures for the recruitment of eukaryotic initiation factors (eIF). Binding of 
the eIF4G protein helps recruit other initiation factors for interaction with the 
ribosome (Martinez-Salas 1999). The cap-independent translation of the 
second gene is less efficient than a typical cap-dependent translation, resulting 
in peptide levels ranging from 3- to 100-fold lower for the second gene 
(Hennecke et al. 2001) (Fig. 2.5). The difference varied based on the IRES, 
genes expressed and cells used. It is possible to use IRES elements to express 
LC, HC and selection marker genes on one transcript (Mielke et al. 2000). 
There only report available for mAb expression using IRES was using a mAb 
fusion protein and the final titers obtained was not clearly stated. CHO cells 
were also not used in the study (Mielke et al. 2000). No comparison with the 
co-transfection and single vector multi-promoter system was done to verify the 





Figure 2.5 Internal ribosome binding on IRES for gene translation. Gene 
1 is downstream of a promoter while genes 2 and 3 downstream of IRES 
elements. The three genes are transcribed together into a single long strand of 
mRNA with 5’ cap protein and a polyA tail. mRNA1 is translated in a normal 
cap-dependent manner while mRNA2 and 3 are translated by ribosomes 
binding to the middle of the transcript on IRES. As IRES driven translation is 
less efficient, mRNA2 and 3 are translated into lower amounts of proteins 2 
and 3 relative to protein 1. 
  
The multiple genes required can be expressed at equal amounts in a 
single open reading frame by using either the foot and mouth virus derived 2A 
self-processing sequence combined with a furin cleavage site (F2A) (Fang et 
al. 2007; Jostock et al. 2010) and inteins (Kunes et al. 2009). 2A elements are 
only about 60 to 80 base pairs long, making it easy to incorporate them into 
vector designs. The 2A linked genes are expressed in one open reading frame 
and self-processing occurs to generate the two separate peptides (Ryan and 
Drew 1994; Donnelly et al. 2001; de Felipe et al. 2006; Jostock et al. 2010). 
Furin cleavage sequences are added to remove amino acids residue at the C-
terminus of the protein upstream of 2A, while the terminal lysine is removed 
by carboxypeptidases (Fig. 2.5) (Fang et al. 2005; Jostock et al. 2010). 
Productivity of clones from a F2A based vector was comparable with clones 
generated using a reference vector using separate expression unit design 
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(Jostock et al. 2010). Interestingly, Davies et al. recently reported that LC was 
still detected in excess for higher producing clones generated using the F2A 
system due to increased HC degradation (Davies et al. 2011). One drawback 
of the F2A system is in the possible formation of unwanted residues or fusion 
proteins (De Felipe et al. 2010; Chan et al. 2011). Careful evaluation of each 
vector design is thus required before F2A can be used for production of mAb 
biologics. 
 
Figure 2.6 Using F2A for antibody expression. HC and LC are transcribed 
together onto one mRNA. During translation, a “ribosomal skip” occurs at the 
site indicated by the black arrow. 2A peptide residues are removed with the 
signal peptide or by furin endoprotease cleavage. HC and LC are then 




2.5.2 Selection strategies 
 In order to efficiently select for stably transfected cells, selection 
marker genes which confer resistance to certain antibiotics or growth 
advantage in a nutrient deficient condition are used. Antibiotics commonly 
used for selection include geneticin (also known as G418), hygromycin and 
puromycin and can act by disrupting protein synthesis in the cell. The cells are 
transfected with neomycin phosphotransferase, hygromycin 
phosphotransferase or puromycin acetyltransferase genes to gain resistance to 
the respective antibiotics. Benefits of antibiotics selection include the ease of 
use and no requirements for modified cell lines. One major drawback is that 
gene amplification cannot be done to increase expression levels.  
 The dihydrofolate reductase (DHFR) is an amplifiable selection marker 
typically used together with the DHFR deficient DG44 or DXB11 CHO cells 
(Urlaub and Chasin 1980; Urlaub et al. 1983; Kaufman et al. 1985; Cacciatore 
et al. 2010). DHFR knockout CHO-K1 mutants have also been generated 
using ZFN to overcome deficiencies like poor growth and inefficient selection 
of current DG44 and DUXB11 cell lines (Sigma-Aldrich 2011). DHFR is 
involved in the reduction of dihydrofolate to tetrahydrofolate, which is in turn 
needed for nucleic acid metabolism. First selection is done in media devoid of 
hypoxanthine and thymidine. Amplification can be further carried out by 
adding a folic acid analog, methotrexate (MTX), which inhibits DHFR 
activity. In order to survive, cells will start to amplify the DHFR gene copy. 
The mAb genes located on the same transfected vector or in nearby sites are 
amplified as well, increasing the gene copies and thus expression levels after 
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several stepwise increases in MTX levels (Kim et al. 1998; Kim et al. 2001; 
Jun et al. 2005; Chusainow et al. 2009). 
  Glutamine synthetase (GS) selection marker catalyzes formation of 
glutamine from glutamate and ammonia (Bebbington et al. 1992; Brown et al. 
1992). This allows successfully transfected cells to survive in media lacking in 
glutamine. The GS selection system works well in NS0 cells which do not 
express their own GS. Using this system with mammalian cells with 
endogenous levels of GS requires using methionine sulphoximine (MSX), a 
GS inhibitor (Brown et al. 1992). Similar to using MTX with DHFR, using 
MSX with GS forces cells to co-amplify the GS gene and the product gene 
(Cockett et al. 1990). One advantage of using the GS system is typically only 
one round of amplification to obtain high expression levels (Bebbington et al. 
1992; Brown et al. 1992). There are concerns of instability when using the 
GS/MSX amplification in CHO K1 cell lines (Jun et al. 2006). Effectiveness 
of the GS system in CHO cells was greatly improved when using the GS-
knockout CHO cell lines. Usage of this mutant new cell line helped improve 
clone selection efficiency by six folds as compared to using regular CHO cell 
lines (Fan et al. 2012).  
 Two novel selection methods have been reported recently that could be 
useful with more optimization. An amplifiable selection marker based on 
hypoxanthine phosphoribosyltransferase (HPRT), which is required for purine 
synthesis, is currently under development (Costa et al. 2012). A toxin/anti-
toxin method commonly used by bacterial cells to maintain plasmid stability 
has also been tested in mammalian cells (Nehlsen et al. 2010).  
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 Vector integration is a random event with no control over whether 
integration is into an active or inactive site and incomplete vectors can get 
integrated resulting in non-expressing clones surviving selection. An active 
integration site leads to higher mAb expression levels. Enhancing selection 
stringency by reducing expression or activity of the selection marker can be 
used to identify integration into active sites. One  way is using a weak 
promoter, such as one from SV40,  to drive expression of the selection marker 
gene (Birch and Racher 2006). Various forms of selection marker sequence 
manipulation or mutations can be carried out in tandem to further improve 
stringency. Using a non-traditional AUG start codon results in inefficient 
translation initiation and can further reduce expression (van Blokland et al. 
2007; Hoeksema et al. 2011).  Deoptimizing codon usage of the wild-type 
(WT) DHFR sequence to reduce translation efficiency improved IgG 
expression level by three-fold (Westwood et al. 2010). Reducing enzymatic 
activity of a neomycin phosphotransferase (NPT) through amino acid 
mutations resulted in 15-fold improvement of expression level as compared to 
a WT-NPT (Yenofsky et al. 1990; Sautter and Enenkel 2005). Protein and 
mRNA destabilizing elements can be used reduce selection marker expression 
without modifying the sequence (Ng et al. 2007). This method could likely be 
applied with greater ease as no sequence modification is required. 
 When the selection marker gene is in an individual expression cassette, 
vector fragmentation can result in only the selection marker cassette being 
integrated intact (Barnes et al. 2007; Chusainow et al. 2009; Ng et al. 2010). 
Such clones would survive selection without expressing any mAb. Coupling 
of the selection marker to the product genes using IRES is a method to 
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minimize the number of these non-expressing clones (Gurtu et al. 1996; Rees 
et al. 1996; Hobbs et al. 1998). Fragmented IRES-based vectors would have 
incomplete expression units and no transcription occurs. The reduced 
translation efficiency of IRES compared to typical cap-dependent expression 
also helps improve stringency. Increased stringency can be achieved by 
modifying the principal translation start site on IRES and further attenuate the 
translation (Rees et al. 1996). Stringency of selection can be further improved 
by combining the two methods, such as using attenuated IRES with activity 
impaired NPT (Chen et al. 2004).  
2.5.3 Signal peptide and codon optimization 
 Each IgG mAb molecule requires the expression two identical light 
chains (LC) and two identical heavy chains (HC) which are linked by disulfide 
bonds. Efficient expression of the genes requires an appropriate signal peptide 
for transport of the transcript to the endoplasmic reticulum (ER) for 
translation. Signal peptide derived from human albumin more than doubled 
the average specific productivity of a stable mAb producing CHO cell mini 




 as compared to using a native IgG LC signal 
peptide (Kober et al. 2013). A signal peptide toolbox has also been generated 
to identify tailored signal peptides for each protein (Stern et al. 2011).  
 Codon optimization for gene expression is important due to differences 
in transfer RNA abundance in different cells and effects on the mRNA 
stability and secondary structures formed by the transcripts (Kim et al. 1997; 
Hung et al. 2010; Angov 2011). Early attempts at codon optimization for gene 
expression improved GFP expression in CHO cells by 42-fold using the 
empirical method of DNA shuffling (Crameri et al. 1996). More rational 
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approaches are now available with increased understanding of mammalian 
cells and a system known as codon adaptive indices (CAI) is used to score 
how optimized a gene is (Angov 2011). A comprehensive assessment of codon 
usage was performed in a recent proteomic analysis of CHO cells and 
preference for certain codons was observed to be especially prevalent for 
proline, threonine, aspartate and cysteine (Baycin-Hizal et al. 2012). Applying 
optimization based on codon usage in CHO and human cells have seen 
improvements in mAb expression by 1.5 to 4 folds (Kalwy et al. 2006; Hung 
et al. 2010). Combination of codon optimization and an optimized gene 
amplification protocol provides a way to get high yielding mAb producers 
with decreased efforts (Kotsopoulou et al. 2010). An interesting application of 
codon usage is to use it for generating mutant endogenous genes with “silent 
mutations” for use in RNAi rescue experiments (Fath et al. 2011).  In another 
study which considered of both individual codon usage for each amino acid 
and additionally the surrounding codon context revealed that the commonly 
used design criteria of codon usage was less important than the codon context 
(Chung et al. 2013). Human interferon-gamma expression increased 13-fold 
with context optimization but only 10-fold with codon usage optimization. 
Another interesting observation made was that optimization based on the 
highly expressed genes was less effective for CHO as compared to microbial 
hosts.        
2.5.4 Chromatin modifying DNA elements 
 Epigenetic status of the integration site can be altered by the DNA 
elements surrounding the site. Some of these elements have been isolated and 
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been tested in vector systems used for cell line generation and shown to 
improve expression level and stability.  
 The ubiquitous chromatin opening element (UCOE) is a un-methylated 
CpG fragment isolated from a region around house-keeping genes that keep 
the region in a transcriptionally active and open configuration (Benton et al. 
2002; Nair et al. 2011). UCOE from both human and mouse sources have been 
identified. The element is placed upstream of the promoter on the vector. 
Using UCOE increase the number of clones with higher expression levels 
(Benton et al. 2002). Recombinant protein expression is also maintained for 
long periods as DNA silencing due to methylation is prevented (Nair et al. 
2011). The element is promoter specific and some optimization of UCOE-
promoter combinations is required (Nair et al. 2011). 
 Matrix attachment regions (MAR) create active chromatin loops within 
the chromosome and can regulate the epigenetic switching of the integration 
site to being transcriptionally active (Girod et al. 2005; Galbete et al. 2009; 
Harraghy et al. 2011). Transfecting it together with the plasmid vector helps 
maintain the integration site in an active configuration for a more 
homogeneous population with high and sustained product expression. 
Expression becomes gene copy number dependent instead of site dependent. 
mAb expression was most improved by either inserting one element upstream 
of the promoter and co-transfecting another MAR only plasmid or at both 5’ 
and 3’ ends of the expression cassette (Girod et al. 2005; Wang et al. 2010). 
MAR from chicken lysozyme, human genome and mouse genome have been 
identified and evaluated to have positive effects in CHO cells (Girod et al. 
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2005; Girod et al. 2007; Harraghy et al. 2011). Due to reported tissue specific 
effects, the MAR should be tested with the cell line to be used. 
 UCOE and MAR elements have been successfully used in gene 
expression platform technologies from Millipore and Selexis respectively. 
Other DNA elements which could also prove to be useful with more 
evaluation include the expression augmenting sequence elements (EASE) 
(Aldrich et al. 2003) and the stabilizing and anti-repressor (STAR) elements 
(Kwaks et al. 2003; Otte et al. 2007). 
 
2.6 Clone selection 
 Random integration and amplification creates highly heterogeneous 
pools, making the selection of high mAb producing clones an extremely time-
consuming and tedious process. Most estimates place the number of clones 
required to be picked to ensure sufficient high producers can be isolated to 
range between several hundred to up to thousands  (Birch and Racher 2006; 
Pichler et al. 2010). Subsequent evaluation of long-term expression stability 
and product quality identify the few rare clones that satisfy requirements of 
production cell lines. Recent developments in methods for selecting high 
producing clones have also seen a heavier reliance on use of automation to 
save on labor and improve process consistency (Eisenstein 2006).  
 Flow cytometry applied to fluorescent activated cell sorting (FACS) is 
one method of high-throughput selecting for high mAb producers (Kumar and 
Borth 2012). Millions of cells can be screened rapidly and specific 
subpopulations isolated from the highly heterogeneous pools. FACS can be 
applied to sorting of surface labeled mAb producing cell lines. The level of 
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secreted proteins is proportional to the protein found on the cell surface. After 
three rounds of reiterative sorting, a 100-fold enrichment of a MTX amplified 
CHO cell line was observed with specific mAb productivity reaching 42 pcd 
(Brezinsky et al. 2003). The cells can be chilled to below room temperature to 
slow down the protein release from the membrane and endocytosis of the 
product-label complex to maximize the signal intensity (Pichler et al. 2009).  
Another way to use surface labeling for sorting is to co-express a surface 
protein not found in CHO cells, such as CD20 (DeMaria et al. 2007). This 
allows surface labeling for cell sorting without worry of signal loss. Surface 
labeling can also be done using a capture matrix composed of biotin, avidin 
and an antibody targeting the product. The matrix will cover the cell surface to 
trap the secreted mAb. The captured mAb can be detected using another 
biotinylated secondary antibody for FACS sorting (Böhm et al. 2004). 
 Linking the product gene to a fluorescent reporter by IRES is another 
way to allow use of FACS for sorting. Cells sorted for high fluorescent levels 
will be co-expressing high levels of the product gene (Freimark et al. 2010). 
High mAb producing cells can be sorted by dual fluorescent activated sorting 
where green fluorescent protein (GFP) and yellow fluorescent protein (YFP) 
are linked to HC and LC expression respectively (Sleiman et al. 2008). 
Another alternative is to use two GFP fragments which reassemble to allow 
FACS of high producers (Kim et al. 2012).    
 Automated colony pickers are becoming an indispensable part of many 
cell line generation platforms. Clonepix from Genetix (Serpieri et al. 2010; 
Dharshanan et al. 2011) and CellCelector from Aviso (Cairns et al. 2011) are 
two systems that have been used for selecting recombinant protein producing 
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colonies. Cells expressing mAb are plated in semi-solid media containing a 
fluorescent detection antibody against the mAb product. The viscous medium 
slows down dispersion of the secreted mAb, keeping it around the colony. 
This allows the detection antibody to label the product. Imaging software is 
used to identify colonies with high productivities that fluoresce with a bright 
halo and are sufficiently isolated from low-expressing or non-expressing cells 
for picking. 
 Production stability is a parameter as critical as productivity in mAb 
cell line development. Long-term stability required of a production clone was 
estimated to be around 60 generation to ensure sufficient time for expansion 
(Brown et al. 1992). Studies have shown that intraclonal expression can be 
stochastic in nature, giving rise to heterogeneous clonal populations 
(Pilbrough et al. 2009). Identification of homogeneous clonal populations 
would identify those with expression at a steady state and more likely to be 
stable (Pilbrough et al. 2009). Screening can be performed by using flow 
cytometry to check population distribution (DeMaria et al. 2007). Automated 
colony pickers can also be used by re-plating a clonally derived population 
back in the semi-solid media. Stable cell lines would have all subcolonies 
expressing mAb and the presence non-expressing colonies would hint of 
unstable production. Methylation status of the promoter and gene copy 
number can also be used as early markers to identify unstable cell lines 
(Osterlehner et al. 2011). Other studies have also shown unstable cell lines to 
be more prone to apoptosis and relevant apoptosis related markers like caspase 
3, Annexin V (Dorai et al. 2012) and GADD153 (Bailey et al. 2012) could 
also be used for early stage screening. 
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       Development of high throughput analytical methods and frameworks 
would help alleviate some existing bottlenecks in the characterization process 
(Konstantinidis et al. 2013). Early prediction of production level and product 
aggregation can be performed by screening LC:HC mRNA of clones and 
selecting those with ratios above 1.5 (Lee et al. 2009). ER stress related 
protein, GRP78, was recently shown to be an indicator of high producing cell 
lines and could be used as a marker to identify clones with high productivity 
(Kober et al. 2012) .  Miniaturized bioreactor systems like ambr
TM
 are also 
being used to mimic bioreactor conditions for medium throughput 
characterization of clone performance under production conditions (Tap 
Biosystems 2014). By using a combination of novel automated systems and 
recently identified early predictors for desirable cell phenotypes, significant 
effort can be conserved during clone selection process. Widespread use of 
automation is still inhibitive for many smaller labs due to the high costs and 
large footprint of such machines. One way to alleviate the labor and cost 
incurred is to use better designed vectors to reduce non-expressing clones and 
improve the clonal consistency. 
 
2.7 Product Quality 
 According to guidelines agreed upon by International Harmonization 
Conference (ICH), characterization of each biologics can include the 
physiochemical properties, biological activity, immunochemical properties 
and purity (ICH 1999). The product has to be sufficiently characterized to 
have established specifications during preclinical and clinical studies. These 
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specifications help ensure product consistency and safety. Some product 
parameters would be discussed in this section.  
2.7.1 Aggregation 
All proteins display the propensity to aggregate. Aggregates can be 
classified by covalent/non-covalent bonds, reversible/non-reversible, size and 
conformation (Mahler et al. 2009). The presence of aggregates in protein 
therapeutics can result in immunogenic reactions, complications during 
product administration and impair product quality and  efficacy (Cromwell et 
al. 2006). Product aggregation can result during the various steps of the mAb 
manufacturing process, starting from the cell line generation to the scale up 
culture process followed by purification, formulation up to storage (Mahler et 
al. 2009; Joubert et al. 2011). The most commonly used protein-A affinity 
chromatography for mAb purification does not discriminate between 
monomers and aggregates as long as the Fc region is intact (Phillips et al. 
2001). The presence of aggregates after filtration and centrifugation 
complicates the purification steps, requiring several other polishing steps like 
size exclusion chromatography (Phillips et al. 2001; Yoo and Ghosh 2012).  
It is beneficial to minimize aggregation from the early steps of 
production during clone selection and culturing. In order to maximize yields, 
high amounts of recombinant mAb peptides are expressed. This could lead to 
intracellular aggregation due to the high amount of unfolded proteins or 
inefficiencies of the molecular chaperones at controlling proper protein 
folding (Zhang et al. 2004). This has been demonstrated in CHO cells where 
overexpression of a simple ATIII glycoprotein beyond a certain level triggered 
aggregation and lowered yield (Schröder et al. 2002). As mentioned in the 
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earlier section of co-expressing both LC and HC peptides, one study managed 
to successfully identify clones with high aggregation by screening for a 
threshold of LC:HC mRNA of 1.5 (Lee et al. 2009). Cell engineering of 
molecular chaperones have mostly been performed to improve cell 
productivity and reports of cell engineering to improve product aggregation 
are still lacking (Gomez et al. 2012).  
2.7.2 Glycosylation 
N-linked glycosylation takes place on the asparagine of an Asn-X-
Thr/Ser consensus sequence where X can be any amino acid but proline. On a 
typical IgG, the oligosaccharides are attached to Asn297 on the CH2 domain 
on the HC peptide (Fig. 2.1). Glycosylation is a multi-step process which 
begins with transfer of a high-mannose oligosaccharide (Glc3Man9GlcNac2) 
from a dolichol phosphate lipid carrier to the nascent HC peptide in the 
endoplasmic reticulum (ER). This is followed by further trimming and residue 
addition by a series of enzymes in the ER and golgi to form the final glycan 
complex (Werner et al. 2007). N-glycosylation takes place co-translationally 
with the peptide assembly (Sakaguchi 1997). The extent of glycan 
modification is influenced by the protein conformation and how various 
enzymes can access the glycan (Krambeck and Betenbaugh 2005; Butler 
2006). Due to the complexity and number of steps involved, the secreted 
mAbs typically ends up with a heterogeneous population of glycan structures, 
such as absence of sialic acid, galactose or fucose residues (Werner et al. 




Figure 2.7 Major N-linked glycans found on human IgG produced in 
CHO cells. Note that the glycans can also exist as afucosylated and asialylated 
forms. G0F would be G0, G1F be G1 and G2F be G2. 
 
N-linked glycosylation is linked to the therapeutic mAb efficacy and 
clearance. Fucosylation is a critical glycan modification for IgGs which 
function by ADCC. A Lec13 CHO mutant cell line with deficient fucose 
addition machinery produced afucosylated IgGs with up to 50-fold improved 
binding affinity to human FcγRIIIa receptor (Shields et al. 2002). This 
improved binding enhanced ADCC related action for Trastuzumab (Suzuki et 
al. 2007). C-type lectin mannose receptors expressed on the surface of 
macrophages and dentritic cells are able to recognize certain mannose and N-
acetylglucosamine (GlcNac) residues (Walsh and Jefferis 2006). G0 and high 
mannose glycans would be more easily recognized by these receptors. The 
IgGs with these glycans would be cleared faster from the patient’s system by 
macrophages after administration (Jefferis 2009; Goetze et al. 2011). There 
could also possibly be increased potentiation of immunogenicity due to greater 
recognition by dendritic cells (Jefferis 2009). Sialylated IgGs typically make 
up a small proportion of the mAb produced. Studies have shown that in a 
mouse model, IgGs bearing sialylated residues were shown to exhibit anti-
inflammatory properties (Kaneko et al. 2006). Terminal galactosylation has 
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been reported to affect CDC related effector functions of antibodies by up to 
2-fold (Raju and Jordan 2012). Studies which developed a cell line expressing 
GNTIII to increase the presence of a bisecting GlcNac, observed a 15-20 fold 
increase in ADCC activity (Jefferis 2009). As glycosylation plays such an 
important role in defining activity of the product, proper characterization of 
the glycol-profile and adherence to this profile is of the utmost importance.  
2.7.3 Other product quality attributes 
Other physiochemical properties of the product that are of concern 
include the mAb structure, the amino acid sequence and related modifications, 
free sulfhydryl groups and disulfide bridges (European Medicines Agency 
2008). The structure and amino acid sequences would be determine the class 
of antibody and also be used to identify sequence variants that could arise 
during the culture or manufacturing process. Fragmentation of the product has 
the potential to cause loss of stability and efficacy and immunogenic responses 
due to the novel epitopes (Page et al. 1995; Eon-Duval et al. 2012).  
Modifications of the C-terminal due to lysine residues are unlikely to 
influence activity and potency of the mAb product (Khawli et al. 2010). Free 
sulfhydryl groups and unwanted disulfide bonding would affect protein 
folding and interactions, resulting in changes to the structure and its activity 
and immunogenic properties (Eon-Duval et al. 2012). 
While general guidelines have been laid down for approval of mAb 
therapeutics, it is still mainly up to the manufacturers to validate that the 
specifications provided are sufficient to prove their product’s safety and 
efficacy through toxicology and pharmacology tests. Biosimilars would be 
required to adhere to the specifications of the existing product in order to 
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obtain approval without extensive preclinical and clinical studies. Having a 
system and process which is able to generate product of consistent quality is 
thus of utmost importance.      
2.8 Future perspectives 
 The expanding use of mAb therapeutics and development of the 
biosimilar market demands a parallel improvement of the production process. 
Initial issues of low production levels have been addressed with the past 
decade of research and development. Titers have increased from milligrams 
per liter to easily reach grams per liter in fed-batch cultures (Wurm 2004; 
Birch and Racher 2006). These improvements in cell line generation have 
been achieved through innovations in cell line engineering, vector design and 
optimization, high-throughput automated clone selection devices, media 
design and process development (Agrawal and Bal 2012). Instead of looking 
for ways to reduce cost of goods through increasing titers, there is now a shift 
towards shortening of development timelines, improving product quality and 
expression stability (Kelley 2009). 
 Technology advancement of the analytical tools like chromatography 
and mass spectrometry available has seen a greater emphasis being placed on 
implementation of process analytical tools (PAT) for analysis of products and 
control of processes. Critical process parameters (CPP) can be tracked to 
identify critical quality attributes (CQA) to enhance the consistency and safety 
of mAb products (Rathore and Winkle 2009). Recent innovations in areas of 
genomics, transcriptomics, proteomics and metabolomics enable the detailed 
study of cellular processes. With the added knowledge, cell line development 
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processes would move away from the empirical and towards more rational 
design, allowing quality by design (QbD) concepts to be applied with greater 
accuracy and effectiveness (Dietmair et al. 2012). Techniques like cell and 
vector engineering and high-throughput automation will also see further 
technological advancements. 
 Along with new mAb therapeutics, the rise of follow-ons for existing 
blockbusters with expiring patents will increase over the next few years 
(Nowicki 2007). The need to have robust platforms for biosimilar production 
is critical due to the number of competitors and importance of maintaining 
similar product quality as the original innovator drugs (Hou et al. 2011). 
Product characterization would need to be carried out with extra care as it is 
hard to compare quality and purity of biotherapeutics unlike chemical generics 
(Ahmed et al. 2012). Companies would rely more and more on smaller scale 
disposable bioreactors to allow them to adopt flexible production lines to a 
wider array of products (Kelley 2009). The approval of the first glyco-
engineered mAb would also pave the way for biobetters of existing products 
and more novel products (Beck and Reichert 2012). 
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 Developing a IRES-mediated Chapter 3:
tricistronic vector for generating high mAb 
expressing CHO cell lines 
 
In this chapter, we describe a vector utilizing internal ribosome entry site 
(IRES) elements to link the light chain (LC), heavy chain (HC) and an 
antibiotic selection marker on a single transcript. The vector is evaluated 
against commonly used vector designs to identify the benefits of using a single 
transcript for all genes and further optimized for high mAb titers.  
 
The following results were first published in “Ho, S. C. L., Bardor, M., Feng, 
H., Mariati, Tong, Y. W., Song, Z., Yap, M. G. S. and Yang, Y. (2012). "IRES-
mediated Tricistronic vectors for enhancing generation of high monoclonal 












A Tricistronic vector utilizing internal ribosome entry site (IRES) 
elements to express the light chain (LC), heavy chain (HC), and a neomycin 
phosphotransferase (NPT) selection marker from one transcript is designed for 
generation of mAb expressing CHO cell lines. As compared to commonly 
used vectors, benefits of this design include: (1) minimized non-expressing 
clones, (2) enhanced stable mAb productivity without gene amplification, (3) 
control of LC and HC expression at defined ratios, and (4) consistent product 
quality. After optimization of the LC and HC arrangement and increasing 
selection stringency by weakening the NPT selection marker, this Tricistronic 
vector is able to generate stably transfected pools with specific productivity 




 (pcd) and titers over 150 mg L
-1
. 5% of 
clones from these pools have qmAb greater than 20 pcd and titers ranging 
from 300 to more than 500 mg L
-1
 under non-optimized shake flask batch 
cultures using commercially available protein-free medium. The mAb 
produced by these clones have low aggregation and consistent glycosylation 
profiles. The entire process of transfection to high-expressing clones requires 
only 6 months. The IRES-mediated Tricistronic vector provides an attractive 
alternative to commonly used vectors for fast generation of mAb CHO cell 







Industrial production of monoclonal antibody (mAb) is carried out by 
transfecting mammalian cells like the Chinese hamster ovary (CHO) cells 
either with two vectors, referred to as Co-transfection (Fig. 3.1A) or with a 
Multi-promoter single vector (Fig. 3.1B) for expression of the light chain 
(LC), heavy chain (HC) and a selection marker. Each gene is driven by its own 
promoter and transcribed in separate units (Wurm 2004; Birch and Racher 
2006; Costa et al. 2010). Upon entering the cell after transfection, the vector 
can be fragmented before integration or have parts of it removed from the 
genome after integration as a result of DNA rearrangement (Barnes et al. 
2007; Chusainow et al. 2009; Ng et al. 2010). As each gene is independently 
expressed, if the expression units for the product genes are damaged while that 
of the selection marker remains intact, cells will only express the selection 
gene. These clones that are not expressing any mAb product will still survive 
the drug selection. For example, it has been reported that up to 50% of non-
expressing clones generated using a Multi-promoter vector could escape drug 
selection (Barnes et al. 2007). 
Another disadvantage of having individual expression units is the lack 
of control of the relative expression of LC over HC. It has been shown that 
when using Co-transfection, the relative amount of each vector integrated into 
chromosome varies from cell-to-cell (Fussenegger et al. 1999; Yahata et al. 
2005; Underhill et al. 2007; Yang et al. 2009). Although using the Multi-
promoter single vector system ensures introduction of LC and HC gene into 
each cell at equal amount, the expression ratio still varies between cells 
because the use of multiple promoters in close succession can result in 
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transcriptional interference. An active transcriptional unit can suppresses the 
expression of another unit and the degree to which gene expression is 
suppressed depends on the integration site in the genome (Eszterhas et al. 
2002; Schlatter et al. 2005). Variations in LC:HC expression ratios have been 
observed in clones generated using both the Co-transfection and Multi-
promoter vector systems (Chusainow et al. 2009; Lee et al. 2009). This change 
in the ratios of LC over HC expression can affect both mAb expression level 
and quality (Gonzalez et al. 2002; Schlatter et al. 2005; Jiang et al. 2006; Lee 
et al. 2009; Van Berkel et al. 2009). 
Internal ribosome entry site (IRES) elements allow expression of 
multiple genes in one transcript (Mountford and Smith 1995; Fussenegger et 
al. 1998; Martinez-Salas 1999). IRES-based polycistronic vectors have been 
used in many studies where expression of multiple genes is desired (Gurtu et 
al. 1996; Fussenegger et al. 1998; Fussenegger et al. 1998; Greber and 
Fussenegger 2007). It has been demonstrated that IRES-based bicistronic 
vectors, which express the product gene and selection marker in one transcript, 
can eliminate non-expressing clones (Rees et al. 1996). However, there are 
currently few studies using IRES for mAb cell line generation probably 
because of its poor translation efficiency impeding generation of high 
producers. In designs which express the LC and HC under the control of one 
promoter via the use of an IRES element and the selection marker under the 
control of another promoter, the mAb expression is comparable with Co-
transfection vector in transient and stable transfections (Jostock et al. 2004; Li 
et al. 2007). As the mAb genes and selection marker were expressed using 
different expression units, the advantage of IRES for alleviating problems 
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related to vector fragmentation is not realized and a large proportion of non-
expressing clones may still exist. In another design which expressed the LC, 
HC, and puromycin selection marker in one transcript by using two IRES 
elements, the cell lines generated had low specific mAb productivity (qmAb) 




 (pcd) (Mielke et al. 2000). A head-to-head comparison 
with commonly used vectors and the mAb quality of the generated clones was 
not conducted in that particular study. 
In this work, we designed an IRES-mediated Tricistronic vector, later 
referred to as Tricistronic vector (Fig. 3.1C) which expressed the LC, HC, and 
neomycin phosphotransferase (NPT) selection marker in one transcript and 
compared its performance with Co-transfection (Fig. 3.1A) and Multi-
promoter (Fig. 3.1B) vectors for generation of mAb expressing CHO cell 
lines. We demonstrated that the Tricistronic vector could minimize non-
expressing clones, enhance productivity and control LC over HC expression at 
defined ratios. High expressing clones were easily isolated through further 
improving the selection stringency and mAb produced by all the clones also 
had consistent N-glycosylation profiles and low product aggregation, 









LC in first cistron 
 




Figure 3.1 Schematic representation of vectors for expressing light chain 
(LC) and (HC) of recombinant monoclonal antibody (mAb) in CHO. (A) 
Co-transfection, expression of LC, HC and neomycin phosphotransferase 
(NPT) in two separate vectors. (B) Multi-promoter, expression of LC, HC and 
NPT in one vector using multiple promoters. (C)  Tricistronic vectors, 
expression of LC, HC, and NPT in one vector using one promoter. Two 
different designs were tested, either LC or HC was placed as the first cistron. 
CMV, human cytomegalovirus IE gene promoter; SV40, simian virus 40 
promoter; BpA, bovine growth hormone polyadenylation signal; SpA, simian 
virus 40 early polyadenylation signal; IRESwt, wild type 
encephalomyocarditis virus (EMCV) internal ribosomal entry site; IRESatt, 
mutated EMCV IRES with attenuated translation efficiency.   
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3.3 Materials and methods 
3.3.1 Cell culture and media 
Adherent CHO K1 cells (American Type Culture Collection, 
Manassas, VA) were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) + GlutaMax
TM
 (Invitrogen, Carlsbad, CA) supplemented with 10% 
fetal bovine serum (FBS) (Sigma-Aldrich, St. Louis, MO), referred to as 
serum medium, in T-flasks. Suspension CHO K1 cells were obtained by in-
house adaptation of the adherent cells into a protein-free medium, consisting 
of HyQ PF (HyClone, Logan, UT) and CD CHO (Invitrogen) at a 1:1 ratio and 
supplemented with 1 g L
-1
 sodium bicarbonate (Sigma-Aldrich), 6 mM 
glutamine (Sigma-Aldrich), and 0.05% Pluronic F-68 (Invitrogen) and grown 
in shake flasks. Routine subculture of both adherent and suspension cells was 
done every 3 to 4 days. Cell density and viability were measured using the 
trypan blue exclusion method on an automated Cedex counter (Innovatis, 
Bielefeld, Germany).     
3.3.2 Vector construction 
The Co-transfection vectors (Fig. 3.1A) were constructed by insertion 
of anti-HER2 LC and HC cDNA into the multiple cloning sites of 
pcDNA3.1(+) (Invitrogen). The Multi-promoter vector (Fig. 3.1B) was 
constructed by insertion of SV40-NPT-SpA cloned from pcDNA3.1(+) into a 
dual-CMV vector described previously (Yang et al. 2009). Construction of the 
Tricistronic vectors (Fig. 3.1C) were based on pcDNA3.1(+). The region 
between the bovine growth hormone polyadenylation signal (BpA) and SV40 
promoter was replaced with an attenuated encephalomyocarditis virus 
(EMCV) IRES (IRESatt) designed based on literature, in which ATG-12 was 
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used as the start codon of NPT, ATG-11 was mutated and 23 extra bases were 
inserted upstream of ATG-12 (Rees et al. 1996).  The anti-HER2 LC or HC 
cDNA was then inserted downstream of the human cytomegalovirus (CMV) 
promoter, followed by insertion of the wild type EMCV IRES (IRESwt)-HC 
or IRESwt-LC element. The IRESwt and HC or LC were linked by 
overlapping PCR. The EMCV IRESwt and IRESatt were cloned from pIRES-
DsRed vector (ClonTech, Palo Alto, CA). The NPT mutants, M1 and M10, 
were generated using QuickChange site-directed mutagenesis kit (Stratagene, 
La Jolla, CA) , with amino acid E at 182 changed to D in M1, or D at 261 
changed to G in M10 (Sautter and Enenkel 2005). All restriction enzymes 
used were from New England Biolabs (Ipswich, MA). 
3.3.3 Transient transfections 
Transient transfections were carried out in 6-well tissue culture plate 
using Fugene 6 (Roche, Indianapolis, IN). 2 mL of adherent CHO K1 cells at 




 in 6-well plates 
24 h prior to transfection. Duplicate transient transfections for each set of mAb 
vectors were performed using a Fugene 6 to plasmid ratio of 6 µL:2 µg. To 
normalize transfection efficiency, a third transfection was carried out in 
parallel for each vector with an added 0.2 µg of pMax-GFP (Amaxa, 
Gaithersburg, MD).  
3.3.4 Generating stable cell lines 
Comparison of stable cell lines generated by Co-transfection, Multi-
promoter, and Tricistronic vectors (Fig. 3.1) was performed in adherent CHO 
K1 cells for easy isolation of clones. Transfections were carried out using 
Fugene 6 as described in transient transfection protocol. The plasmids were 
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linearized using a unique BglII site prior to transfection. Selection with G418 
(Sigma-Aldrich) at 600 µg mL
-1
 in serum medium was started 48 h post-
transfection.  Non-transfected cells died after 7-10 days of selection and stably 
transfected pools were obtained after 2 weeks. Clones were isolated by 
limiting dilution in 96-well tissue culture plates.  
Evaluation of stable cell lines from the Tricistronic vector containing 
the NPT mutants was performed using suspension CHO K1 cells because of 
their higher cell densities compared to adherent cultures. Another reason for 
using suspension cells was that we observed easier adaptation of suspension 
cells back into suspension cultures after selection in the more robust adherent 
conditions. In each transfection, 5×10
6
 cells were transfected with 5 µg of 
plasmids linearized at BglII site using Nucleofector (Amaxa). The transfected 
cells were then resuspended with 2 mL of protein-free medium into 6-well 
suspension culture plates. At 24 h post-transfection, cells were centrifuged at 
~100 x g rpm for 5 minutes, resuspended into 6-well tissue culture plates using 
2 mL of serum medium with 600 µg mL
-1
 of G418. Changing from protein-
free to serum medium allowed the suspension cells to become adherent. 
Selection with G418 followed by a recovery period took up to a total of 5 
weeks before clone isolation was carried out using limiting dilution method. 
The stable pool and high expressing clones, based on specific productivity 
(qmAb), were adapted back into suspension in protein-free medium with G418 
at 600 µg mL
-1
 by stepwise decrease of FBS from 10% to 1%, 0.5%, and 0%. 
     
51 
 
3.3.5 Determining cell productivity by ELISA and nephelometry 
Productivities of stable pools and clones under adherent condition were 
determined in 6-well tissue culture plates by seeding 2 mL of culture in each 




. After 72 h, cells were detached for 
cell density analysis using Cedex (Innovatis) and supernatant was collected for 
analysis of mAb concentration using enzyme-linked immunosorbent assay 
(ELISA). Each well of a 96 well plate was first coated with 50 µL of goat anti-
human IgA+IgG+IgM (H+L) (KPL, Gaithersburg, MD) in PBS at 37°C for 60 
min. The plate was washed three times with a wash buffer of PBS + 0.1% 
Tween 20 (Promega, Madison, WI). 300 µL of blocking buffer, 3% bovine 
serum albumin (BSA) (Sigma), was added to each well and incubated again 
for 60 min at 37°C. Plate was washed again as before. 50 µL of diluted 
samples were added in duplicates together with purified myeloma IgG1 
standard (Sigma) and incubated again at 37°C for 60min. After another round 
of washes, 50 µL of detection antibody of goat anti-human IgG (Fc-specific) 
conjugated to alkaline phosphatase (Sigma-Aldrich) was added, followed by 
another 60 min of incubation. A final round of washing was performed and 50 
µL of p-nitrophenyl phosphate substrate (Sigma) added. The reaction was 
stopped after 30 min incubation at room temperature with 1 M sodium 
hydroxide (Sigma). Absorbance was read at 405 nm with 630 nm reference 
using microplate reader from Bio-Tek (Winooski, VT).     
Productivities of suspension adapted stable pools and clones were 
determined in 250 mL shake flasks. Cells were seeded in 50 mL of medium at 




. Growth and mAb concentration in the 
supernatant were monitored every other day until viability dropped below 
52 
 
50%. mAb concentrations were measured using a nephelometric method on an 
IMMAGE 800 immunochemistry system (Beckman Coulter, 
Buckinghamshire, England). The qmAb in both adherent and suspension 
cultures was calculated as the mAb concentration measured at the end of 
culture divided by the integrated viable cell density (Balcarcel and 
Stephanopoulos 2001). 




 (pcd) and calculated 





where [mAb] is the mAb concentration in the culture supernatant. IVCD is the 
integrated viable cell density calculated by the following equation: 
𝑰𝑽𝑪𝑫 =





where N and N0 are the initial and final viable cell densities and t is the length 
of culture.   
3.3.6 Determining intracellular polypeptides of LC:HC ratios 
2×10
6
 cells collected from 6-well plate cultures were washed with 1X 
PBS (Sigma-Aldrich) and lysed in RIPA buffer (Thermo Scientific, Waltham, 
MA). The cell lysates were centrifuged at ~18,000 × g for 30 min at 4°C. The 
supernatants were quantified for concentrations of LC and HC polypeptides 
using ELISA. Steps were as described above in 3.3.5 except now detection 
antibodies used were goat anti-human IgG (Fc-specific) conjugated to alkaline 
phosphatase (Sigma-Aldrich) targeting HC and goat anti-human IgG (LC-
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specific) conjugated to alkaline phosphatase (Sigma-Aldrich) targeting LC, 
respectively. The ratio of intracellular LC:HC polypeptides in each clone was 
calculated as the measured LC concentration divided by the HC concentration. 
3.3.7 Western blotting analysis 
The product pattern in different clones generated using Co-
transfection, Multi-promoter, and Tricistronic vectors (Fig. 3.1) was 
determined using western blotting analysis. 12 µL of supernatant from 6-well 
plate cultures were mixed with 4 µL of loading buffer, boiled for 10 min at 
70°C, separated on a E-PAGE
TM
 48 protein Electrophoresis System, and 
transferred to PVDF membranes according to manufacturer’s instructions 
(Invitrogen). Membranes were blocked in 5% blocking milk (Bio-Rad 
Laboratories) in TBS with 0.1% Tween-20 (Bio-Rad Laboratories) for 1 h at 
room temperature. AffiniPure mouse anti-human IgG (H + L) polyclonal 
primary antibody (Jackson ImmunoResearch, West Grove, PA) followed by 
horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG secondary 
antibody (Jackson ImmunoResearch) were used. Proteins were detected using 
the ECL system (Amersham Biosciences). Membranes were exposed using 
Lumi-Film Chemiluminescent Detection Film (Roche).  
3.3.8 Purifying mAb using protein A column 
Culture supernatant containing mAb was loaded on a Tricorn 5/150 
Protein A column packed with MabSelect SuRe (GE Healthcare, Uppsala, 
Sweden) using 1×PBS as a loading buffer and 0.1 M glycine buffer (Merck, 
Darmstadt, Germany)  at pH 2.7 for elution. Samples were neutralized with 
1M sodium bicarbonate at pH 8 (Merck).  The purification was performed 
using a GE AKTA explorer 100 (GE Healthcare) and UV detection at 280 nm. 
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3.3.9 Glycosylation analysis of protein A purified mAb 
The N-linked glycan distribution of mAb was analyzed using matrix-
assisted laser desorption ionization-time of flight mass spectrometry (MALDI-
TOF MS). Briefly, 200 g of purified mAb was incubated with 8 g of 
sequencing grade modified trypsin (Promega, Madison, WI) at 37°C in a 50 
mM ammonium bicarbonate buffer (Merck) at pH 8.2. The digestion was 
stopped after 4 h by heating at 95°C for 15 minutes. The resulting mixture was 
deglycosylated overnight with 70 U of PNGase F (Prozyme, Hayward, CA) at 
37°C. The released N-glycans were then purified using the Hypersep 
Hypercarb cartridges (Thermo Scientific). The N-glycan preparation was 
permethylated (Ciucanu and Kerek 1984; Dell et al. 1994) and cleaned-up 
using a Sep-Pack C18 cartridge (Waters Corporation, Milford, MA) (North et 
al. 2010).  
The MALDI-TOF data was acquired on a 5800 MALDI-TOF/TOF 
mass spectrometer (AB Sciex, Foster City, CA) in positive reflectron mode. 
Permethylated samples were reconstituted in 30 µL of 80% (v/v) methanol in 
water and then spotted on a target plate on a ratio 1:1 with 2,5-
dihydroxybenzoic acid matrix at 10 mg mL
-1
 (Water Corporation) dissolved in 
80% (v/v) methanol in water. The 4700 calibration standard kit, calmix (AB 
Sciex) was used as an external calibrant for the MS mode. The laser intensity 
used to acquire the data was 50%. Relative quantification of the different N-
glycan species was based on the MALDI-TOF MS data (Kang et al. 2007; 
Wada et al. 2007). Statistical significance at the 95% confidence level of the 




3.3.10 Aggregation analysis of protein A purified mAb 
The aggregation of protein A purified mAb was determined using size 
exclusion chromatography (SEC).  The instrument setup consisted of a HPLC 
system (Shimadzu, Kyoto, Japan), with a binary pump, an auto injector, a 
thermostat column oven and a UV-visible detector. Dawn 8 (light scattering), 
Optilab (refractive index), and QELS (dynamic light scattering), were 
connected in series following the UV-visible detector. All the three detectors 
were purchased from Wyatt Technology Corporation (CA, USA) and operated 
using ASTRA software. The Chromatography columns used were TSK Guard 
column SWXL, 6×40 mm and TSK gel G3000 SWXL, 7.8×300 mm (Tosoh 
Corporation, Tokyo, Japan). Column Oven temperature was set at 25ºC and 
mobile phase included 0.2M sodium phosphate (Merck) and 0.1M potassium 





3.4.1 Design of Tricistronic vectors 
IRES-mediated Tricistronic vectors were designed to express the LC, 
HC and NPT under the control of a CMV promoter (Fig. 3.1C). Arrangement 
of LC or HC as the first cistron allowed changing of the ratios of LC : HC 
expression. EMCV IRES was chosen to drive translation of the second mAb 
gene as it was reported to be less affected by the flanking coding sequences 
and mediates accurate translation (Borman et al. 1995; Borman et al. 1997; 
Hennecke et al. 2001). For higher translation efficiency, the sequence around 
ATG-10, ATG-11, and ATG-12 was maintained and ATG-12 was used as the 
start codon of mAb gene (Davies and Kaufman 1992; Kaminski et al. 1994; 
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Qiao et al. 2002; Bochkov and Palmenberg 2006; Martin et al. 2006). ATG-11 
is known to be the dominant translation initiation site (Davies and Kaufman 
1992) and the three extra amino acids added to the IRES-driven mAb gene 
would be cleaved together with the signal peptide (Li et al. 2007). In order to 
avoid gene amplification to reduce the time required for cell line generation, a 
NPT selection marker was chosen instead of amplifiable markers, such as 
DHFR. To enhance stringency of selection for high producer, a less effective 
IRESatt was applied on NPT to reduce its expression or using a combination 
of IRESatt and NPT mutants with reduced efficacy. The strategy is based on 
the principle that when the selection marker is weakened, only clones with 
greater transcriptional activity or more copies of the integrated vector can 
survive the selection process (Fussenegger et al. 1999; Ng et al. 2007).  
3.4.2 Evaluation of Tricistronic vectors for transient mAb expression  
Tricistronic vectors with either LC or HC as the first cistron were 
compared with the Co-transfection and Multi-promoter vectors in transient 
transfections in CHO K1 cells. The Co-transfection and Multi-promoter 
vectors exhibited similar mAb expression levels (Fig. 3.2). When compared to 
the Co-transfection system, expression was 33% lower for Tricistronic design 
with LC as the first cistron and 84% lower with HC as the first cistron.  As 
cap-dependent translation of the gene in the first cistron is more efficient than 
IRES-driven translation, placement of LC downstream of CMV promoter 
would see LC expressed in excess of HC. HC would then be in excess when 
LC and HC positions were changed. Higher expression from the configuration 
that provided excess LC was consistent with the reports that excess LC was 
more favorable for mAb expression (Gonzalez et al. 2002; Schlatter et al. 
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2005). Having the LC as the first cistron was chosen as the optimal 
configuration for the Tricistronic vector design and used for subsequent 
experiments.  
 
Figure 3.2 Comparison of different vectors for mAb expression levels in 
transient transfections. CHO K1 cells were transfected with different vector 
systems for expression of the anti-HER2 mAb. At 48-h post transfection, the 
mAb concentration in the culture supernatant was measured by ELISA. 
Results represent mAb concentration normalized to an internal control, GFP 
expression measured by FACS Calibur (Becton Dickinson, Bedford, MA). 
Each point represents the average and standard deviation of measurements of 
duplicates from two independent transfections. 
 
3.4.3 Evaluation of Tricistronic vector for mAb expression in stable 
transfections 
The Tricistronic vector with LC in the first cistron was then compared 
with the Co-transfection and Multi-promoter vectors in stable transfections. In 
stably transfected pools, the Co-transfection and Multi-promoter vectors gave 




 (pcd) respectively. In contrast to 
the lower expression in transient transfections, using the Tricistronic vector 
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Analysis of clonal productivities indicated that higher productivity in stable 
pools generated using the Tricistronic vector was a result of the enhanced 
proportion of positive clones and higher productivity of clones. Among 20 
clones randomly picked from stable pools generated by each of the three 
vector systems, 40% of clones generated by Co-transfection system and 60% 
of clones generated by Multi-promoter system produced detectable levels of 
mAb using ELISA with Fc-specific antibody for detection, while 75% of the 
clones generated using the Tricistronic vector were positive (Fig. 3.3B).  The 
average qmAb of 20 clones from the Tricistronic vector is 0.25 pcd and the 
highest expressing clone had qmAb of 1.16 pcd compared to average qmAb of 
0.01 pcd and highest qmAb of 0.07 pcd for Co-transfection vectors, and 
average qmAb of 0.02 pcd and highest qmAb of 0.09 pcd for the Multi-
























Figure 3.3 Comparing mAb expression levels of different vectors in stable 
transfections. (A) Specific mAb productivity (qmAb) of stably transfected 
pools. Each point represents the average and standard deviation of three 
transfected pools. (B) qmAb and percentage of expressing clones out of 20 
picked from each pool. Each point represents the mAb productivity of a single 
clone. mAb concentration was determined using ELISA and detection 
antibody targeting against the Fc region of mAb.     
 
The clones were then sorted in ascending order based on their qmAb 
for further analysis using western blotting. Besides expressing complete 
antibody, HC2LC2, various combinations of antibody fragments including 
LC2, LC monomer and HC2 were observed in different clones. Among the 
clones examined, only two clones generated using Co-transfection vectors and 
four clones generated using Multi-promoter vector produced complete 
antibodies, the rest of the clones produced mainly fragments or no detectable 
antibody components (Fig. 3.4A and B). These results suggested that a portion 
of the positive clones detected using ELISA were in fact false positive clones 
expressing HC fragments. In contrast, the Tricistronic vector had 15 out of 20 



























Figure 3.4 Western blot analysis of HC and LC polypeptides secreted 
from different clones generated using (A) Co-transfection, (B) Multi-
promoter, and (C) Tricistronic vector. Non-reduced supernatant from 
different clones was loaded in each lane. A commercial human affinity 
purified myeloma IgG1 (Sigma-Aldrich) and supernatant from cells 
transfected with either a vector expressing only HC or a vector expressing 
only LC were loaded in separate lanes as controls. Supernatant from non-
transfected cells (N) was loaded as negative control. Migration of the different 
secreted forms, HC2LC2, HC2, LC2, and LC, are indicated in the left side.   
 
Further analysis of the ratios of intracellular abundance of LC over HC 
polypeptides provided insights to the different product patterns observed in 
clones generated using different vectors. Corresponding to the different 
product patterns in clones generated using the Co-transfection and Multi-
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promoter vectors, the intracellular LC:HC polypeptides ratios varied from 
more than 7 to close to 0 (Fig. 3.5A and B). When the ratio was close to one 
like in Multi-promoter clones 15, 17, 18 and 20, the secreted product was 
mainly complete mAb. Unbalanced LC over HC expression could have 
resulted in secretion of mAb fragments, like Co-transfection clone 9 and 
Multi-promoter clone 11 to 14. The Tricistronic vector controlled the ratio of 
LC:HC polypeptides around 4:1 in all positive clones (Fig. 3.5C). This 
matched with the consistent product pattern of a mixture of HC2LC2, LC2 and 


























































Figure 3.5 Ratios of intracellular abundance of LC over HC polypeptides 
in different clones generated using (A) Co-transfection, (B) Multi-
promoter, and (C) Tricistronic vector. Clone numbers are represented on 
the horizontal axis. Equal numbers of cells from each clone with detectable 
levels of mAb production were lysed in RIPA buffer. The concentration of LC 
and HC polypeptides in the lysates was determined by using ELISA, with 
detection antibody targeting against LC and Fc region, respectively.   
 
3.4.4 Weakening selection marker in Tricistronic vector for selection of 
high producers 
To improve the stringency of selection for high producers, the NPT 
selection marker on the Tricistronic vector was further weakened through the 
use of NPT mutants, M1 and M10. M1 and M10 mutations reduced the 
enzymatic activity of NPT to 22% and 3% as compared to the wild-type NPT 
(Fig. 3.6) (Sautter and Enenkel 2005). In preliminary attempts, stable pools 
were successfully generated using Fugene 6 for the Tricistronic vectors 
containing wild type NPT and M1 mutant, but no clones could survive 
selection in cells transfected with the Tricistronic vector containing M10 
mutant. This was likely a result of the high stringency of selection and low 
transfection efficiency. To address this issue, suspension cells were transfected 
using nucleofection to obtain more transfectants and selection was done under 
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adherent condition. This protocol allowed successful generation of stable 
pools for all three vectors. As compared to the Tricistronic vector containing 
the wild type NPT which generated pools with qmAb of 0.28 pcd, the 
improved one containing M1 mutant increased the qmAb of the stable pool by 
over 2-fold to 0.72 pcd and using the even weaker M10 pushed qmAb higher 
to 4.73 pcd (Fig. 3.6). A stable pool generated using M10-mutant Tricistronic 
vector was adapted to suspension in protein-free medium. Specific 
productivity remained around 5 pcd after adaptation. The culture reached a 




 and a titer of 168 mg L
-1
 in a 9 days 
batch shake flask culture.  
A total of 111 clones were randomly picked from a stable pool 
generated using the M10 Tricistronic vector and screened for high expressing 
clones in 6-well plates. Based on the qmAb measured, the top 20 clones were 
adapted to suspension in protein-free medium and characterized in shake 
flasks for growth and productivity. The results of the 5 clones with highest 
qmAb, clone 50, 63, 87, 97, and 98, were listed in table 3.1. In non-optimized 
shake flask batch cultures using commercial protein-free medium, the 5 clones 







. The qmAb, calculated based on the entire 
culture process, ranged from 20 to 33 pcd and the peak titer of the highest 
expressing clone, 87, reached 513 mg L
-1
. Productivities of these clones are 
considered high as the culture conditions were under non-optimized shake 




Figure 3.6 Specific productivity (qmAb) of stably transfected pools 
generated using Tricistronic vectors with the wild type NPT (WT), 
mutant M1, and mutant M10 as selection markers. The NPT mutants were 
generated based on literature (Sautter and Enenkel, 2005). The amino acid 
substitution and reported enzyme activity for each mutant were listed. Each 
point represents the average and standard deviation of measurements from 
three stable pools.  
 
Table 3.1 Productivity of the 5 top mAb expressing clones in shake flask 
batch culture. VCD represents viable cell density. 













50 2.1 8 399 31 
63 4.0 7 434 33 
87 5.6 9 513 20 
97 7.6 9 461 20 























3.4.5 Product quality in clones generated using improved Tricistronic 
vector  
Aside from high productivity, it is also desired that cell lines are able 
to produce mAb of good quality. Parameters to be considered include the 
glycosylation profile and protein aggregation, which can affect the mAb 
activity, immunogenicity and clearance (Rudd et al. 2001; Jefferis 2005; 
Cromwell et al. 2006). MALDI-TOF mass spectrometry was used to provide 
detailed identification and quantification of N-glycan on the mAb produced in 
the top 5 expressing clones (Fig. 3.7A and Table 3.2). 2% of the glycans were 
sialylated and around 80% fucosylated for all 5 clones (Fig. 3.7B). High-
mannose type N-glycan composition ranged from 5% to 8%. Complex type 
G0, G1 and G2 glycan distribution ranged from 48% to 53%, 36% to 39% and 
3.5% to 4.3% respectively for the 5 clones analyzed. The glycan distribution 
observed in these clones was similar to that reported by the manufacturer of 
anti-HER2 mAb (Fig 3.7C) (Junttila et al. 2010). Statistical analysis (ANOVA 
test) of all the observed glycoforms showed that there were no significant 











Figure 3.7 Glycan structures and distribution of recombinant mAb 
produced in the 5 top expressing clones. (A) MALDI-TOF analysis of the 
permethylated N-glycans released from the recombinant mAb produced in the 
clone 50 as an example. Solid square, N-acetylglucosamine; solid circle, 
mannose; open circle, galactose; solid triangle, fucose and solid diamond, 
sialic acid. (B) Glycan distribution on recombinant mAb produced in the 5 top 
expressing clones. N-glycans are categorized into sialylated which are 
substituted at least by one sialic acid residue in terminal position, fucosylated 
complex N-glycans, high mannose-type, G0 without bearing terminal 
galactose residue, G1 bearing one terminal galactose residue and G2 bearing 
two terminal galactose. The numbers presented here are the average and 
standard deviation of 3 independent N-glycan preparations. (C) Reported 
glycosylation profile for commercial anti-HER2 mAb (Juntilla T. 2010). 




Table 3.2 Microheterogeneity of N-glycan structures found on the 
purified mAb produced in the 5 top expressing clones. 
Five categories of N-glycans have been distinguished: high mannose-type, 
complex-type G0 which are the ones bearing no terminal galactose residue, G1 
which are having one terminal galactose, G2 which are the ones with two 
terminal galactose and then, sialylated which are the complex structures 
substituted by one or two sialic acids. The numbers reported here correspond 
to the percentage (%) of each N-glycan and are the mean of 3 independent 
analyses. Solid square, N-acetylglucosamine; solid circle, mannose; open 




The aggregation of protein A purified mAb was determined by SEC 
followed by detection using dynamic light scattering and UV. Typical SEC 
chromatograms of the purified mAb are shown in Fig. 3.8. The peak P1 was 
identified as aggregates and the second peak P2 as IgG monomers, based on 
their average molecular weights of 2.87 x 10
5
 g/mol and 1.45 x 10
5
 g/mol 
respectively as determined by dynamic light scattering (Fig. 3.8A). The level 
of aggregation was then quantified using the peak areas detected by the UV 
detector (Fig. 3.8B). In all samples, the IgG monomer fractions had 
hydrodynamic radius (Rh) of 5.6 nm and represented more than 98 % of total 

















Figure 3.8 Typical chromatograms obtained for the top 5 expressing 
clones. (A) Species within protein A purified mAb from the top 5 expressing 
clones were separated by size exclusion chromatography followed by the 
identification of species based on molecular weight generated by light 
scattering detection. Peak P1 corresponds to aggregates and peak P2 
corresponds to non-aggregated IgG monomers. (B) Chromatogram from UV 
detector showing similar peaks. Peak areas were used for the quantification of 
proteins detected as P1 and P2.  
 
3.5 Discussion 
As compared to Co-transfection and Multi-promoter vectors, using 
Tricistronic vectors minimized non-expressing clones, enhanced productivity, 
and controlled consistent product quality. These advantages obtained using the 
Tricistronic vector rely on three key designs:  (1) expression of LC, HC, and 
selection marker in one transcript, (2) arrangement of LC as the first cistron, 
and (3) IRESatt driven translation of a weakened mutant NPT. The first 
observed benefit of using the Tricistronic vectors was the higher stable mAb 
expression although the transient expression levels were lower. This was 
likely due to the reduced non-expressing clones and better selection stringency 
using IRES compared to a weaker promoter. Tight coupling of the three genes 
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in one transcript minimized the non-expressing clones to 25%, as compared to 
50 to 60% observed in those generated using Co-transfection and Multi-
promoter vectors. It was expected that expression of the product and selection 
genes in one transcript would eliminate all non-expressing clones. The 
observation of non-expressing clones surviving drug selection is likely a result 
of insertion of an intact NPT gene from a fragmented Tricistronic vector 
downstream of an endogenous promoter. Expression of LC and HC in one 
transcript also enabled control of LC:HC at fixed ratios, giving consistent 
product patterns between clones which will simplify the clone selection 
process. Without a strict control of LC:HC expression in Co-transfection and 
Multi-promoter, clones generated could produce full mAb, HC fragments, LC 
fragments, or a mixture of them. While we observed no statistically significant 
differences in the mAb glycan distribution between our clones, variations of 
up to 18% and 14% for G0F and G1F respectively had been previously 
reported for mAb produced in clones generated using a Multi-promoter vector 
(Van Berkel et al. 2009). It was also suggested in the same study that N-
glycosylation could be affected by the folding and assembly process, which in 
turn is affected by the LC:HC ratio. The fixed ratio of LC:HC expression of 
our clones generated using the Tricistronic vector could be the reason for the 
observed N-glycan distribution consistency.  
Arrangement of LC as the first cistron in Tricistronic vectors expressed 
LC in excess, which had higher mAb expression than arrangement of HC as 
the first cistron. Extra expression of LC may be also beneficial for 
minimization of the mAb aggregation. In a study based on a Multi-promoter 
vector, it was observed that the level of mAb aggregation was reversely 
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correlated with the LC : HC mRNA levels (Lee et al. 2009). When the LC:HC 
ratio was greater than 3, most clones had aggregation less than 2% for the 
unspecified mAb. Another study has also shown that excess HC could be a 
reason explaining mAb aggregation (Vanhove et al. 2001). These results fit 
well with our observations that clones generated using the Tricistronic vector 
with a LC:HC ratio of 4 presented less than 2% of mAb aggregation.  
Selection marker weakening is a common approach for enhancing 
selection of high producers. The Tricistronic design makes this strategy more 
effective by minimizing non-expressing clones. In theory, the weaker the 
selection marker is, the higher the threshold expression level is required for 
clones to survive selection. Application of IRESatt on the wild type NPT or 
mutant NPT M1 in the Tricistronic vector enhanced productivity but it was 
still less than 1.00 pcd in stable pools. High expression clones are expected to 
be still of a small proportion. Only further weakening selection marker, 
application of IRESatt on NPT mutant M10, enabled generation of clones with 
qmAb greater than 30 pcd by picking only a hundred clones. It is not clear 
whether further weakening NPT can further enhance productivity but we 
speculate that further reduction of NPT strength will result in failure of clone 
survival.  
By avoiding gene amplification and enhancing stringency of selection, 
our optimized Tricistronic vector enabled generation of stably transfected 
pools with titers over 150 mg L
-1
 within two months and clones with specific 
productivities greater than 30 pcd within 6 months. The timeline could be 
further shortened by carrying out the drug selection and clone screening 
process under optimized suspension conditions. This shortened process is 
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beneficial to different stages of mAb development. High expressing pools can 
be quickly generated to provide mAb for preclinical studies, where smaller 
amounts of mAb are needed and timing is greater importance.  In parallel, 
high expressing clones are picked for mAb production for late stage clinical 
trials and large scale manufacturing where high productivity is more critical. 
As compared to the use of transient transfection technology, use of stable pool 
for preclinical studies is preferred as product quality between stable pool and 





 Comparing IRES and Furin-2A Chapter 4:
(F2A) for mAb expression in CHO cells 
 
Using IRES to express LC and HC as in chapter 3 would result in higher 
expression of one of the genes due to the reduced translation efficiency of 
IRES. This might not be optimal for mAb production due to wastage of the 
excess peptides. It is still unclear if equimolar amounts of LC and HC would 
perform worse than having either one in excess in stable mAb producing cell 
lines. In this chapter we evaluated the use of F2A elements to link LC and HC 
genes for expression of biosimilar mAbs in CHO cells. Use of F2A should 
allow LC and HC to be expressed at equal amounts for subsequent studies on 
stable LC:HC ratio. This study would also allow us to compare the IRES 
vector design with a single transcript design which had been reported to 
generate high mAb titers. 
 
The following results were first published in “Ho, S. C. L., Bardor, M., Li, B., 
Lee, J. J., Song, Z., Tong, Y. W., Goh, L.-T. and Yang, Y. (2013). "Comparison 
of Internal Ribosome Entry Site (IRES) and Furin-2A (F2A) for Monoclonal 









4.1 Abstract  
Four versions of tricistronic vectors expressing IgG1 light chain (LC), 
IgG1 heavy chain (HC), and dihydrofolate reductase (DHFR) in one transcript 
were designed to compare internal ribosome entry site (IRES) and furin-2A 
(F2A) for their influence on monoclonal antibody (mAb) expression level and 
quality in CHO DG44 cells. LC and HC genes are arranged as either the first 
or the second cistron. When using mAb quantification methods based on the 
detection antibodies against HC Fc region, F2A-mediated tricistronic vectors 
appeared to express mAb at higher levels than the IRES-mediated tricistronic 
vectors in both transient and stable transfections. Further analysis revealed that 
more than 40% of products detected in stably transfected pools generated 
using the two F2A-mediated tricistronic vectors were aggregates. LC and HC 
from the F2A stably transfected pools were not properly processed, giving rise 
to LC+F2A+HC or HC+F2A+LC fusion proteins, LC and HC polypeptides 
with F2A remnants, and incorrectly cleaved signal peptides. Both IRES-
mediated tricistronic vectors express mAb with correct sizes and signal 
peptide cleavage. Arrangement of LC as the first cistron in the IRES-mediated 
tricistronic vectors exhibits increased mAb expression level, better growth, 
and minimized product aggregation, while arrangement of HC as first cistron 
results in low expression, slower growth, and high aggregation. The results 
obtained will be beneficial for designing vectors that enhance mAb expression 







Monoclonal antibodies (mAbs) are currently the fastest growing class 
of biotherapeutic molecules (Aggarwal 2010; Nelson et al. 2010). Most mAbs 
in the market are immunoglobulin G (IgG) consisting of two identical heavy 
chain (HC) and two identical light chain (LC) polypeptides assembled via 
disulfide bridges. MAbs are commonly produced by stable transfection of 
Chinese hamster ovary (CHO) cells with the HC, LC and selection marker on 
either one or two separate vectors (Kim et al. 1998; Wurm 2004; Birch and 
Racher 2006; Costa et al. 2010). CHO DG44 cells are commonly used due to 
their compatibility with dihydrofolate reductase (DHFR), an amplifiable 
selection marker. Each gene is under the control of its own promoter and 
transcribed separately. One disadvantage of such designs is that vector 
fragmentation could result in non-expressing clones surviving drug selection 
(Barnes et al. 2007; Ng et al. 2010). The other disadvantage is the lack of 
control over the ratio of LC:HC expression. LC is required to facilitate the 
folding and release of HC from BiP to form a complete IgG monomer (Lee et 
al. 1999). While it has been demonstrated that expression of LC in excess was 
beneficial for mAb expression (Gonzalez et al. 2002; Schlatter et al. 2005; 
Jiang et al. 2006; Li et al. 2007; Chusainow et al. 2009; Ho et al. 2012). The 
ratio of LC:HC expression can also affect mAb qualities such as aggregation 
and glycosylation (Schlatter et al. 2005; Lee et al. 2009; Ho et al. 2012). 
Having HC in excess can cause ER stress (Lenny and Green 1991) and 
proteasome overloading (Fagioli et al. 2001), creating a burden to the cell 
machinery and can inhibit cell proliferation (Schlatter et al. 2005). 
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Tricistronic vectors that express LC, HC, and selection marker genes in 
one mRNA are able to alleviate the above problems of traditional vectors. 
When vectors get fragmented, the mRNA unit would be incomplete and no 
genes would be expressed. Internal ribosome entry site (IRES) elements, 
which have a length of several hundred base pairs, allow expression of 
multiple genes in one mRNA. When IRES elements are included between 
multiple open reading frames (ORFs), the first ORF is translated by the 
canonical cap-dependent mechanism while the rest are translated through a 
cap-independent mechanism (Mountford and Smith 1995; Hellen and Sarnow 
2001). The IRES-driven cap-independent translation has lower efficiency than 
the cap-dependent translation, resulting in lower expression of IRES-driven 
genes (Kaufman et al. 1991; Houdebine and Attal 1999; Hennecke et al. 
2001).  A few studies have used IRES for expressing mAb in mammalian cells 
(Mielke et al. 2000; Jostock et al. 2004; Li et al. 2007; Li et al. 2007; Ho et al. 
2012). It has been demonstrated that an IRES-mediated tricistronic vector 
expressing LC, HC and neomycin in one transcript reduced the occurrence of 
non-expressing clones and controlled the LC:HC ratios at similar levels for all 
clones (Ho et al. 2012). Clones generated using this vector expressed mAb at 
high levels with low aggregation and consistent glycosylation (Ho et al. 2012).    
An alternative approach for co-expressing multiple genes in one 
mRNA is using 2A elements. 2A elements are much shorter than IRES, having 
only 60 to 80 base pairs. 2A linked genes are expressed in one single open 
reading frame and “self-cleavage” occurs co-translationally between the last 
two amino acids, GP, at the C-terminus of the 2A polypeptide, giving rise to 
equal amounts of co-expressed proteins (de Felipe et al. 2006; Doronina et al. 
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2008; Doronina et al. 2008). The exact mechanism involved is still unclear but 
it has been suggested to involve a “ribosomal skip” between the two codons 
with no peptide bond formation between G and P (Donnelly et al. 2001).  
Recent designs have added a furin cleavage sequence upstream of 2A to 
eliminate the additional amino acids which would otherwise remain attached 
to the upstream protein after cleavage (Fang et al. 2005; Fang et al. 2007). 
Furin-2A (F2A) elements have been used for mAb expression in mammalian 
cells (Fang et al. 2005; Fang et al. 2007; Jostock et al. 2010; Camper et al. 
2011; Davies et al. 2011) and for in vivo gene therapy (Li et al. 2012). It has 
been demonstrated that the productivities of F2A-vector derived clones were 
comparable with those derived from an industry reference vector based on 
separate expression unit design (Jostock et al. 2010). The design of the F2A 
vector used in that particular study was not released.  
In studies conducted using F2A for mAb expression, mAb quality has 
only been characterized by western blotting. Detailed quality characterization 
of mAb expressed using F2A has not been reported. Only one study has 
compared IRES and F2A for mAb expression in transient transfections in 
HEK293 cells (Fang et al. 2005) , in which the vector with a HC-F2A-LC 
arrangement gave higher mAb expression than the vector with a HC-IRES-LC 
arrangement. It is unclear which element is better when the positions of HC 
and LC are reversed. In this work, we sought to identify whether IRES or F2A 
works better for expression of humanized IgG1 in gene amplifiable CHO 
DG44 cells. We designed four tricistronic vectors expressing the LC, HC, and 
dihydrofolate reductase (DHFR) in one mRNA to compare transient and stable 
mAb expression in CHO DG44 cells. The quality of expressed mAb, including 
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LC and HC polypeptide size, signal peptide cleavage, and aggregation, was 
characterized by western blotting, LC-MS/MS, and size exclusion 
chromatography (SEC), respectively.       
 
4.3 Materials and methods 
4.3.1 Cell culture and media 
Parental DHFR-deficient CHO DG44 cells (Life Technologies, 
Carlsbad, CA) were cultured in suspension using a protein-free medium 
consisting of HyQ PF (Hyclone, Logan, UT) and CD CHO (Life 
Technologies) at a 1:1 ratio and supplemented with 1 g L
-1
 sodium bicarbonate 
(Sigma-Aldrich, St. Louis, MO), 6 mM glutamine (Sigma-Aldrich), 0.1% 
Pluronic F-68 (Life Technologies), and 1% hypoxanthine and thymine (HT) 
(Life Technologies). Regular passaging was carried out every 3 to 4 days in 




 in 25 
mL fresh medium. Cell density and viability were measured using the trypan 
blue exclusion method on an automated Cedex counter (Innovatis, Bielefeld, 
Germany).  
4.3.2 Vector construction 
Two tricistronic vectors, L-IRES-H and H-IRES-L (Fig. 4.1), were 
obtained by replacing neomycin with DHFR in the previously described IRES-
mediated tricistronic vectors expressing a biosimilar IgG1 mAb, Herceptin 
(anti-HER2) in section 3.3.2. The IRES used to link the LC and HC genes is a 
wild-type encephalomyocarditis virus (EMCV) IRES (IRESwt). DHFR cDNA 
was cloned from the pSV2-DHFR vector (ATCC, Manassas, VA). Another 
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two tricistronic vectors, L-F2A-H and H-F2A-L, were constructed by 
replacing the region of LC-IRESwt-HC with either LC-F2A-HC or HC-F2A-
LC (Fig. 4.1). F2A, the furin cleavage sequence linked to the foot-and-mouth 
disease virus (FMDV) 2A sequence, was designed based on the literature 
(Fang et al. 2007). The cDNA encoding F2A was synthesized by 1
st
 BASE 
(Singapore). The LC cDNA, F2A, and HC cDNA were assembled by 
overlapping PCR. F2A vectors expressing biosimilar IgG1 Humira (anti-
TNFα) and Avastin (anti-VEGF) were generated by changing the LC and HC 
variable regions of the anti-HER2 vectors. The anti-TNFα and anti-VEGF 
variable region DNA were synthesized by Genescript (Piscataway, NJ). All 



















Figure 4.1Schematic representation of the four tricistronic vectors for 
mAb expression. (A) Structure of different vectors. (B) DNA sequences of 
the 3’ end of IRESwt and IRESatt, amino acid sequences of signal peptide, 
F2A peptide, N- and C-termini of LC and HC are listed. The conserved 
regions of furin cleavage site and 2A peptide are highlighted in dotted boxes. 
CMV, human cytomegalovirus IE gene promoter; SpA, simian virus 40 early 
polyadenylation signal; IRESwt, wild type encephalomyocarditis virus 
(EMCV) internal ribosomal entry site; IRESatt, mutated EMCV IRES with 
attenuated translation efficiency; F2A, furin-2A peptide; LC, light chain 
cDNA; SPL, LC signal peptide; HC, heavy chain cDNA; SPH, HC signal 
peptide; DHFR, dihydrofolate reductase cDNA.  
 
4.3.3 Transient transfections 
Transient transfection of DG44 cells were carried out using 
Nucleofector kit V and program U-24 on a Nucleofector I system (Lonza, 
Cologne, Germany). In each transfection, 2×10
6
 cells were co-transfected with 
2 µg of the appropriate mAb encoding plasmid and 0.2 µg of a green 
fluorescence protein (GFP) encoding plasmid pMax-GFP (Lonza). The GFP 
plasmid acted as an internal control to account for variations in transfection 
efficiency. The transfected cells were then resuspended with 2 mL of HT-
containing protein-free medium in 6-well suspension culture plates (Greiner 
Bio-One GmbH, Germany). Transfections were carried out in duplicates. At 
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48 h post-transfection, cells and supernatant were collected to measure GFP 
fluorescence intensity using a FACS Calibur (Becton Dickinson, MA) and to 
measure the mAb concentration using an enzyme-linked immunosorbent assay 
(ELISA) respectively. ELISA was performed as previously described in 
section 3.3.5 using capture antibody of affinity purified goat anti-human 
IgA+IgG+IgM (HC+LC) (KPL, Gaithersburg, MD) and detection antibody of 
goat anti-human IgG (Fc specific) conjugated to alkaline phosphatase (Sigma-
Aldrich).   
4.3.4 Stable transfections 
Transfections to generate stably transfected pools were also performed 
using Nucleofector Kit V and program U-24 on a Nucleofector I system 
(Lonza). 1×10
7
 CHO DG44 cells were transfected with 5 µg of BglII 
linearized mAb expressing plasmid. Transfection for each of the four vectors 
was carried out in duplicates. The transfected cells were each incubated in 2 
mL HT-containing protein-free medium in a 6-well suspension culture plate 
for 24 h. Samples were next centrifuged at ~100×g for 5 min and cell pellets 
resuspended in 15 mL HT- and protein-free medium in 125 mL shake flasks to 
select for stable transfectants. Selection required around 2 to 3 weeks. When 
the stably transfected pools recovered with viability above 95%, gene 
amplification was induced by passaging in medium containing 50 nM 
methotrexate (MTX) (Sigma-Aldrich). The amplification process also required 
2 to 3 weeks. Productivity of stable transfection pools at 50 nM of MTX was 
determined in 125 mL shake flask batch cultures. Cells were seeded in 25 mL 




. Growth was monitored every 
day until the end of culture when viability measurements dropped below 50%. 
83 
 
Supernatant was collected at the end of culture and analyzed for mAb 
concentration using a nephelometric method on an IMMAGE 800 
immunochemistry system (Beckman Coulter, Buckinghamshire, England). 
The IMMAGE 800 system utilized anti-human Fc region antibodies for IgG 
detection. The specific productivity (qmAb) was calculated as the mAb 
concentration divided by the integrated viable cell density (IVCD) which was 
determined based on the trapezoidal method (refer to section 3.3.5). 
Intracellular LC and HC amounts were performed as described in 3.3.6.     
4.3.5 Western blotting analysis  
Supernatants, which were collected from stably transfected pools at the 
end of culture, containing 10 ng of mAb as determined using the 
nephelometric method were mixed with NuPAGE sample loading buffer and 
reducing buffer (Life Technologies) and heated at 70°C for 2 min. Samples 
were loaded onto NuPAGE 4-12% Bis-Tris gel (Life Technologies) in MES 
buffer (Life Technologies). Precision plus protein dual color standards (Bio-
Rad Laboratories, Hercules, CA) were used as molecular weight ladder and to 
check for transfer to the membrane. Proteins were transferred to 
polyvinylidene difluoride (PVDF) membranes (Life Technologies) using the 
iBlot system (Life Technologies). Membranes were blocked in 5% blocking 
milk (Bio-Rad Laboratories) in TBS with 0.1% Tween-20 (Bio-Rad 
Laboratories) for 1 h at room temperature and incubated overnight in HRP 
conjugated goat anti-human IgG Fc antibody (1:5000; Bethyl Laboratories, 
Montgomery, TX) and HRP conjugated goat anti-human IgG Kappa LC 
(1:20000; Bethyl Laboratories). Detection was done using ECL Prime 
(Amersham-GE Healthcare Life Sciences, Piscataway, NJ) and exposed on 
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Lumi-Film Chemiluminescent Detection Film (Roche Applied Science, 
Indianapolis, IN). 
4.3.6 Purifying mAb using protein A column  
mAb in the supernatant collected at the end of culture of stable 
transfection pools was purified by affinity chromatography using protein A 
column on a GE AKTA explorer 100 (GE Healthcare, Uppsala, Sweden) as 
previously described in section 3.3.8. This was carried out for duplicate 
transfected pools generated using each of the four tricistronic vectors.  
4.3.7 SDS-PAGE separation of protein A purified sample 
Protein A purified mAb in stable transfection pools generated using 
different tricistronic vectors were separated by SDS-PAGE. Prior to SDS-
PAGE separation, 10 µg of each purified mAb sample was denatured by 
boiling in the presence of 2-mercaptoethanol (Sigma-Aldrich) at 95
o
C for 5 
min in the loading buffer containing 0.063 M Tris-HCl at pH of 6.8, 10.5% 
glycerol (BDH Chemicals, London, England), and 10% (w/v) SDS (Bio-Rad, 
Hercules, CA) and 0.1% bromophenol blue (GE Healthcare), and then ran at 
15 mA for 90 min in a 10% T polyacrylamide gel (in-house created). Upon 
completion, the gel was immediately fixed and stained using 0.3% (w/v) 
Coomassie Brilliant Blue R-250 (Peirce, St. Louis, IL) in 45% methanol and 
10% acetic acid, and washed with 10% methanol and 5% acetic acid to 
remove the background staining. The gel was scanned on Imagescanner III 
(GE Healthcare) and the relative intensities of the protein bands for each lane 
were quantified using the ImageQuant TL 7.0 software (GE Healthcare) based 
on the peak heights of each generated line graph. 
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4.3.8 LC-MS/MS analysis of protein A purified mAb 
LC-MS/MS analysis was performed on each visible protein bands 
observed on the coomasie blue stained SDS-PAGE page gel. The bands on the 
gel were excised and washed in 150 µL of 50% acetonitrile (Fisher Scientific, 
Pittsburgh, PA) solution containing 25 mM ammonium bicarbonate. The 
washing solution was removed and the excised gels were dried using the 
Savant Speedvac (Savant Instruments, Holbrook, NY). Proteins within the 
excised gels were reduced by adding 25 µL of 20 mM DTT and incubated at 
55°C for 60 min. Upon removal of the reducing agent, alkylation of the 
reduced proteins was facilitated by adding 25 µL of 55 mM iodoacetamide 
(Fluka, Steinheim, Germany) and incubated at room temperature in the dark 
for 45 min. The excised gels were then washed repeatedly in 100mM 
ammonium bicarbonate solution, followed by 100% acetonitrile. After drying 
the excised gels using the Savant Speedvac, 20 µL of trypsin (Promega, 
Madison, WI) at 0.04 µg µL
-1
 in 25 mM ammonium bicarbonate solution was 
added to each excised gel sample. The enzyme-sample mixtures were 
incubated with agitation at 37°C overnight. Each digested sample was 
extracted by adding 20 µL of acetonitrile with sonication. Each acetonitrile 
solution containing digested proteins was transferred to a new clean vial and 
dried using the Savant Speedvac. Prior to injecting the samples onto the LC-
MS/MS system, each sample was reconstituted in 5 µL of aqueous buffer 
containing 0.1% formic acid (Sigma-Aldrich) and 1% methanol (Fisher 
Scientific).  
LC-MS/MS analyses were performed on a Velos Orbitrap mass 
spectrometer (Thermo Fisher Scientific, San Jose, CA) coupled to a 
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nanoAcquity UPLC system (Waters, Milford, MA) fitted with a 180 µm x 20 
mm Symmetry C18 peptide trap (Waters) and a 75 µm x 200 mm BEH130 
C18 1.7-µm particle size analytical column (Waters). Depending on the 
peptide concentration of each sample, 1 to 2 µL of peptide digest was injected. 
Peptides were resolved by applying a linear binary gradient from 2 to 35% 
solvent B at 300 nL min
-1
 over 60 min at 35 °C, where solvent A and B were 
0.1% (v/v) formic acid in Milli-Q water (Millipore, Billerica, MA) and 0.1% 
formic acid in acetonitrile, respectively. To minimize sample carryover, a 
dedicated column wash run (10 to 95% B in 30 min) followed by column re-
equilibration (2% B for 30 min) was performed prior to the next sample 
injection. The nano-ESI source was fitted with a 30-µm stainless steel nano-
bore emitter (Thermo Fisher Scientific) with 1.7 kV applied near the tip. The 
MS instrument method used was the data-dependent acquisition mode that 
specified each orbitrap survey scan (at resolution 60,000) to be linked to a 
maximum of 10 MS/MS events; each with maximum ion trap fill time of 25 
ms and isolation window of 2 m/z. The threshold for triggering an MS/MS 
was set at 500 counts. The ion trap CID fragmentation employed an activation 
time of 10 ms, q value of 0.25 and normalized collision energy of 35%. 
Charge state screening was enabled, with unknown and singly charged states 
excluded. Dynamic exclusion was enabled with a list size of 500 and 
exclusion time of 60 s. 
Acquired LC-MS/MS data were processed by the Proteome Discoverer 
1.3 software (Thermo Fisher Scientific) using the Sequest search engine. The 
peptide and fragment ion mass tolerances used were ± 5 ppm and ± 0.5 Da, 
respectively. The specified search parameters were carbamidomethylation of 
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cysteine as fixed modification, oxidation of methionine as dynamic 
modification and tryptic digestion with 2 missed cleavages. Depending on the 
tricistronic vector configuration used (Fig. 4.1), each sample LC-MS/MS data 
was searched against the relevant full protein sequence to determine the actual 
expressed protein sequence for each excised gel band, with its corresponding 
sequence coverage calculated. 
4.3.9 Aggregation analysis of protein A purified mAb  
The aggregation of protein A purified mAb collected at the end of 
culture of stable transfection pools was determined using size exclusion 
chromatography (SEC) coupled to a UV-visible detector and a dynamic light 
scattering detector. Analysis was carried out for duplicate pools generated 
using each tricistronic vector. The instrument setup consisted of a HPLC 
system (Shimadzu, Kyoto, Japan) as previously described in section 3.3.10. 
The hydrodynamic radius measured by the light scattering detector was used 
to calculate the molecular weight of the different compounds present under 
each peak. The different fractions were assigned respectively to aggregates, 
monomer and fragments based on their measured molecular weights and 
elution time. The small rightmost peaks are a result of components in the 
buffer which the protein A purified samples are eluted in. 
 
4.4 Results 
4.4.1 Design of IRES- and F2A-mediated tricistronic vectors 
An anti-HER2 IgG1 biosimilar was first used as a model mAb to 
compare IRES and F2A for mAb expression level and quality. Four 
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tricistronic vectors were designed to express the anti-HER2 LC, anti-HER2 
HC, and DHFR under the control of one CMV promoter (Fig. 4.1). LC and 
HC were arranged in either the first or the second cistron. The two vectors in 
which LC and HC are linked by a wild type EMCV IRES (IRESwt) are 
designated as L-IRES-H and H-IRES-L, respectively. Vectors in which LC 
and HC are linked by F2A are designated as L-F2A-H and H-F2A-L, 
respectively. The DHFR selection marker downstream of an attenuated EMCV 
IRES (IRESatt) in the third cistron was used for all the vectors for fair 
comparison. Application of IRESatt on DHFR will reduce its expression and 
can enhance stringency of selection for high producers (Ng et al. 2007). Tight 
coupling of product gene and selection marker in one mRNA can reduce 
occurrence of non-expressing clones (Rees et al. 1996; Ng et al. 2007; Ho et 
al. 2012).  
4.4.2 Comparing IRES and F2A for mAb expression   
IRES and F2A were first compared for transient expression levels of 
anti-HER2 in 6-well plate cultures (Fig. 4.2A and B). As cap-dependent 
translation of the first cistron is more efficient than IRES-driven translation, 
the L-IRES-H vector will express LC in excess, and the H-IRES-L vector will 
express HC in excess. Consistent with previous reports that LC is more 
favorable for mAb expression (Gonzalez et al. 2002; Schlatter et al. 2005; Li 
et al. 2007; Ho et al. 2012), we observed that the mAb expression level from 
the L-IRES-H vector to be around double that from the H-IRES-L vector. A 
previous study had reported that mAb expression from a F2A vector similar to 
H-F2A-L was greater than that from a EMCV IRES vector similar to H-IRES-
L in transient transfections performed using HEK293 cells (Fang et al. 2005). 
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We observed that both F2A-mediated tricistronic vectors, showed higher mAb 
expression levels than those from the IRES-mediated tricistronic vectors 
regardless of LC and HC positions. L-F2A-H had the highest expression with 
titers at around 500 ng mL
-1
, three-fold higher than the titer of the best 
performing IRES vector, L-IRES-H.   
Stable anti-HER2 expressions for the four vectors were next compared 
using shake flask batch cultures (Fig. 4.3A). Specific mAb productivity 
(qmAb) from the four vectors displayed a similar trend as that in transient 





(pcd). The H-IRES-L stably transfected pools had lower qmAb of 2.7 pcd, 
which was 70% of the L-IRES-H stable pools. Both F2A-mediated tricistronic 
vectors still exhibited higher qmAb than the IRES-mediated tricistronic 
vectors. Compared to L-IRES-H, L-F2A-H qmAb was 1.4-fold and H-F2A-L 
was 1.2-fold higher, reaching 5.4 pcd and 4.4 pcd, respectively.  
Stably transfected pools generated using the four vectors also exhibited 
differences in growth (Fig. 4.3B). The L-IRES-H stable pools grew fastest, 
followed by pools generated using the L-F2A-H, H-F2A-L and H-IRES-L 
vectors. The viability of the former two pools dropped below 50% at day 10, 
one day earlier than the latter two pools. The L-IRES-H stable pools also had 
highest peak cell density and IVCD, followed by L-F2A-H, H-F2A-L, and H-
IRES-L. Due to the lower qmAb and even lower IVCD as compared to L-
IRES-H, the H-IRES-L stable pool had 50% lower titer (Fig. 4.3C). The lower 
IVCD of the F2A pools also resulted in titers of L-F2A-H dropping to 1.1-fold 








Figure 4.2 Comparison of the four tricistronic vectors for mAb expression 
in transient transfections. CHO DG44 cells were co-transfected with an 
appropriate mAb expressing vector containing IRES or F2A between the LC 
and HC gene and a GFP expressing vector. At 48 h post-transfection, 
supernatant and cells were collected for analysis of mAb concentration using 
ELISA and GFP expression using FACS, respectively. (A) Sample results of 
measured mAb concentration (black bars) and GFP mean fluorescence 
intensity (gray bars). Each value and standard deviation were obtained from a 
set of duplicate transfections.   (B) Normalized mAb expression for each 
vector. Results represent mAb concentration measured in the culture 
supernatant normalized to firstly the internal control, GFP expression, to 
normalize the transfection efficiency and next mAb expression from the L-
IRES-H vector. Each point represents the average and standard deviation of 





 We next evaluated the stable intracellular LC:HC ratio for each vector 
using ELISA (Fig. 4.3D). The two IRES vectors L-IRES-H and H-IRES-L had 
ratios of around 4.5 and 0.5 respectively. This was expected as expression of 
the genes downstream of IRES was lower due to less efficient IRES 
translation. Surprisingly the F2A vectors L-F2A-H and H-F2A-L had ratios of 
2.8 and 5.4 with significant variation. Based on the mechanism of F2A, ratios 
closer to one were expected. Follow-up western blotting of the products 











Figure 4.3 Comparison of the four tricistronic vectors for mAb expression 
in stable transfections. Stably transfected pools were generated by 
transfection of CHO DG44 cells with different tricistronic vectors containing 
either IRES or F2A between the LC and HC gene. Each pool was 
characterized for (A) specific mAb productivity (qmAb) measured in 
pg/cell/day (pcd), (B) growth data collected including viable cell density 
(VCD) and culture viability, (C) titer and (D) intracellular LC:HC ratio. Each 
point represents the average and standard deviation of two measurements of 




4.4.3 Western blotting analysis of mAb products expressed by IRES and 
F2A 
Supernatant collected at the end of culture of CHO DG44 stably 
transfected pools generated using each of the tricistronic vectors were first 
analyzed under non-reducing conditions to characterize the products being 
secreted (Fig. 4.4A). Product from the L-IRES-H vector contained complete 
IgG1 monomers HC2LC2, LC2 dimer, and LC monomer, a sign that the L-
IRES-H vector expressed LC in excess. Product from the H-IRES-L vector 
consisted of HC2LC2 complete IgG1 and HC2 dimers, providing evidence of 
expression of excess HC. Products from both F2A-mediated tricistronic 
vectors presented a smear with molecular weight greater than 100 kDa. The 
fractions above 150 kDa could correspond to mAb aggregates, and those 
around 150 kDa could be degraded IgG1 monomers, suggesting that mAb 
expressed from F2A was not stable. The two thin bands expressed from the L-
F2A-H and H-F2A-L vectors with molecular weights of 100 kDa could be 
HC2, and the one band from the L-F2A-H vector with a molecular weight of 
80 kDa could be a fusion protein of LC+F2A+HC.   
Western blotting analysis of reduced products in the supernatant was 
next performed to identify the different components in the IgG1 being 
produced using the various vectors (Fig. 4.4B). Two bands were detected 
within supernatants from the two IRES-mediated tricistronic vectors, L-IRES-
H and H-IRES-L. Their molecular weights corresponded to the standard HC 
and LC, respectively. Comparing the relative intensities of these two bands 
indicated that the L-IRES-H vector expressed LC in excess and the H-IRES-L 
vector expressed HC in excess. Interestingly, three bands were detected in 
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reduced products from the L-F2A-H vector. The top band presents a molecular 
weight of approximately 80 kDa, which is equal to the sum of the molecular 
weights of LC, F2A, and HC suggesting that it is a fusion protein of 
LC+F2A+HC. The middle band exhibited similar size to the standard HC. The 
bottom band had slightly greater size than the standard LC, indicating a 
possible failed removal of 2A polypeptide residue by furin cleavage. Four 
bands were detected in products from the H-F2A-L vector. The top two bands 
could be the fusion proteins of HC+F2A+LC and HC+F2A based on their 
molecular weights. The other two bands had similar sizes to the standard HC 
and LC, respectively. Presence of these fusion proteins could also be affecting 
binding of the detection antibodies used for ELISA, causing the unexpected 







(B)     
  
Figure 4.4 Western blot analysis of supernatant in stably transfected 
pools generated using the four tricistronic vectors. Each sample of crude 
supernatant was analyzed under both (A) non-reducing and (B) reducing 
conditions by western blot. A commercial human affinity purified myeloma 
Ig1 (Sigma-Aldrich) and supernatants from cells transfected with either a 
vector expressing only HC or a vector expressing only LC were used as 
positive control, and supernatant from non-transfected cells as negative control 
(N). All blots shown are only from the first replicates generated as duplicates 
were observed to exhibit the same product patterns. 
 
 IRESwt has three ATGs at the 3’ end, which are designated as ATG-
10, ATG-11, and ATG-12 as described previously (Kaminski et al. 1990). 
ATG-12 is used as the start codon of mAb gene for higher translation 
efficiency (Davies and Kaufman 1992; Kaminski et al. 1994; Qiao et al. 2002; 
Bochkov and Palmenberg 2006; Martin et al. 2006). Translation initiation of 
EMCV IRES-driven gene primarily occurs at ATG-11 and partially at ATG-
12 (Davies and Kaufman 1992). Four extra amino acid residues, MATT, will 
be attached to the signal peptide of the IRES-driven LC or HC in those 
polypeptides which translation initiation occurs at ATG-11. “Self-cleavage” of 
2A occurs between the last two amino acids, GP. Following self-cleavage, P 
will be attached to the signal peptide of LC or HC downstream of 2A and the 
rest of the 2A residues will attach to the C-terminus of the upstream gene. 
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Addition of a furin cleavage site upstream of 2A can eliminate the 23 amino 
acid residues which would otherwise be attached to the HC or LC (Fang et al. 
2005). When HC is arranged upstream of F2A, design of a furin cleavage 
sequence with a second basic amino acid, such as RRKR, allowed 
carboxypeptidases to cleave both the RR residues left after furin cleavage 
together with the K on the C-terminus of HC  (Fang et al. 2007). 
To characterize the protein more accurately than just using western 
blotting, the reduced protein A purified mAb samples from duplicate pools of 
each vector were separated on SDS-PAGE (Fig. 4.5) and the bands were 
excised for LC-MS/MS analysis. The estimated molecular weight of each 
band, the polypeptide sequence as determined by peptide mapping and its 
associated sequence coverage, and the relative abundance of the expressed 
mAb chains are shown in Table 4.1.  
 
Figure 4.5 SDS-PAGE analysis of purified mAb in stably transfected 
pools generated using the four tricistronic vectors. Protein A purified 
supernatant was reduced and analyzed on a SDS-PAGE gel. Protein bands 
were visualized by coomasie blue staining. All gels shown are only from the 






































Table 4.1 Relative abundance analysis of reduced antibody HC and LC variants by densitometry and sequence identity confirmation by 
peptide mapping.  
Each point represents the average and standard deviation of two measurements from two stable transfection pools. “ND” means not detected. 
Gel band 
(kDa) 
Peptide mapping detected 
sequence (#Amino acids) 


























LC (214) 87.0 ± 1.4 47.5 ± 2.1 87.5 ± 6.4 44.0 ± 0.0 ND ND ND ND 
SPL+LC(236) ND ND ND ND ND ND 79.0 ± 1.4 39.0 ± 2.8 
30 LC+F2A (242) ND ND ND ND 86.5 ± 12.0 37.0 ± 0.0 ND ND 
50 
HC (450) 70.5 ± 0.7 52.5 ± 2.1 72.0 ± 0.0 56.0 ± 0.0 ND ND 71.0 ± 1.4 32.0 ± 0.0 
SPH+HC (469) ND ND ND ND 74.0 ± 0.0 42.0 ± 0.0 ND ND 
55 SPH+HC+F2A (496) ND ND ND ND ND ND 45.5 ± 29.0 12.5 ± 0.7 
80 
LC+F2A+SPH+HC (711) ND ND ND ND 67.0 ± 2.8 21.0 ± 0.0 ND ND 




The excised gel bands from the L-IRES-H or H-IRES-L vector at 
molecular weights of 25 and 50 kDa were confirmed by LC-MS/MS analyses 
as LC and HC polypeptides, respectively. The excised gel bands from the L-
F2A-H vector corresponding to molecular weights of 30, 50, and 80 kDa were 
LC and F2A fusion proteins (LC+F2A), HC with incorrect or uncleaved signal 
peptide (SPH+HC), and fusion proteins of LC+F2A+SPH+HC, respectively. 
The four excised gel bands from the H-F2A-L vector with molecular weights 
of 25, 50, 55 and 80 kDa were LC with incorrectly cleaved signal peptide 
(SPL+LC), HC, SPH+HC+F2A, and SPH+HC+F2A+SPL+LC, respectively. No 
incorrect signal peptide cleavage was observed on LC and HC in the IRES 
generated pools. The four extra amino acids which might attach to the signal 
peptides during translation initiation at IRES ATG-11 did not seem to affect 
the signal peptide cleavage. In contrast, incorrectly cleaved signal peptides 
were detected in both LC and HC expressed downstream of F2A as indicated 
by the detection of SPL+LC and SPH+HC with signal peptide residues 
attached. This is possibly due to attachment of the extra P from F2A to the 
signal peptide.  
Cleavage of F2A was less efficient in products expressed from the L-
F2A-H vector than the H-F2A-L vector. Occurrence of LC+F2A+HC or 
HC+F2A+LC fusion proteins indicates cleavage failure at both furin and 2A 
recognition sites. Existence of LC+F2A or HC+F2A indicates successful 
cleavage at the 2A recognition site but cleavage failure at the furin recognition 
site. 21% of the LC and HC expressed from the L-F2A-H vector existed as a 
LC+F2A+SPH+HC fusion protein. The rest were cleaved into similar 
abundances of LC+F2A (37%) and SPH+HC (42%) as expected. 16.5% of 
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product expressed from the H-F2A-L vector was detected as 
SPH+HC+F2A+SPL+LC fusion proteins. The remaining was cleaved into 
products consisting of 32% HC, 12.5% SPH+HC+F2A, and 39% SPL+LC. The 
amount of SPL+LC was similar to the sum of HC and SPH+HC+F2A. 
4.4.4 Aggregation analysis of mAb products expressed by IRES and F2A 
Aggregation of protein A purified anti-HER2 IgG1 mAb produced in 
stable transfection pools was analyzed and quantified using SEC coupled to a 
UV and a dynamic light scattering detector. As replicate pools gave identical 
chromatograms, only one representative UV chromatogram is shown for each 
vector (Fig. 4.6A to D). Molecular weight of each peak was calculated based 
on their respective hydrodynamic radius. Peaks with average molecular weight 
greater than the complete IgG1 monomer were grouped as aggregates and 
those with lower molecular weight were grouped as fragments. Relative mass 
amounts of aggregates, monomers and fragments were determined using the 
respective peak area under the UV chromatograms. The IgG1 monomer, 
aggregate and fragment distributions for each vector design is shown in figure 
4.6E. The level of aggregates was less than 1% in products from the L-IRES-
H vector. In contrast, products from H-IRES-L vector had 28% of aggregates 
and 13% of mAb fragments. Products from both F2A-mediated vectors had 
approximately 45% of aggregates and less than 1% of mAb fragments. In 
contrast to multiple aggregate peaks observed in H-IRES-L (Fig. 4.6B), F2A-
mediated vectors only had one aggregate peak (Fig. 4.6C and D), suggesting 
different aggregation mechanisms. Interestingly, aggregates in H-IRES-L did 
not show up on western blots performed using the unpurified supernatant 
while aggregates in the F2A vectors were visible (Fig. 4.4A). This is possibly 
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due to differences in the nature and components of the aggregates. The amount 
of fragments detected also appeared lower than the levels observed during 
western blotting in 4.4A. The fragments could possibly be composed mainly 
of incompletely processed peptides which do not bind as well to protein A and 
could be washed off during the wash step of protein purification. The 


















Figure 4.6 SEC analysis of protein A purified mAb in stably transfected 
pools generated using the four tricistronic vectors. Species within protein A 
purified mAb were separated by SEC followed by the identification and 
quantification of species by UV detection and light scattering, respectively. 
Analysis was done for duplicate stable transfection pools generated using each 
of the four tricistronic vectors. As results were consistent, only one typical 
chromatogram of the first pools analyzed from UV detector for vector (A) L-
IRES-H, (B) H-IRES-L, (C) L-F2A-H, (D) H-F2A-L, are shown. (E) 
Quantitative comparison of aggregates, complete IgG1 monomers and 
incomplete IgG1 fragments of four vectors for different species. Each bar in 
figure E represents the average and standard deviation of four measurements 
from two stable transfection pools. 
 
4.4.5 Cleavage efficiency of F2A for other IgG1 mAbs 
Previous reports which utilized F2A for expressing mAb did not report 
any issues with 2A peptide cleavage under their tested conditions (Fang et al. 
2005; Fang et al. 2007; Jostock et al. 2010; Davies et al. 2011) while we 
observed inefficient F2A cleavage for anti-HER2 IgG1 expression in CHO 
DG44 cells. To investigate whether cleavage efficiency is mAb product 
dependent, we expressed two more IgG1 mAbs, anti-TNFα and anti-VEGF, in 
transient transfections and checked for cleavage efficiency using western 
blotting under reducing conditions (Fig. 4.7). Bands corresponding to 





























for reduced anti-HER2 IgG1 expressed using the L-F2A-H vector and similar 
LC+F2A+HC, HC+F2A, HC and LC bands were observed for H-F2A-L. The 
products detected for anti-HER2 in the transient transfections are similar to 
that in products from stable transfections from both F2A vectors as shown 
earlier in figure 4.4B. Fusion proteins and uncleaved F2A residues were also 
observed for reduced samples of anti-TNFα and anti-VEGF. Reduced product 
bands similar to anti-HER2 were observed for the blots of both L-F2A-H and 
H-F2A-L except for an extra smaller band corresponding to LC for product 
from the L-F2A-H vectors in addition to the LC+F2A product band.            
 
Figure 4.7 Western blot analysis of transiently expressed anti-HER2, anti-
TNFα and anti-VEGF IgG1 mAbs. CHO DG44 cells were transfected with 
an appropriate mAb expressing tricistronic vector expressing anti-HER2, anti-
TNFα, and anti-VEGF. At 48 h post-transfection, supernatant was collected 
for western blotting under reducing condition. The mAb loaded into each lane 
is identical as determined by ELISA. A commercial human affinity purified 
myeloma Ig1 (Sigma-Aldrich) and supernatants from cells transfected with 
either a vector expressing only HC or a vector expressing only LC were used 
as positive control, and supernatant from non-transfected cells as negative 
control (N). All blots shown are only from the first replicates generated as 





We designed four tricistronic vectors to compare the use of EMCV 
IRES and F2A for IgG1 mAb expression level and quality in CHO DG44 
cells. The mAb quantification methods that we used in this work, ELISA and 
nephelometric methods are based on detection antibodies against the Fc region 
of the product mAb. Besides the complete IgG monomer, these assays would 
detect any components containing HC, such as high molecular weight 
aggregate and HC2 dimer, resulting in falsely high mAb titers. By measuring 
mAb in crude supernatant with these two assays, F2A vectors appeared to give 
higher mAb expression than IRES vectors in both transient and stable 
transfections. However, after considering the product distribution of complete 
IgG1 monomers, aggregates and fragments detected during SEC analysis (Fig. 
4.6E), the amount of actual IgG1 monomer was significantly lower using H-
IRES-L and the F2A constructs (Fig. 4.8). Actual titer in L-IRES-H stable 
transfection pools was unchanged and the highest at 123 mg L
-1
, while titer of 
the H-IRES-L, L-F2A-H and H-F2A-L stable transfection pools dropped to 32 
mg L
-1
, 75 mg L
-1
 and 60 mg L
-1
 respectively.  
Arrangement of LC as the first cistron gave higher mAb expression 
than arrangement of HC as the first cistron in both IRES- or F2A-mediated 
tricistronic vectors. This is understandable for the IRES-mediated tricistronic 
vectors as the L-IRES-H vector expressed LC in excess (Fig. 4.4) and extra 
LC is favorable for mAb expression (Gonzalez et al. 2002; Schlatter et al. 
2005; Li et al. 2007; Ho et al. 2012). Both L-F2A-H and H-F2A-L vectors 
expressed LC and HC in similar amounts (Table 4.1). One possible 
explanation is LC+F2A from the L-F2A-H vector can still be processed and 
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does not create any burden to the cell’s protein folding and assembly 
machinery while HC+F2A from the H-F2A-L vector has detrimental effects. 
Another possible explanation is that LC+F2A+HC and HC+F2A+LC mRNAs 
have different secondary structures, and the former one has higher translation 
efficiency and thus yielding higher mAb expression level.  
 
 
Figure 4.8 Estimation of the actual amount of complete IgG1 monomer 
produced in stably transfected pools generated using the four tricistronic 
vectors. The actual monomer amount was estimated based on the product 
titers measured by the nephelometer and the relative monomer peak area 
observed on SEC as shown in figure 4.6E. Each point represent the average 
and standard deviation of two measurements from two stably transfected 
pools. 
 
 Secretory proteins like the IgG1 LC and HC are bound by signal 
recognition particles (SRP) at their signal peptide sequence as they emerge 
from the ribosome within the cytosol and are targeted to SRP receptors of 
translocon complex on the ER membrane for translocation into the ER (Walter 



































regions: a hydrophilic and net-positively charged N-terminal region, a central 
hydrophobic region and a polar C-terminal region (von Heijne 1985). Studies 
have shown that an increase in the hydrophobicity of the N-terminal region 
can cause cleavage of the signal peptide to shift upstream (Nothwehr and 
Gordon 1990). In our vector designs, four additional amino acid residues, 
MATT, would be added to the IRES driven LC or HC peptides and one 
additional proline residue would be added for F2A driven peptides. 
Hydrophobicity index of the 19 amino acid HC signal peptide (SPH), HC 
signal peptide with MATT residues (MATT+SPH) and HC signal peptide with 
an additional P (P+SPH) were analyzed using the Kyte and Doolittle 
hydrophobicity index (Fig. 4.9) (Kyte and Doolittle 1982). MATT residues 
would cause a lower net change in hydrophobicity of 0.533 as compared to 
addition of only one P residue causing a change of -1.067. This larger 
increased difference in hydrophobicity due to the P residue from F2A could be 
the reason causing incorrect cleavage of the signal peptide. Another reason for 
poor signal peptide cleavage could be due to the F2A reaction being inhibited 
by interactions between the  nascent protein structure and the translocon 
complex (De Felipe et al. 2010). SRP binding to the signal peptide 
downstream of F2A does not occur and in turn proper signal peptide cleavage 
is inhibited. It is also interesting to note that signal peptide cleavage prediction 
using SignalP 4.1 (Petersen et al. 2011) did not indicate any changes to the 
cleavage site even with the additional residues.  
Incomplete cleavage of F2A had been observed when used with 
various fluorescent reporter proteins (De Felipe et al. 2010; Chan et al. 2011). 
Previous reports of using F2A successfully for mAb expression had been in 
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CHOK1 (Fang et al. 2007; Jostock et al. 2010), CHOK1SV (Davies et al. 
2011) and HEK 293 (Fang et al. 2005) cells and none of the reports stated that 
they were using humanized IgG1 as model mAb. This is the first report of 
using the F2A for humanized IgG1 expression in CHO DG44 cells and the 
possibility of cell and product specificity affecting cleavage should also not be 
discounted. All three humanized IgG1 products expressed using the F2A 
system in CHO DG44 cells exhibited the presence of incompletely processed 
LC and HC products showing that the processing issues was not specific to 
only the anti-HER2 mAb that was initially characterized. While the 2A 
peptide cleavage was an issue regardless of product or arrangement, we made 
some interesting observations regarding the furin cleavage. Firstly, the 
different cistron arrangements affected the furin cleavage efficiency. 
Arrangement of LC upstream of F2A inhibited cleavage efficiency more than 
arrangement of HC upstream of F2A. This can be seen from the greater 
abundance of uncleaved LC+F2A in the L-F2A-H pools as compared to 
HC+F2A in the H-F2A-L pools in the western blot (Fig. 4.4B). Secondly, 
furin cleavage appeared to be dependent on 2A processing as we did not 
observe fusion proteins with F2A attached to the N-terminal of the protein 
translated from the second cistron, e.g. F2A+HC or F2A+LC. Thirdly, the 
furin cleavage efficiency was higher for anti-TNFα and anti-VEGF as 
compared to anti-HER2 in the L-F2A-H vectors. It is unclear why this was 
observed as the C-terminal ends of the LC attached to the furin cleavage 
sequence were the same for all three IgG1 products. One reason could be due 
to differences in structure of the complete IgG1 monomers due to different 
variable regions. IgGs are typically fully assembled as HC2LC2 in the ER 
107 
 
(Feige et al. 2010) while furin endoproteases are mainly localized to the golgi 
(Nakayama 1997). The differences in structure of the three products within the 
golgi could affect furin cleavage efficiency. Less variation was observed for 
furin cleavage of the HC possibly due to the furin cleavage site being located 
further away from the differing Fab region. 
The L-IRES-H was the best vector design for expressing IgG1 mAb in 
CHO DG44 cells among the four versions of tricistronic vectors. While the 
F2A system is a promising design, issues with 2A processing and furin 
cleavage affected product yield and quality. Further optimization of the type of 
2A peptide to be used, addition of GSG linkers and the furin cleavage 
sequence need to be performed (Fang et al. 2007; Szymczak-Workman et al. 








Figure 4.9 Hydrophobicity analysis of HC signal peptide attached with 
MATT and P amino acid residues at the N-terminal end. (A) Wild type HC 
signal peptide (SPH). (B) SPH with MATT amino acid residues attached to the 
N-terminal end (MATT+SPH). (C) SPH with amino acid P attached to the N-
terminal end (P+SPH). The 19 amino acids of the HC signal peptide are shown 
as amino acids 0 to 19. Additional residues at the N-termini due to IRES and 
F2A processing are numbered starting from -1. Kyte-Doolittle index is 
computed using Protscale online tool (http://web.expasy.org/cgi-






 Using IRES vectors to control Chapter 5:
LC:HC ratio for studying effect of the ratio 
on mAb expression in stably transfected 
CHO cells   
 
The effect of LC:HC ratio on mAb expression has been demonstrated in in-
silico and transient experiments but not in stably transfected conditions . In 
this chapter, we used four variations of IRES vectors to control LC and HC at 
different ratios in stable transfections. Due to the reported issues of using F2A 
in chapter 4, redesigned IRES vectors were used to generate cell lines with 
equal amounts of LC and HC. MAb expression level and quality at the 
different ratios are determined and discussed.  
 
The  following was first published in “Ho, S. C. L., Koh, E. Y. C., van Beers, 
M., Mueller, M., Wan, C., Teo, G., Song, Z., Tong, Y. W., Bardor, M. and 
Yang, Y. (2013). "Control of IgG LC:HC ratio in stably transfected CHO cells 
and study of the impact on expression, aggregation, glycosylation and 




Immunoglobulin G (IgG), the most common class of commercial monoclonal 
antibodies (mAbs), exists as multimers of two identical light chains (LC) and 
two identical heavy chains (HC) assembled together by disulfide bridges. Due 
to the kinetics of mAb assembly, it is suggested that expression of LC and HC 
in equal amounts is not optimal for IgG production. We designed a set of 
vectors using internal ribosome entry site (IRES) elements to control LC and 
HC expression. Using those IRES-mediated vectors, it was demonstrated that 
the intracellular LC:HC ratio of stable IgG expressing Chinese hamster ovary 
(CHO) cell pools can be controlled effectively at four different ratios of 3.4, 
1.2, 1.1, 0.3. The stable pools were used to study the impact of LC:HC ratio on 
mAb expression and quality. Gene amplification was most effective for pools 
with excess LC and generated the highest mAb titers among the transfected 
pools. When LC:HC ratio was greater than one, more than 97% of the secreted 
products were IgG monomers. The products also have similar N-glycosylation 
profiles and conformational stabilities at those ratios. For pools which 
presented a lower LC:HC ratio (0.3), monomers only constituted half of the 
product with the other half being aggregates and mAb fragments. High 
mannose-type N-glycans increased while fucosylated and galactosylated 
glycans decreased significantly at the lowest LC:HC ratio. Product stability 




Monoclonal antibodies (mAbs) are the best-selling class of biologics 
on the market (Aggarwal 2011). The most common type of mAb, 
immunoglobulin G (IgG), is composed of two identical light chains (LC) and 
two identical heavy chains (HC) linked by disulfide bonds. Assembly in the 
endoplasmic reticulum (ER) involves interactions between partly folded HC 
dimers, LC monomers, BiP chaperones and catalysts like protein disulfide 
isomerase (PDI) (Lee et al. 1999; Vanhove et al. 2001; Gonzalez et al. 2002; 
Feige et al. 2010). Although there is an equal numbers of LC and HC in each 
IgG mAb, having LC and HC peptides at a balanced ratio may not be optimal 
for its expression (Gonzalez et al. 2002; Davies et al. 2011). Mathematical 
modeling of the IgG mAb synthesis pathway indicated that assembly time 
decreases as the relative amount of LC to HC increases (Gonzalez et al. 2002). 
It has been shown that for CHO cells, excess LC is favorable for transient 
mAb expression (Li et al. 2007; Yang et al. 2009; Ho et al. 2012) and high 
producing stably transfected cell lines typically express LC in excess 
(Schlatter et al. 2005; Lee et al. 2009; O'Callaghan et al. 2010). Most natural 
lymphoid cells and IgG expressing myeloma cells also express light chain in 
excess (Shapiro et al. 1966; Baumal and Scharff 1973). Incompletely formed 
heavy chains can be prone to aggregation (Vanhove et al. 2001; Ellgaard and 
Helenius 2003) and there is evidence that higher relative HC level is a possible 
cause for aggregation (Vanhove et al. 2001; Lee et al. 2009). N-glycosylation 
of HC takes place co-translationally within the ER and complements the 
assembly of secreted mAb (Sakaguchi 1997). The degree of late glycan 
modifications occurring in the golgi apparatus is influenced by the protein 
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conformation as well (Krambeck and Betenbaugh 2005; Butler 2006). The 
ratio of LC:HC expression may thus affect mAb glycosylation as the ratio 
affects both mAb folding and assembly.  
 MAb expression in CHO cells can be achieved by having LC and HC 
genes under the control of individual promoters and either co-transfected on 
separate vectors or on the same vector (Trill et al. 1995; Costa et al. 2010). 
Ratio of LC: HC expression can be controlled by changing the relative 
amounts of each plasmid of two co-transfected vectors carrying LC and HC, 
respectively (Lee et al. 1999; Schlatter et al. 2005). Controlling LC:HC ratio 
by this approach is affected by variations in transfection efficiencies. It is also 
not appropriate for studies in stably transfected cells as vector integration is 
highly random and the integration site has significant effect on the expression 
level (Fussenegger et al. 1999; Mielke et al. 2000). Control LC:HC ratio can 
also be achieved using one large vector carrying all the required expression 
cassettes and varying the relative expression using promoters (Yahata et al. 
2005) or poly-adenylation signals (Yang et al. 2009) with different strengths. 
Although all genes are integrated at the same site, one issue that arises with 
having multiple promoters in close proximity is transcriptional interference 
(Eszterhas et al. 2002). Incomplete vectors can also get integrated due to 
vector fragmentation and affect the gene ratios (Barnes et al. 2007; Chusainow 
et al. 2009; Ng et al. 2010).  
 Single vectors with genes linked together in one transcript would allow 
all genes to be integrated at the same site for stricter control of relative LC to 
HC expression. This can be achieved by using internal ribosome entry site 
(IRES) elements to express all genes of interest in one transcript under a single 
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promoter. When placed between two genes, IRES allows ribosomes to bind in 
the middle of the transcript for cap-independent translation of the second gene 
(Mountford and Smith 1995; Martinez-Salas 1999). IRES driven translation of 
the second gene is less efficient than a typical cap-dependent translation, 
resulting in lower peptide levels for the second gene. IRES elements can be 
used to control the relative level of two genes. The technique has been applied 
to transient studies of mAb expression in CHO cells where an intracellular 
excess of HC was observed to decrease IgG yield (Li et al. 2007). We have 
previously used an IRES-mediated tricistronic vector to maintain LC:HC at a 
constant ratio of excess LC in stable clones (Ho et al. 2012). Those clones 
exhibited high expression levels, low aggregation and consistent N-
glycosylation profiles possibly due to the controlled LC:HC ratio.  
Reports where LC:HC ratio is controlled for studying the impact on 
mAb expression and quality have mainly been performed in transient 
transfections (Schlatter et al. 2005; Li et al. 2007; Yang et al. 2009). However, 
the industry relies mainly on stably transfected cell lines for therapeutic mAb 
production. There are currently no reports of controlling LC:HC ratio at 
different levels in stably transfected mAb producing cell lines for study of 
both mAb expression and quality. In this work, we designed four IRES-
mediated tricistronic vectors to control LC:HC at different ratios. Depending 
on the position of LC, HC and the selection marker gene on the vector, stably 
transfected pools exhibited either excess of LC, excess of HC or similar levels 
for both. Product titers and quality characteristics such as aggregation, N-
glycosylation and conformational stability were compared. Three biosimilar 
mAbs, Herceptin (anti-HER2 IgG1), Humira (anti-TNFα IgG1) and Avastin 
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(anti-VEGF IgG1), were generated at various LC:HC ratios. MAb produced at 
the highest LC:HC ratio and of the best quality. As ratio decreased, it was 
observed that expression dropped, aggregates increased and other quality 
attributes changed.  
 
5.3 Materials and methods 
5.3.1 Cell culture and media 
DHFR deficient CHO DG44 cells (Life Technologies, Carlsbad, CA) 
were grown in protein free media (PFM) as described in section 4.3.1. Cells 





fresh media. Cell viability and density were determined by Trypan blue 
exclusion method using a Vi-Cell XR cell viability analyzer (Beckman 
Coulter, CA). 
5.3.2 Construction of vectors for control of LC:HC ratio and cell 
engineering 
Vectors were designed as shown in figure 5.1. LIHID and HILID were 
constructed by replacing the neomycin phosphotransferase gene of two 
previously described IRES-mediated tricistronic vectors in section 3.3.2 with a 
dihydrofolate reductase (DHFR) gene. DILIH was constructed by modifying 
LIHID. Firstly, IRES-DHFR-pA was replaced with only a pA sequence. Next, 
IRES-LC was cloned from HILID and used to replace LC. Finally, DHFR was 
inserted between the CMV promoter and the first IRES. DIHIL was 





Figure 5.1 Schematic representation of IRES-mediated tricistronic 
vectors for mAb expression. CMV, human cytomegalovirus IE gene 
promoter; pA, simian virus 40 early polyadenylation signal; IRESwt, wild type 
encephalomyocarditis virus (EMCV) internal ribosomal entry site; IRESatt, 
mutated EMCV IRES with attenuated translation efficiency; LC, light chain 
cDNA; HC, heavy chain cDNA; DHFR, dihydrofolate reductase.  
 
IRES-driven expression is known to be lower than cap-dependent 
expression (Martinez-Salas 1999; Hennecke et al. 2001). This characteristic of 
IRES was used to vary the LC:HC ratio. We had shown earlier that by placing 
the LC downstream of the promoter and the HC downstream of the wild-type 
IRES (IRESwt) all stably transfected clones expressed LC:HC at a ratio of 
around 4:1 (section 3.4.3). For vectors DIHIL and DILIH, DHFR is in the first 
cistron downstream of the promoter and both LC and HC expression were 
driven by identical IRESwt. LC and HC expression was expected to be similar 
for these designs. Vector HILID, with promoter driven HC expression and 
IRES driven LC expression should have a LC:HC ratio less than one due to 
HC being expressed in excess of LC. 
Vectors for cell engineering experiments to reduce aggregates were 
modified from LIHID vector. DHFR sequence was changed to a Zeocin 
selection marker cloned from a pCDNA 3.1/Zeo vector (Life Technologies). 
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Subsequently, LC-IRES-HC was replaced with either LC or CHO BiP cDNA 
(Genbank: GCA_000223135.1). 
5.3.3 Transfection and cell line generation 
All transfections were performed using Nucleofection kits from Lonza 
(Cologne, Germany) following the manufacturer’s instructions. Transient 
transfections were performed using 2×10
6
 cells, 2 µg of each plasmid and 0.2 
µg of pMAX-GFP (Lonza). Transfected cells were placed in 6-well 
suspension culture plates containing 2 mL of HT supplemented with PFM. 
After 48 hours, supernatant was collected for quantification of mAb 
expression by an enzyme linked immunosorbent assay (ELISA) as previously 
described in section 3.3.5 and cells were collected to measure GFP fluorescent 
intensity using a FACS Calibur (Becton Dickinson, MA). 
Stable transfections were performed using 1×10
7
 cells and 5 µg of each 
linearized plasmid in duplicates. Cells were transferred to 6-well plates 
containing 2 mL of HT supplemented with PFM for 24 hours. Next, cells were 
inoculated to shake flasks and the media was replaced with 25 mL of PFM for 




 during the 
selection process. Selection and recovery was considered complete for each 
selection step when viability was above 95%. Stepwise methotrexate (MTX) 
amplification was then carried out with concentrations of 50 nM, 250 nM, 
1000 nM, 5000 nM and 25000 nM. MTX concentrations of 50 nM, 250 nM, 
1000 nM were used for LIHID and HILID. Higher concentrations up to 25000 
nM MTX were used for DIHIL and DILIH as their promoter driven DHFR 
expression were higher than the IRES driven expression for LIHID and 




 and maintained until 
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viability dropped to 50% for supernatant collection. The supernatant was used 
for product quantification and characterization. Cell pellets were collected 
during either day 3 or 4 for analysis of intracellular LC and HC polypeptide 
abundance. Titers were measured using an IMMAGE 800 immunochemistry 
nephelometer (Beckman Coulter, Buckinghamshire, England) and cell counts 
were carried out using the Vi-Cell XR (Beckman Coulter). 
5.3.4 Intracellular LC and HC polypeptide ELISA 
Cell pellets were washed with phosphate buffered saline (PBS; 1
st
 BASE, 
Singapore) and lysed in RIPA buffer (Thermo Scientific, Waltham, MA) 
supplemented with ProteoBlock protease inhibitor cocktail (Fermentas, 
Thermo Scientific). Concentrations of LC and HC polypeptides were 
quantified using ELISA as previously described in section 3.3.5 and 3.3.6. 
5.3.5 Western blotting of cell lysates and supernatant  
Cell lysates prepared for ELISA and supernatant collected at the end-
point of batch cultures were used for western blot analysis. NuPAGE sample 
loading buffer and reducing buffer (Life Technologies) were added as required 
for each sample. Non-reduced and reduced samples were heated at 70 °C for 2 
min and 10 min, respectively. Protocols were as listed in section 4.3.5. 
5.3.6 Purifying mAb using protein A column 
Purification was performed using a GE ÄKTA Explorer 100 (GE 
Healthcare, Uppsala, Sweden) and UV detection at 280 nm. Buffers used 
differ from that described in 3.3.8 to improve the purification process. Cleared 
culture supernatant was loaded on a Tricorn 5/150 Protein A column packed 
with MabSelect SuRe (GE Healthcare) pre-equilibrated using PBS. Sample 
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was injected at a flow rate of 3 mL/min. A terminator wash buffer of 2 M 
sodium chloride (Merck, Darmstadt, Germany), 250 mM imidazole (Merck), 
10 mM EDTA (Sigma-Aldrich), 4 M urea (Sigma-Aldrich) adjusted to pH 7.0 
was passed through the column followed by an elution buffer of 100 mM 
acetate (Sigma-Aldrich) and 100 mM arginine (Sigma-Aldrich) at pH 3.5. 
Eluted samples were neutralized using 1 M Tris (Sigma-Aldrich) and column 
was regenerated using 0.1 M glycine (Merck) adjusted to pH 2.5.     
5.3.7 Aggregation and glycosylation analysis of purified mAb 
Aggregation of protein A purified mAb was analyzed immediately 
after the purification using size exclusion chromatography (SEC) in order to 
avoid formation of aggregates during storage similar to the protocol listed in 
section 3.3.10. The N-glycan distribution was analyzed using matrix assisted 
laser desorption ionization-time of flight mass spectrometry (MALDI-TOF 
MS) using methods listed in section 3.3.9.  
5.3.8 Conformational stability analysis of purified mAb 
Differential scanning calorimetric (DSC) measurements were 
performed using a VP-Capillary DSC system (Microcal Inc, Northampton, 
MA, USA) which was equipped with tantalum cells with an active volume of 
130 µL. The samples were analyzed at a concentration of 1 mg mL
-1
 in 50 mM 
HEPES buffer at pH 7.0 using a scan range from 35 to 100°C and a scan rate 
of 1°C per minute. HEPES buffer at pH 7.0 was used as a blank reference. 
Data were analyzed using Origin 7.0 software (OriginLab Corporation, 
Northampton, MA, USA). Thermograms were corrected by subtraction of 
buffer blank scans and normalization to the protein concentration. The 
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transition curves were fitted using a non-2-state model to obtain the 
temperature midpoint of transition (Tm).  
 
5.4 Results 
5.4.1 Anti-HER2 mAb expression using the four IRES-mediated vectors 
designed 
We designed four IRES-mediated vectors to control LC:HC ratio in 
stably transfected IgG expressing pools. Transient expression levels of a 
model anti-HER2 biosimilar mAb using the four vectors were first evaluated 
(Fig. 5.2A). LIHID vector was used as a reference and GFP was co-transfected 
as a control for transfection efficiency variations. Pools transfected with the 
LIHID vector which was designed to express LC in excess had the highest 
expression, followed by vectors designed for balanced LC:HC ratio. DIHIL 
and DILIH had expression levels about half that of LIHID. HILID transfected 
pools had the lowest transient expression at only 30% that of LIHID. These 
observations fit well with earlier reports that excess LC is beneficial to mAb 
expression in CHO cells (Schlatter et al. 2005; Yang et al. 2009). 
The vectors were transfected into CHO DG44 cells and underwent 
stepwise MTX amplification to generate stably transfected pools. Titer was 
measured after each amplification step using a nephelometer (Fig. 5.2B). 
Amplification of stable pools generated by LIHID was most effective. There 
was 3-fold titer increase when MTX was stepped up from 50 nM to 250 nM, 
followed by a 1.5-fold titer increase to reach a final titer of 380 mg L
-1
 at 1000 
nM MTX. Titers of stably transfected pools generated using DIHIL and 
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DILIH increased gradually during MTX amplification, reaching 110 mg L
-1
 
and 79.5 mg L
-1
, respectively, at 25000 nM MTX. Titer for HILID was 68.3 
mg L
-1
 at 50 nM MTX and reached a peak of 83 mg L
-1
 at 250 nM MTX with 
no improvements at 1000 nM MTX. 
 LIHID pools at 50 nM MTX, DIHIL and DILIH pools at 5000 nM 
MTX and HILID pools at 50 nM MTX had similar titers and were chosen for 
subsequent studies of LC:HC ratios and the effects on mAb quality. Western 
blot analysis of supernatant from pools generated by each vector was 
performed using anti-LC and anti-Fc detection antibodies (Fig. 5.2C). For 
LIHID, IgG monomer (HC2LC2) was the main product detected together with 
some excess of LC dimers (LC2). Those were possibly due to expression of 
excess LC. Only IgG monomers were detected for pools DIHIL and DILIH. 
Product from HILID consisted of IgG monomer and HC dimers (HC2) 









Figure 5.2 Comparison of IRES-mediated tricistronic vectors for 
expression of anti-HER2 in transient and stable transfections. (A) 
Comparison of transient expression of CHO DG44 cells transfected with each 
of the four vectors, LIHID, DIHIL, DILIH and HILID. mAb expression was 
quantified by ELISA 48 h post transfection and normalized to an internal GFP 
control. GFP normalized expression was further normalized to LIHID results. 
(B) Titers of stably transfected pools generated using each tricistronic vector. 
The transfected cells next underwent selection and amplification at various 
MTX concentrations. (C) Western blot analysis of non-reduced supernatants in 
stably transfected pools from LIHID at 50 nM MTX, DIHIL and DILIH at 
5000 nM MTX and HILID at 50 nM MTX. Each point in (A) and (B) 
represents the average and standard deviation of duplicate measurements from 




5.4.2 Stable intracellular LC:HC ratio 
 Intracellular LC and HC peptide abundances in LIHID stable pools at 
50 nM MTX, DIHIL and DILIH stable pools at 5000 nM MTX, and HILID 
stable pools at 50 nM MTX were measured using ELISA to obtain the LC:HC 
ratio for each vector (Fig. 5.3A). LIHID exhibited a LC:HC ratio of 3.43. This 
high ratio indicated that there was an excess of intracellular LC and is a 
possible reason for LC2 detection in the supernatant. DIHIL had a LC:HC ratio 
of 1.24 while DILIH had a ratio of 1.12. A ratio of 0.32 was measured for 
HILID pools, indicating that these pools had excess intracellular HC. This 















Figure 5.3 Comparison of intracellular LC:HC ratio for CHO DG44 
stably expressing anti-HER2 IgG. (A) ELISA analysis of the ratios of 
intracellular abundance of LC over HC polypeptides in stably transfected. 
LC:HC ratio was calculated as the concentration of intracellular LC 
polypeptides determined by ELISA divided by the HC polypeptides. (B) 
Western blot analysis of intracellular abundance of LC and HC polypeptides 
in stably transfected pools under reducing conditions. (C) LC:HC ratio for 
LIHID and HILID at different MTX concentrations. Each point in (A) and (C) 
represents the average and standard deviation of duplicate measurements of 




Western blot was performed using the same intracellular lysates to 
verify the LC:HC ratio differences determined by ELISA between the samples 
(Fig. 5.3B). Samples were reduced before analysis and detection was 
performed using antibodies for both LC and HC monomers. The band 
intensity corresponding to HC was similar for all four samples as sample 
loading was based on the amount of IgG Fc measured during ELISA. LIHID 
presented the darkest LC band, corresponding to the highest LC:HC ratio. At a 
similar amount of HC, DIHIL and DILIH had fainter LC bands than LIHID, 
indication of lower LC levels. HILID with the lowest LC:HC ratio also had the 
faintest band corresponding to the LC species. Intensities of all the bands 
observed were as expected when compared to the ELISA results.  
 To further ascertain that we were able to control LC:HC ratio using 
IRES-based vectors, LC:HC ratios for LIHID and HILID at 250 MTX and 
1000 MTX were also measured (Fig. 5.3C). LC:HC ratios for LIHID were 
3.96 and 3.58 at 250 nM MTX and 1000 nM MTX, respectively. HILID had 
ratios of 0.31 and 0.29 at the higher MTX concentrations. LC:HC ratios 
remained similar for all pools at all the MTX concentrations analyzed, 
showing that the vector designs were indeed able to control LC:HC ratio.    
5.4.3 Aggregation at different LC:HC ratios 
Protein A purified supernatant was analyzed by size exclusion 
chromatography and species were identified using UV detectors (Fig. 5.4). 
The respective amounts of IgG monomer, higher molecular weight aggregates 
and lower molecular weight mAb fragments were quantified by calculating the 
peak areas detected by the UV detector. When there was a greater excess of 
LC in LIHID pools, 99.6% of the product was IgG monomers while 
125 
 
aggregates and incomplete mAb fragments contributed only to 0.2% each (Fig. 
5.4A). Product from DIHIL with LC:HC ratio of 1.24 was similar to LIHID 
with 99.3% monomers, 0.5% aggregates and 0.2% fragments (Fig. 5.4B). 
Aggregation increased to 2.2% when LC:HC ratio dropped to 1.12 in DILIH 
(Fig. 5.4C). Monomers and fragments contributed 97.5% and 0.2%, 
respectively. For HILID with excess HC, the aggregates and incomplete mAb 
fragments increased to 13.5% and 26.5%, respectively. Only around 60% of 
the total product was composed of IgG monomers (Fig. 5.4D). Average 
distributions of each product type at each ratio measured from two 











Figure 5.4 Representative SEC chromatograms and distribution of the 
monomer, aggregates and fragments for the mAb produced with the 
different versions of the IRES-mediated tricistronic vectors. SEC 
chromatograms were registered using a UV detector and anti-HER2 mAb 
purified from stably transfected pools generated using (A) LIHID, (B) DIHIL, 
(C) DILIH, (D) HILID vectors. Agg: Aggregates, IgG: Full mAb monomer, 
Frag: mAb fragments. (E) Quantitative comparison of the different species 
detected for each mAb vector. Protein A purified product from two 
independently transfected pools for each vector were quantified but only the 
chromatogram of the first pool is shown in (A) to (D) as the replicates are 
highly similar. Values shown in (E) are the average of two measurements of 
two independently generated stable pools.  
 
5.4.4 Glycosylation at different LC:HC ratios 
MALDI-TOF mass spectrometry was used to identify the glycans on 
protein A purified anti-HER2 IgG. Relative quantification was calculated 
based on the MALDI-TOF analysis of permethylated N-glycans. To 
summarize the results, N-glycans were categorized into high mannose type, 
sialylated, fucosylated, G0 (complex type glycans not bearing any terminal 
galactose), G1 (bearing one terminal galactose) and G2 (bearing two terminal 
galactose) N-glycan species (Fig. 5.5). A similar set of around 20 glycans was 
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observed for mAb generated at ratios of 3.43, 1.24 and 1.12, consisting as 
expected of mainly high mannose type N-glycans and bi-antennary complex 
type N-glycans (Fig. 5.5A, B and C). Vector HILID, which generated pools 
with LC:HC ratio of 0.32, exhibited 34 different glycans (Fig. 5.5D for mass 
peaks below 2500, 5.5E for peaks above 2500) with the appearance of more 
tri-antennary and tetra-antennary complex type N-glycans not seen previously. 
Relative quantification of the different major N-glycans showed variations 
between the different LC:HC ratios (Fig. 5.5F). For example, the percentage 
of high mannose increased with decreasing LC:HC ratios. LIHID with a 
LC:HC ratio of 3.43 had the lowest high mannose fraction, 14.5%. A slight 
increase to 19% was observed in DIHIL and DILIH pools with LC:HC ratios 
controlled at 1.24 and 1.12, respectively, while a dramatic increase of high 
mannose fraction to 32.95% was observed in HILID pools with a LC:HC ratio 
of 0.32. Accordingly, products from LIHID, DIHIL, and DILIH exhibited 
similar percentage of fucosylated species around 78%, while a dramatic drop 
to 60 % was observed on products from HILID. A similar trend was observed 





















Figure 5.5 Representative MALDI-TOF mass spectra and N-glycan 
distribution obtained for anti-HER2 mAb generated at different LC:HC 
ratio. MALDI-TOF analysis of the permethylated N-glycans released from the 
purified mAb produced by pools generated using (A) LIHID, (B) DIHIL, (C) 
DILIH, (D,E) HILID, respectively. Solid square, N-acetylglucosamine; solid 
circle, mannose; open circle, galactose; solid triangle, fucose; solid diamond, 
sialic acid and open diamond, N-glycolylneuraminic acid. (F) Glycan 
distribution for the product generated at the different ratios is shown. LC:HC 
ratios of 3.43, 1.24, 1.12 and 0.32 were observed for LIHID, DIHIL, DILIH 
and HILID, respectively. N-glycans were categorized into high-mannose type, 
sialylated type that carry at least one terminal sialic acid, fucosylated complex 
type N-glycans, G0 glycans which carry no galactose residues, G1 which carry 
one terminal galactose residue and G2 which carry two terminal galactose 
residues. Each bar represents the average of the results collected from two 
independently generated pools. Protein A purified product from two 
independently transfected pools were quantified but only the spectra of the 
first pool is shown in (A) to (E) as the replicates are highly similar. 
 
5.4.5 Conformational stability at different LC:HC ratios 
Conformational stabilities of the protein A purified products collected 
for the different LC:HC ratios were measured by DSC at neutral pH. IgGs can 
have either two or three thermal transitions indicated by the unfolding 
temperatures (Tm). Those are contributed by the unfolding of the Fc (CH2 and 
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CH3 regions) and Fab segments (Garber and Demarest 2007; Ionescu et al. 
2008). A higher Tm represents greater stability. The DSC profiles observed for 
the anti-HER2 LIHID, DIHIL and DILIH pools were similar to those reported 
previously  (Ionescu et al. 2008). Three transitions around 70°C, 80°C and 
82°C were observed (Fig. 5.6. and Table 5.1). Product from LIHID, the pools 
with excess LC, had the highest melting points for all transitions. HILID had 
lower Tm1, which corresponds to unfolding of the CH2 domain (Ionescu et al. 
2008; Mueller et al. 2013). 
5.4.6 Effect of excess LC and HC on product quality of other mAbs 
We next generated stably transfected CHO cell lines expressing anti-
TNFα and anti-VEGF IgG antibodies to investigate whether the impact of 
LC:HC ratio on mAb expression level and quality is mAb dependent. LIHID 
and HILID (Fig. 5.1) vectors were used to generate pools which expressed LC 
or HC in excess for these two other mAbs. Expression level, intracellular 
LC:HC ratio and product quality were determined and consolidated in Table 
5.2. Regardless of the IgG studied, LIHID generated pools exhibited high 
LC:HC ratios while HILID pools had low ratios, albeit with some differences 
in the values. LIHID generated pools exhibited LC:HC ratios of 2.77 and 3.53, 
while using a HILID design generated ratios of 0.35 and 0.38 for anti-TNFα 
and anti-VEGF, respectively. LC:HC ratio for anti-TNFα produced using 
LIHID was lower possibly due decreased translation efficiency or increased 
clearance for LC. Consistent with the observed impact of LC:HC ratios on 
anti-HER2 expression, expression of LC in excess enhanced expression of 
anti-TNFα and anti-VEGF. Amplified pools of LIHID had titers four-fold 
higher than HILID for both antibodies.  
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 The impact of LC:HC ratio on aggregation of anti-TNFα and anti-
VEGF was similar to that observed for anti-HER2. Under excess LC 
conditions using LIHID, anti-TNFα had 99.01% IgG monomers, 0.49% 
aggregates and 0.50% fragments and anti-VEGF mAb had 98.71% monomers, 
1.10% aggregates and 0.19% fragments. While HILID pools with HC 
expressed in excess displayed increased levels of aggregation of 22.36% for 
anti-TNFα and 14.96% for anti-VEGF. Incomplete mAb fragments were also 
observed for these two antibodies at low LC:HC ratios although the amount 
was less than that observed for anti-HER2. Anti-TNFα had 9.05% fragments 
while anti-VEGF had 1.02% of fragments.  
Similar changes in glycosylation at different LC:HC ratios were also 
observed for these two antibodies as seen earlier for anti-HER2. There was 
still an increase in variety of glycans and the appearance of more matured 
tetra-antennary glycans for mAb generated with excess HC (data not shown). 
High mannose type N-glycans were elevated even more significantly for anti-
TNFα and anti-VEGF as compared to anti-HER2. Only 6.42% and 13.05% of 
glycans were high mannose for anti-TNFα and anti-VEGF, respectively, at 
high LC:HC ratios. This increased dramatically to 54.23% and 44.11% for 
pools at low LC:HC ratios. The amount of fucosylated glycans in excess LC 
pools when compared to excess HC pools decreased from 84.49% to 41% and 
from 78.77% to 50.42% for anti-TNFα and anti-VEGF.  
Pools with excess LC also displayed superior stability as compared to 
excess HC pools. Two transitions and Tms were detected at around 70°C and 
80°C for both antibodies generated using LIHID. DSC analysis for both 
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antibodies at low LC:HC ratio could not be performed successfully due to 
rapid aggregation during sample preparation, indicating low stability.  
A) B) 
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Figure 5.6 Representative thermograms for differential scanning 
calorimetry (DSC) observed for anti-HER2 purified mAb produced in 
stably transfected pools generated using the A) LIHID, B) DIHIL, C) 
DILIH, D) HILID vectors. Dotted curves symbolize deconvolution analysis 
for the different thermal transitions. Protein A purified product from two 
independently transfected pools were quantified but only the thermogram of 
the first pool is shown in (A) to (D) as the replicates are highly similar. Tms 





Table 5.1 Conformation stability of the anti-HER2 mAb in stably 
transfected pools generated using different IRES-mediated tricistronic 
vectors 
  anti-HER2 IgG1 
  LIHID DIHIL DILIH HILID 
Stability 
(°C) 
Tm1 72.1 ± 0.1 71.8 ± 0.1 71.6 ± 0.3 69.9 ± 0.2 
Tm2 80.9 ± 0.2 79.3 ± 0.3 80.1± 0.2 79.7± 0.5 
Tm3 82.6 ± 0.0 81.8 ± 0.2 82.2 ± 0.1 82.2 ± 0.1 
 
Table 5.2 Expression level, aggregation, N-glycosylation and 
conformation stability of anti-TNFα and anti-VEGF mAb in stably 
transfected pools generated at different LC:HC ratios. 
 
anti-TNFα IgG1  anti-VEGF IgG1 
LIHID HILID  LIHID HILID 
LC:HC 2.77 ± 0.05* 0.35 ± 0.02  3.53 ± 0.34 0.38 ± 0.01 
Titer (mg L
-1
) 54.6 ± 10.18 14.05 ± 2.47  102 ± 11.31 21.4 ± 0.85 
Aggregation 
(%) 
IgG 99.01 ± 0.15 68.59 ± 2.74  98.71 ± 0.11 84.02 ± 1.21 
Aggregates 0.49 ± 0.05 22.36 ± 1.97  1.10 ± 0.12 14.96 ± 1.80 
Fragments 0.50 ± 0.20 9.05 ± 0.78  0.19 ± 0.02 1.02 ± 0.59 
Glycosylation 
(%) 
High Mannose 6.42 ± 0.46 54.23 ± 0.06  13.05 ± 3.15 44.11 ± 3.98 
Sialylated 3.03 ± 0.61 3.38 ± 0.49  2.46 ± 0.83 3.57 ± 1.49 
Fucosylated 84.49 ± 0.07 41.00 ± 0.20  78.77 ± 3.99 50.42 ± 4.56 
G0 27.66 ± 0.52 15.30 ± 0.16  21.17 ± 0.41 11.96 ± 0.16 
G1 43.87 ± 0.46 17.41 ± 0.05  45.58 ± 0.12 24.36 ± 3.01 
G2 16.74 ± 1.41 9.02 ± 0.41  15.54 ± 0.92 14.73 ± 2.89 
Stability 
(°C) 
Tm1 73.0 ± 0.1 ND  72.7 ± 0.0 ND 
Tm2 83.5 ± 0.3 ND  83.2 ± 0.2 ND 
* Value is significantly different from anti-Her2 LIHID based on two-tailed 
student t-test. 
ND: could not be determined because of high aggregation during sample 




Previous studies which controlled LC:HC ratio at different levels to 
study its impact on mAb expression in CHO cells were conducted in transient 
conditions (Schlatter et al. 2005; Li et al. 2007). Control of LC:HC ratio in 
stably transfected CHO cells with high IgG expression has yet to be reported. 
We designed four IRES-mediated vectors and verified that LC:HC ratios could 
be controlled at ratios of 3.43, 1,24, 1,12 and 0.32 in CHO DG44 cell lines 
stably expressing anti-HER2 IgG. Strict control of the LC:HC ratio was 
achieved by our vector design as indicated by the consistent ratio for each 
vector even under gene-amplified conditions (Fig. 5.3C). Our results 
demonstrated that the LC:HC ratio affects both mAb expression level and 
quality and this impact is not antibody dependent.  
LC:HC ratios reported here are based on peptide amounts measured by 
ELISA while the ratio is reported at gene or mRNA level in other studies (Lee 
et al. 2009; Yang et al. 2009). We chose peptide quantification for two 
reasons: (1) as our LC and HC genes would be on one transcript linked by 
IRES, there would be no differences in their relative mRNA levels, (2) protein 
folding and glycosylation would be affected at peptide level and thus peptide 
ratios would be more relevant to this study. Amplification was more effective 
and achieved higher mAb titers at LC:HC ratio of 3.43 as the excess LC 
allows for more efficient mAb folding and assembly and HC clearance 
(Gonzalez et al. 2002; Schlatter et al. 2005; O'Callaghan et al. 2010). Schlatter 
et al. (2005) had observed and reported similar LC:HC peptide ratios of 2, 2.5 
and 3.1 in three stable high mAb producing cell lines. The absence of mAb 
fragments in the product generated by the pools with more balanced LC:HC 
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ratios is a possible sign that LC and HC peptides are used more efficiently for 
mAb assembly with no wasted resources. However, the peak titers achieved at 
balanced LC:HC ratios were much less than when expressing LC in excess 
even though MTX concentration was increased to a much higher level. The 
lower titer achieved at balanced LC:HC ratios may be also due to the stronger 
DHFR expression. We also observed higher mAb expression from the LIHID 
vector than the DIHIL and DILIH vectors in transient transfection to support 
that expression of excess LC is indeed more favorable for mAb expression. It 
is interesting that there are contrary reports which observed excess HC being 
beneficial to IgG expression levels in CHO cells (Jiang et al. 2006; Fallot et al. 
2009). Based on our results, titers at 50 nM MTX were indeed comparable for 
anti-HER2 IgG for both excess LC pools (LIHID) and excess HC pools 
(HILID) when detection was performed using HC-specific antibodies (Fig. 
5.2B). It was only upon further analysis of the product that we noticed a 
significant proportion of the product was not the desired IgG monomers (Fig. 
5.2C and 5.4). This false detection of high titer in pools or clones could be an 
issue when generating mAb expressing cell lines with poor control of LC:HC 
ratio. 
 Maintaining low mAb aggregation is of critical importance during 
production as it reduces efficacy and may cause immunogenicity (Hermeling 
et al. 2004; Cromwell et al. 2006). Earlier observations of a correlation 
between LC:HC ratio and aggregation were at a clonal level and it is unclear if 
the reported effects could have been due to a clone specific effect (Lee et al. 
2009; Gomez et al. 2012). When LC:HC ratio decreased from 3.43 to 1.24, 
aggregation levels remained at a level below 0.5%, but aggregation increased 
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to above 2% when ratio further decreased slightly to 1.12, suggesting there is a 
threshold between LC:HC ratios of 1.12 and 1.24 for aggregation to occur. An 
earlier report which selected clones expressing a different unknown mAb with 
LC:HC mRNA ratios above 1.5 to minimize product aggregation issues were 
still unable to identify all clones with low aggregation (Lee et al. 2009), 
suggesting that the threshold of LC:HC ratio causing aggregation may be 
different from mAb to mAb. Based on our observation of low levels of 
aggregates for all mAbs generated with greater excess LC, having LC in 
greater excess is likely a better method to minimize aggregation. Aggregation 
increased significantly when HC was in excess at LC:HC ratios of around 0.3 
for all mAbs tested. Excess HC which are unable to be properly folded with 
limited LC is one possible source of aggregation (Vanhove et al. 2001). The 
excess HC had different effects on different mAb products. Significant mAb 
fragments were observed only in pools of anti-HER2 and anti-TNFα. 
Although all mAbs produced under excess HC conditions had aggregates, 
aggregation for anti-TNFα and anti-VEGF worsened more significantly to 
form visible aggregates quickly upon sample preparation after purification. 
 It is still unclear how LC:HC ratios can cause changes in glycosylation 
in stably transfected cell lines. mAb glycosylation affects product efficacy and 
immunogenicity (Jefferis 2005). The distribution of N-glycans on anti-HER2 
was similar between pools generated using DIHIL and DILIH with LC:HC 
ratios close to one. When LC:HC ratio was increased to 3.43 using LIHID, 
there was a drop in high mannose species and an increase in the complex-type 
N-glycans, especially the galactosylated ones. Decreasing LC:HC ratio to 0.32 
resulted in elevated high mannose glycans, less fucosylated and appearance of 
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tri- and tetra-antennary structures which can result from an abnormal folding 
of the mAb. Protein folding and glycosylation are indeed parallel processes 
which could compete and affect each other (Gonzalez et al. 2001). There is 
possibly a better folding and assembly with excess of LC, resulting in an 
enhanced fraction of the desired complex glycans. High mannose glycans play 
a part in the protein quality control process occurring within the ER (Fagioli 
and Sitia 2001). The elevated level of high mannose species detected is a 
possible sign of the cell's folding and quality control machinery being 
overloaded. As protein A purified mAb at low LC:HC ratios contained 
incomplete fragments, highly matured N-glycans such as tri- and tetra-
antennary N-glycans observed could be due to mAb fragments with altered 
conformations having the glycosylation site more exposed, allowing for a 
greater level of glyco-modifications within the Golgi apparatus. 
 The increased aggregation, altered N-glycosylation, and decreased 
conformation stability we observed when there was excess HC are possibly 
correlated as protein folding, glycosylation, and conformation stability are 
closely related events (Krambeck and Betenbaugh 2005; Butler 2006). Several 
reports have indicated that the type and presence of glycosylation plays an 
important role in the likelihood of protein aggregating (Hristodorov et al. 
2012; Schaefer and Plückthun 2012). It has also been reported that 
glycosylation does affect the stability of mAb products (Liu et al. 2006; 
Hristodorov et al. 2012). Glycans destabilize the unfolded state, making the 
folded state more desirable (Shental-Bechor and Levy 2008). Melting 
temperature for the CH2 domain which was observed to be most affected is 
also the region where N-glycosylation takes place. When the CH2 domain is 
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less stable and unfolds more easily, stability of the other domains are affected 
as well. Glycosylation is not the only factor contributing to the differences in 
conformational stability as even though glycosylation for the product from 
pools of the balanced ratio were similar to the excess LC pools, stability was 
still lower. This difference could be due to LC:HC ratios affecting the early 
stages of protein folding and glycosylation. An interesting follow-up to this 
work could be to study how long LC and HC are retained within the ER at 
each ratio. It is possible that having excess LC to minimize the retention time 
of the incomplete HC dimers within the ER is preferred, giving the best 
folding conditions and thus the greatest stability. Near and far UV circular 
dichroism analysis of the two different products could be carried out to 
observe for differences in their secondary and tertiary structures. 
 The observations we made at the different LC:HC ratios for a variety 
of mAbs in stably transfected mAb show that LC:HC ratio plays an important 
role in mAb expression and quality. Having LC in excess is not only beneficial 
for mAb expression, it also keeps aggregate and fragment levels low. This is 
beneficial in ensuring maximal product yield. Protein A purification would be 
more efficient and less polishing steps would be needed. The glycosylation 
profile is more consistent and high mannose species which can reduce 
circulation time is lower. Methods to improve the product from cells with low 
LC:HC ratio were also tested. In recent years, there has been a push for 
implementation of Quality by Design (QbD) principles for development of 
biologics. The aim of QbD is to ensure consistency of product quality through 
understanding and optimization of the production process instead of through 
rigorous testing (Rathore and Winkle 2009; van Beers and Bardor 2012). This 
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can be achieved partly through control of LC:HC ratio by using specific vector 
designs. More work is required to validate that excess LC is beneficial to 
product quality as several other factors like culture condition, media 
formulation and cell types are also important. The ratio which we have 
controlled our LC and HC levels at are possibly not optimal due to wastage of 
excess LC. The high excess LC could still be beneficial when dealing with 
difficult to express mAbs where transfected LC:HC ratios of up to 9:1 were 
tested and shown to improve expression (Pybus et al. 2014). Future work 
could include further studies using more refined vector designs to identify 
ratios where peptide usage is maximized, mAb expression level is highest, and 




 IgG aggregation in cells Chapter 6:
expressing excess HC and strategies to 
reduce the aggregates 
 
When there is excess HC in mAb producing CHO cells, the mAb produced was 
observed to be aggregation prone. In this chapter, we identified some reasons 
for the aggregates forming and evaluated some methods to reduce the 
aggregates like over-expression of chaperones and increasing LC expression.   
 
The following results are undergoing minor revision at the time of writing of 
the thesis to be published in “Ho, S. C. L., Wang T., Song, Z., and Yang, Y. 
(2015). "IgG aggregation mechanism for CHO cells expressing excess heavy 





Aggregates in protein therapeutics like IgG monoclonal antibodies 
(mAb) are detrimental to product safety and efficacy. It has been reported that 
aggregates form in Chinese hamster ovary (CHO) cell lines expressing greater 
amount of heavy chain (HC) than light chain (LC). In this study, we observed 
that aggregates could form within the cells with excess HC and was partially 
secreted into the supernatant. The aggregates in the supernatant consisted of 
mainly HC and were partially dissociated under either reducing or denaturing 
conditions. Mutation of a predicted free cysteine on HC to prevent disulfide 
bonding did not reduce aggregation. Re-transfecting CHO cells with excess 
HC with more BiP, an important IgG molecular chaperone, reduced unwanted 
aggregates and fragments possibly by helping retain more incomplete products 
within the cell for either proper assembly or degradation. A second 
transfection of LC into CHO cells with excess HC to increase the LC 
expression to a level greater than the HC expression successfully removed all 
aggregates and fragments. mAb product aggregation in CHO cells with excess 
HC occur due to a combination of limited chaperones and LC:HC ratio. These 
results provide added insights to aggregate formation in and would be useful 





All proteins including monoclonal antibody (mAb) therapeutics have 
the tendency to aggregate. Aggregates can be classified by their covalent/non-
covalent bonds, reversible/non-reversible nature, size and conformation 
(Cromwell et al. 2006; Mahler et al. 2009). The presence of aggregates in 
protein therapeutics like IgG mAb can result in immunogenic reactions, 
complications during product administration and impair product quality and  
efficacy (Cromwell et al. 2006). Aggregation can occur during the various 
steps of the mAb manufacturing process, starting from cell line generation to 
the scale up culture process followed by purification, formulation all the way 
to storage (Cromwell et al. 2006; Mahler et al. 2009; Joubert et al. 2011). The 
presence of aggregates after filtration and centrifugation of the culture 
complicates the purification steps as the commonly used protein A affinity 
mAb purification method does not discriminate between monomers and 
aggregates as long as the Fc region is intact (Phillips et al. 2001). Several extra 
polishing steps like size exclusion and ion-exchange chromatography are 
required after affinity purification to remove aggregates (Phillips et al. 2001; 
Yoo and Ghosh 2012).  
It is beneficial to minimize aggregation from the early steps of 
production during clone selection and culturing. In order to maximize yields, 
high amounts of recombinant mAb peptides are expressed by each cell. This 
could lead to intracellular aggregation due to the high amount of unfolded 
proteins or inefficiencies of the molecular chaperones at controlling proper 
protein folding (Zhang et al. 2004). This has been demonstrated in Chinese 
hamster ovary (CHO) cells where the expression of a simple ATIII 
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glycoprotein above a threshold triggered aggregation and lowered yield 
(Schröder et al. 2002). mAb expression is further complicated by its 
multimeric nature where the heavy chain (HC) and light chain (LC) peptides 
are translated separately before being assembled with the aid of various ER 
proteins (Gonzalez et al. 2002; Feige et al. 2010). One study observed that 
aggregate levels were reversibly correlated to the LC:HC mRNA ratios in 
stable mAb producing clones and high level of aggregates formed in clones 
with the LC:HC mRNA ratio over 1.5 (Lee et al. 2009). It was also observed 
that increased aggregates were associated with decreased LC:HC mRNA 
ratios in response to a temperature shift from 37 °C to lower temperatures 
(Gomez et al. 2012). We had generated two mAb producing stably transfected 
CHO cell pools, LIHID and HILID, with controlled intracellular LC:HC ratios 
of 3.4 and 0.3 respectively. The mAb produced by HILID stable pools with 
excess HC comprised of over 10% aggregates while LIHID stable pools with 
excess LC had less than 1% aggregate (Ho et al. 2013). Further analysis of the 
nature and mechanism of mAb aggregation in CHO cells with excess HC was 
not reported in our previous study.  
In this work, we studied where aggregates formed in HILID cells with 
excess HC, characterized and investigated the nature of aggregates. Cell 
engineering of molecular chaperones have mostly been performed to improve 
cell productivity (Borth et al. 2005; Hayes et al. 2010; Mohan and Lee 2010), 
with little reports of chaperone engineering to reduce product aggregation 
(Gomez et al. 2012). Chaperone engineering is not always a straight-forward 
experiment due to the complexity of the mammalian protein folding 
machinery (Borth et al. 2005; Nishimiya 2014). We studied how CHO cells 
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with excess HC would respond to the accumulation of intracellular HC 
polypeptides and the effect of overexpressing a BiP chaperone on the mAb 
aggregate formation. An extra transfection of only LC had been suggested as a 
solution to reduce aggregates arising due to excess HC but was not evaluated 
as the authors had considered that the mechanisms of aggregation was 
unknown and simply altering the LC:HC ratio could be insufficient (Lee et al. 
2009). We designed a strategy to increase LC expression in HILID stable 
pools using stringent selection markers and demonstrated that a second 
transfection of LC was effective at reducing aggregates. The results obtained 
would provide insights to the causes of mAb aggregation and to generate cell 
lines with reduced aggregates. 
 
6.3 Materials and methods 
6.3.1 Vector construction 
Vectors used were modified from a previously described LIHID vector 
which LC, HC, and dihydrofolate reductase (DHFR) genes were linked by 
internal ribosome entry site elements (IRES) (Ho et al. 2013). The HID vector 
was constructed by replacing LC-IRES-HC with HC (Fig. 6.1A). The IRES 
upstream of the DHFR selection marker was replaced with a mutant IRES 
variant we had generated, IRESv11 (Koh et al. 2013). Variants of the HID 
vector with mutations to the cysteine on the HC which normally forms a 
disulfide bond with a LC to either alanine (nucleotide substitutions of T725G 
and G725C) or serine (substitution of G725C) were obtained by using 
QuikChange multi site-directed mutagenesis kits (Agilent, Santa Clara, CA). 
The variants were labelled as HalaID and HserID. To generate LIZ and BIZ 
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vectors (Fig. 6.1B and C), the DHFR selection marker on the LIHID vector 
was first replaced by a Zeocin antibiotics selection marker cloned from 
pCDNA3.1/Zeo (Life Technologies, Carlsbad, CA). Following which, LC-
IRES-HC was replaced with either just LC or CHO BiP cDNA (genbank: 
GCA_000223135.1). Finally, the IRES sequence upstream of Zeocin for LIZ 
vector was replaced with a mutant IRESv18 with an estimated 1.4% strength 
of the wild-type IRES, and the IRES sequence upstream of Zeocin for BIZ 
was replaced with either IRESv18 or IRESv11 with a relative 25% strength of 
the wild-type IRES. HID, HalaID and HserID were transfected to DG44 cells 
while LIZ and BIZ were used to re-transfect earlier generated HILID stable 








Figure 6.1 Plasmid vectors used in the study. (A) Vectors for expression of 
HC and HC mutants, (B) vector re-transfected into HILID pool to increase BiP 






6.3.2 Cell culture and transfections 
DHFR deficient CHO DG44 cells (Life Technologies) were grown in 
protein free media (PFM) supplemented with 0.1 mM sodium hypoxanthine 
and 0.016 mM thymine (HT; Life Technologies). PFM was prepared from a 
1:1 mixture of HyQ PF (Hyclone, Logan, UT) and CD CHO (Life 
Technologies), supplemented with 1 g/L sodium bicarbonate (Sigma-Aldrich, 
St-Louis, MO), 6mM Glutamine (Sigma-Aldrich) and 0.05% Pluronic F-68 
(Life Technologies). Cell lines LIHID and HILID were generated in an earlier 
report (Ho et al. 2013) and cultured in PFM supplemented with 50 mM 
methotrexate (MTX, Sigma-Aldrich). Cells were passaged every 3 to 4 days 
by diluting the cultures to 2×10
5 
cells/mL in fresh media. Cell viability and 
density were determined by trypan blue exclusion method using a Vi-Cell XR 
cell viability analyzer (Beckman Coulter, CA). 
Transfections were performed using SG solution and program FF-137 
on a 4D-Nucleofector system (Lonza, Cologne, Germany). 1×10
7
 cells and 5 
µg of plasmid were used for each experiment. Transfected DG44 cells with 
HID vector series were transferred to selection media of PFM media without 
HT followed by gene amplification using 50 mM MTX. HILID pools that 
were re-transfected with LIZ or BIZ vectors underwent selection using 200 
µg/mL Zeocin
TM
 (Invivogen, San Diego, CA). Selection was deemed 





supernatant was collected after 10-11 days when 
viability dropped to 50% for further experiments. All transfections were 
performed in duplicates. 
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6.3.3 ELISA and Western blotting 
Cell lysis was performed using CellLytic
TM
 M with added protease 
inhibitor cocktail (both from Sigma-Aldrich). Intracellular protein from 1×10
7
 
cells was extracted using 200 µL of the mix. Cell lysates were used to 
determine intracellular polypeptides of LC:HC ratio by enzyme linked 
immunosorbent assay (ELISA) and identify intracellular mAb components by 
western blotting. ELISA and western blotting were performed as previously 
described (Ho et al. 2013). Precision Plus dual color protein pre-stained 
standards (Bio-Rad, Hercules, CA) were added to each blot to identify species 
sizes. Undiluted cell lysates and 10 ng of mAb in the supernatant were used 
for western blotting. 
6.3.4 Purifying of mAb products 
mAb was purified using a Tricorn 5/150 protein A column packed with 
MabSelect SuRe (GE Healthcare, Uppsala, Sweden) loaded on a GE ÄKTA 
Explorer 100 (GE Healthcare). Sample was injected at a flow rate of 3 
mL/min. A terminator wash buffer of 2 M sodium chloride (Merck, 
Darmstadt, Germany), 250 mM imidazole (Merck), 10 mM EDTA (Sigma-
Aldrich), 4 M urea (Sigma-Aldrich) adjusted to pH 7.0 was passed through the 
column followed by an elution buffer of 100 mM acetate (Sigma-Aldrich) and 
100 mM arginine (Sigma-Aldrich) at pH 3.5. Eluted samples were neutralized 
using 1 M Tris (Sigma-Aldrich) and the column was regenerated using 0.1 M 
glycine (Merck) adjusted to pH 2.5.     
6.3.5 Aggregation analysis of protein A purified mAb 
The aggregation of protein A purified mAb was determined using size 
exclusion chromatography (SEC). The instrument setup consisted of a HPLC 
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system (Shimadzu, Kyoto, Japan), with a binary pump, an auto injector, a 
thermostated column oven and a UV-visible detector. The chromatography 
columns used were TSK Guard column SWXL, 6×40 mm and TSK gel G3000 
SWXL, 7.8×300 mm (Tosoh Corporation, Tokyo, Japan). Column Oven 
temperature was set at 25ºC and the regular mobile phase included 0.2M 
sodium phosphate (Merck) and 0.1M potassium sulfate buffer at pH 6.0 
(Merck). Flow rate was 0.5 mL/min. All samples were analyzed immediately 
after protein A purification. 
Subsequent SEC analysis of aggregates was performed using methods 
with modified mobile phases similar to that previously reported by Gomez et 
al (2012). One experiment was performed using mobile phase with added 6 M 
guanidine (Sigma Aldrich). Another was performed with 30mins incubation at 
37 °C of the product with 10 mM DTT (Promega) prior to injection and 
running with mobile phase containing 10 mM DTT. The final experiment was 
performed with doubling K2SO4 salt concentration from 0.1 M to 0.2 M. 
Duplicate measurements were performed for two separately collected samples 
for each experiment.   
6.3.6 Quantitative real-time PCR (qRT-PCR) 
Total RNA was isolated from LIHID and HILID pools using a 
RNeasy® Mini Kit (Qiagen, Valencia, CA). mRNA levels for binding 
immunoglobulin protein (BiP) were then analyzed using a two-step qRT-PCR 
protocol. β-actin was used as the internal control. Briefly, 100 ng of RNA was 
reverse transcribed to cDNA using the ImProm II
TM
 reverse transcription 
system (Promega) in a 40 µL reaction. These cDNA samples were analyzed on 





 Evagreen® Supermix (Bio-Rad), 500 nM (final concentration) of 
forward and reverse primers (Research Biolabs, Singapore), 2.0 µL of above 
synthesized cDNA, and topped up with HPLC water (Merck, San Diego, CA, 
USA) for a 20 µL reaction. Primers used are shown in table 1. mRNA was 
extracted from two independently transfected cultures and analyzed with 
duplicate measurements for each sample. The collected threshold cycle (Ct) 
values were analyzed using a 2
-∆∆Ct
 method (Livak and Schmittgen 2001). 
 
Table 6.1 Primers used for qRT-PCR 
Primer  Sequence  
BiP-Forw 5’- CGGTGGAACCTTCGATGTG -3’ 
BiP-Rev 5’- TCCATAACCCGCTGATCAAAG -3’ 
Actin-Forw 5’- AGCTGAGAGGGAAATTGTGCG -3’ 







6.4.1 Analysis of aggregate formation 
We performed western blotting analysis of the cell lysate and 
supernatant to determine where aggregates formed in HILID stable pools with 
excess HC (LC:HC ratio of 0.3) and to identify the possible components 
within the aggregates. Cell lysate and supernatant for LIHID cell pools with 
excess LC and low mAb aggregates (LC:HC ratio of 3.4) were also analyzed 
for comparison. The samples were analyzed separately using anti-HC and anti-
LC detection antibodies (Fig. 6.2). Over-exposure during development of the 
blot ensured even small amounts of aggregates present would be visualized. 
LIHID lysate and supernatant samples had similar results for both detection 
antibodies and no aggregates were observed. HILID lysates exhibited a myriad 
of species with HC which appeared as a smear starting from 50 kDa, the size 
of a single HC to the start of the gel. Appearance of these unwanted products 
was likely exacerbated by the excess HC as the smearing was not visible using 
the anti-LC primary antibody. While this might not represent the actual 
species present within the cell due to differences between the cellular 
environment and the blot, this shows that HC species highly prone to 
aggregation are abundant within HILID pools. This smearing was not as 
evident in the HILID supernatant with slight smearing above the 150 kDa IgG 
monomer band and a high molecular weight band above. The high molecular 
weight species (above 150 kDa) comprised mostly of HC as the band was 
significantly darker using the anti-HC antibody compared to the faint band 




Figure 6.2 Western blotting of intracellular proteins and supernatant 
from LIHID and HILID using separate anti-HC and anti-LC detection 
antibodies. Samples were non-reduced and the increased exposure was 
performed to enable visualization of products present in small amounts.  
 
SEC analysis was performed on the protein A purified anti-HER2 IgG 
from HILID pools to identify the mechanisms causing the aggregates to form. 
Three conditions were tested: reducing condition with 10 mM DTT, 
denaturing condition with 6 M guanidine and increased salt concentration to 
0.4 M K2SO4. The conditions were determined based on a previous report 
(Gomez et al. 2012). The reducing condition would test for disulfide bonding, 
the denaturing conditions for hydrophobic interactions and the change to salt 
concentration for charge interactions. Purified sample from LIHID and HILID 
were first analyzed using the regular mobile phase buffer as a control (Fig. 
6.3A and E). LIHID only had a single monomer peak. HILID had 13% 
aggregates, 60% monomers and 27% of IgG fragments. Testing the various 
processes on IgG monomers from a LIHID pool ensured the treatments did not 
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affect IgG monomers. Only a single monomer peak was observed during SEC 
analysis for all three conditions (Fig. 6.3B, C and D). Treatment of HILID 
samples resulted in a drop in the amount of aggregates from 13% to 4% and 
6% in the reducing and denaturing conditions respectively (Fig. 6.3F and G). 
Peaks on the chromatogram profile for HILID in the mobile phase with 6M 
guanidine was less distinct compared to the regular mobile phase and the 
aggregate and fragment peaks became a shoulder off the main IgG peak (Fig. 
6.3G). The aggregate peak in this case was identified by comparing the LIHID 
and HILID chromatograms obtained using the same buffer. There was no 
change in the amount of aggregates in the increased salt buffer (Fig. 6.3H). 
Analysis was done for samples from two sets of LIHID and HILID cell pools 
and similar results were observed. The average amount of aggregates 
measured after each treatment of duplicate cell pools is shown in Fig. 6.3I. 
Based on these observations, the aggregates in HILID CHO cell pools with 
excess HC likely formed due to a combination of disulfide bonding and 








Figure 6.3 Chromatograms of protein A purified mAb produced by 
LIHID (A,B,C,D) and HILID (E,F,G,H). Samples analyzed with addition of 
either 10 mM DTT, 6 M guanidine or 0.2M K2SO4 to the liquid phase during 
SEC analysis. The main peaks labelled IgG are peaks for full IgG monomers. 
Peaks or peak shoulders appearing before the IgG were considered higher 
molecular weight aggregates. Peaks and shoulders after the main peak are low 
molecular weight IgG fragments. (I) Amount of aggregates detected in the 
normal SEC mobile phase and with the various additions. Each experiment 
was performed in replicates. * denotes the change was statistically significant 
using a two-tailed student t-test (p<0.05). 
 
mAb synthesis involves formation of HC2 dimers before folded LC are 
added (Feige et al. 2010; O'Callaghan et al. 2010). HC polypeptides are highly 
hydrophobic and inclined to aggregate. BIP binds to exposed HC hydrophobic 
region to prevent aggregation. BIP is released when a folded LC becomes 
available. HC dimer pairs with LC through disulfide bonding at fifth cysteine 
on HC (C223) and the last cysteine on LC (C236) (Liu and May 2012). Under 
the condition of excess HC and limited BIP, hydrophobic regions of variable 
region and first constant domains would be exposed. We hypothesized 
incomplete mAb fragments, HC2 and HC2LC would aggregate through 
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disulfide bonding at free cysteine 223 and hydrophobic interactions. We 
designed three experiments to test this hypothesis: (1) Mutation of cysteine on 
HC (C223A, C223S), (2) overexpression of BIP, and (3) a second transfection 
of only LC.   
6.4.2 Effect of mutating cysteine 223 on HC on aggregate formation 
As aggregates mainly consisted of HC polypeptides, we had 
hypothesized that one reason for the aggregates forming in the HILID pools 
was due to excess HC with unpaired free cysteines forming unwanted 
disulfide bonding. To test this hypothesis, a series of plasmids expressing only 
HC were generated (Fig. 6.1A). HID has the same HC sequence as used on the 
HILID plasmid, and another two with the cysteine which was to pair with a 
cysteine on a LC mutated to either alanine or serine, HalaID and HserID. HC 
expressed from HalaID and HserID vectors should not form high molecular 
weight aggregates due to disulfide bonding. Aggregates were visible in HC 
with mutation of the free cysteine to either alanine or serine, suggesting that 
mechanisms other than disulfide bonds were contributing to the aggregates 
(Fig. 6.4). This result complemented the earlier observations that the 
aggregates were comprised by a majority of HC and formed with a 





Figure 6.4 HC aggregates after cysteine mutation. Expression of only IgG 
HC (HID) and HC mutants with the cysteine for disulfide paring with LC 
mutated to alanine (HalaID) and serine (HserID). Samples were probed with 
anti-FC detection antibody.       
 
6.4.3 Increased expression of BIP to reduce aggregates 
 BiP expression levels were examined for non-transfected CHO DG44 
cells, LIHID and HILID pools by qRT-PCR (Fig. 6.5A). BIP was upregulated 
at 4.3 and 7 fold higher for LIHID and HILID respectively compared to non-
transfected CHO DG44 cells (NT). This could be due to the cell having to 
cope with the increased IgG expression for LIHID and large amounts of 
excess HC for HILID. BiP overexpression is linked to the unfolded protein 
response (UPR) that cells activate to handle the protein overload. Although 
BiP binds directly to incorrectly folded HC to aid in retaining them in the ER, 
we observed incomplete products being secreted. It is possible that the cell’s 
own BiP upregulation could be still insufficient, leading to a breakdown in the 
cell’s quality control mechanism and elevated product aggregation.  
 In order to test if an increase BIP expression could reduce aggregates, 
a HILID pool was re-transfected in duplicates with the BIZ vector carrying the 
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CHO BiP cDNA and a Zeocin selection marker (Fig. 6.1B). The transfected 
HILID pools underwent a second selection using Zeocin antibiotics to 
generate new stable pools referred to as HILID+BiP. Transfected cells failed 
to survive selection using the weaker IRESv18 on Zeocin selection marker. 
HILID+BiP pools generated using IRESv11, with greater translation 
efficiency than IRESv18, to drive Zeocin selection marker expression survived 
selection. Cells were collected for qRT-PCR analysis of chaperone expression 
levels and the supernatant collected to check product aggregate levels. 
Analysis of mRNA expression levels for the re-transfected HILID+BiP cells 
showed that BiP expression increased 2.7 fold compared to the original HILID 
pool (Fig. 5A). The amount of aggregates decreased to 8.2% for HILID+BiP 
compared to the initial 12% of the HILID pool and an increase in monomers 
from 62.9% to 68.7% (Fig. 6.5B and C). IgG titer detected increased from 70 
mg/L to 80 mg/L. There are currently no reports of how BiP chaperone over-
expression could affect IgG product quality.  It is possible that the increased 
BiP levels helped retain more incomplete and aggregation prone IgG within 














Figure 6.5 Analysis of BiP expression. (A) mRNA expression level of BiP 
for non-transfected DG44 cells (NT), LIHID, HILID and HILID+BiP were 
checked using qRT-PCR with β-actin used as the internal control. Samples 
were normalized to NT. (B) SEC chromatograms for HILID before (top) and 
after increasing BiP expression (HILID+BiP, bottom). Monomer peak is 
labelled as IgG. Peaks appearing before the main peak were considered high 
molecular weight aggregates and peaks after considered fragments. (C) 
Product distribution comparison of HILID and HILID+BIP. Each bar and 
standard deviations are obtained from two measurements each of biological 
replicates. * and ** denotes the differences were statistically significant using 
a two-tailed student t-test at p<0.1 and p<0.05 respectively. 
 
6.4.4 A second transfection of LC to reduce aggregates 
 Over-expression of BiP chaperone did not completely remove the 
aggregates. We next explored an alternative method to reduce product 
aggregation in the HILID pools by re-transfecting the cells with more LC 
cDNA to increase the intracellular LC peptide amount and thus LC:HC ratio. 
A HILID pool was re-transfected with the LIZ vector carrying the LC cDNA 
and a Zeocin selection marker (Fig. 1C) and underwent antibiotics selection 
similar to how HILID+BiP pools were generated. IRESv18 was applied onto 
Zeocin to enhance selection stringency and maximize LC expression. The 
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newly generated stable cell pools were labeled as HILID+LC. Intracellular 
LC:HC ratio was verified to have increased from the initial 0.3 for HILID to 
1.3 in HILID+LC pools (Fig. 6.6A). Titer for HILID+LC increased to 160 
mg/L as compared to 70 mg/L for HILID. Only a single IgG monomer peak 
was observed for purified HILID+LC product during SEC analysis (Fig. 
6.6B). Cells producing mAb with poor product quality due to low LC:HC ratio 











Figure 6.6 Increasing expression of LC to reduce aggregates and 
fragments in HILID pools. (A) Intracellular LC:HC ratio of HILID and after 
second transfection of LC only vector (HILID+LC). Data and standard 
deviation are from two measurements each of biological duplicates. (B) SEC 
chromatograms for HILID before (top) and after increasing LC expression 
(HILID+LC, bottom). Monomer peak is labelled IgG. Species appearing 
before the peak are aggregates and after the peak are fragments. 
 
6.5 Discussion 
In this study, we used a previously generated set of mAb producing 
CHO cell lines with LC:HC ratio controlled at either 3.4 (LIHID) or 0.3 
(HILID) to understand the mechanism of aggregation formed under the 
condition of excess HC. Analytical studies of product from the HILID pool 
revealed that the aggregates consists a majority of HC polypeptides and were 
partially dissociated under reducing and denaturing conditions. We 
hypothesized that incomplete mAb fragments containing excess HC, such as 
HC2 and HC2LC were inclined to aggregate due to free cysteines and exposed 
hydrophobic regions on HC. HC was secreted when expressed in the absence 
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of LC and aggregates still formed between HC polypeptides when the free 
cysteine was mutated to alanine and serine. The level of aggregate was not 
significantly reduced compared to the wild-type HC as determined by western 
blotting. In a study using COS-7 cells expressing murine IgG, HC was only 
secreted in the absence of LC when cysteines on the first HC constant region 
(CH1) were removed (Elkabetz et al. 2005). Unmodified HC and HC2 were 
still being secreted in our CHO cells likely due to its high expression level 
under a DHFR/MTX amplification system exceeding the cell’s capacity. Most 
of the aggregation prone motifs on IgG1 (class of the IgG used in this study) 
are concentrated around the hinge region of the HC (Chennamsetty et al. 
2009). This is also the region where the free cysteine due to LC absence 
resides. This could explain why we did not see increased aggregation in the 
wild-type HC as the two main aggregating mechanisms, disulfide bonding at 
free cysteines and hydrophobic interactions, likely occur at the same region. A 
previous report conducted a similar study on aggregates but only observed 
aggregate levels decreasing upon adding guanidine and not in DTT (Gomez et 
al. 2012). In that study, LC:HC peptide ratios not determined but they reported 
a greater increase in HC mRNA levels as compared to LC mRNA levels for 
two of the three cell lines studied. It is possible that at the protein level, the 
LC:HC ratio was still close to one and the incomplete products composed of 
more mAbs lacking only one LC. In our study, more HC dimers were formed.   
BiP upregulation to handle increased protein expression is part of the 
cell’s unfolded protein response (UPR) (Lee et al. 1999; Schröder and 
Kaufman 2005). Over-expressing BiP in mAb expressing CHO cell lines had 
been reported to reduce specific secretion rate and increase HC accumulation 
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(Borth et al. 2005). There are still no reports on the effect of over-expressing 
BiP on mAb aggregation. The result here provides evidence that BiP over-
expression could help reduce secretion of mAb aggregates and fragments 
caused by excess HC. BiP binds to the CH1 domain of the unfolded HC to aid 
retention within the ER and release is triggered by LC (Hendershot et al. 1987; 
Vanhove et al. 2001). The increased BiP could help with retention of the 
excess HC within the ER, reducing the secretion of fragments like the HC2 
which are more prone to aggregation. Weakening the selection marker is 
effective to increase the stable expression of a gene as only clones with more 
copies of the integrated vector and/or vectors integrated into transcriptionally 
active site in chromosomes can survive the selection (Ho et al. 2012). We 
attempted to control BiP expression by using IRES variants with different 
strengths to control the resistance gene (Koh et al. 2013). Over-expression of 
BiP using the BIZ vector with Zeocin under the control of IRESv11 did not 
prevent aggregates forming possibly due to a combination of the limitations of 
the cell and insufficient BiP to handle all the excess HC. When we tried to 
maximize BiP expression by using a weaker IRESv18 on Zeocin on BIZ, the 
transfected cells failed to survive selection. IRESv18 had been successfully 
used with Zeocin in this report for LC re-transfection. We speculate that the 
higher BiP levels, due to greater selection stringency from the weaker IRES, 
resulted in over-accumulation of unfolded IgG and eventually cell death due to 
inability to cope with the load. The protein folding machinery is a complex 
process involving multiple enzymes and engineering of the pathway would 
likely require more than one target to successfully remove more of the 
aggregates. Further work is needed to understand how over-expression of 
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chaperones lowers aggregation and if a combination of BiP with other 
chaperones would have a greater effect.     
Cell lines generated using commonly used vectors, co-transfection and 
multi-promoter single vector have varied ratios of LC:HC. Lee et al., had 
previously found that product from clones with low LC:HC mRNA levels 
were prone to aggregate and suggested super-transfection of LC into clones 
exhibiting high levels of mAb aggregation but did not perform the experiment 
(2009). In our study, we show that re-transfecting of cells with low LC:HC 
ratio with more LC to increase the ratio was an effective method to reduce 
aggregation. The excess LC expression was obtained by using a very weak 
IRESv18 to drive low levels of Zeocin expression to increase the stringency of 
selection for high producers in stably transfected pools. LC:HC ratios affect 
expression level and is a critical parameter for mAb aggregation and other 
quality parameters, such as glycosylation (van Berkel et al. 2009; Yang et al. 
2009; Ho et al. 2013; Koh et al. 2013). It is favorable to generate cell lines 
using vectors with the ability to control LC:HC at optimal ratios for both 
expression level and quality.  For cell lines forming aggregate due to excess 
HC, re-transfection of LC is the easiest and most effective way to reduce 
aggregates HC. 
Aggregates in protein therapeutics like IgG monoclonal antibodies 
(mAb) are detrimental to product safety and efficacy. We studied the 
underlying mechanism causing product aggregation in mAb producing CHO 
cell lines with excess HC. Product was highly aggregation prone within the 
cell but the majority of these aggregates were not secreted. The poorly folded 
mAb which managed to escape the cell’s quality control mechanisms and 
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enter the supernatant could be dissociated by reducing and denaturing 
conditions. Interestingly, mutation of a potential free cysteine on HC did not 
reduce the amount of aggregates observed between HC dimers. Aggregates 
could be reduced by over-expression of BiP chaperone and totally removed by 
a second transfection of LC. mAb aggregation in CHO cells with excess HC 
occurs due to a combination of limitations of the chaperone levels and LC:HC 
ratio. Further experiments using clones with varying levels of intracellular HC 
and BiP before BiP over-expression could yield even more interesting results. 
Overall, the results here would be useful for designing methods to break up 
aggregates post-purification or to rescue previously generated mAb cell lines 




 Conclusion and future work Chapter 7:
 
In this chapter, we conclude the work done in this thesis and suggest some 





The main aim of this thesis was to design a single vector system which 
expressed the LC, HC and selection marker genes required for mAb 
expression in CHO cells on a single transcript. This would reduce non-
expressing clones due to vector fragmentation and aid in controlling LC:HC 
ratio. The vector can subsequently be used to evaluate the effect of different 
LC:HC ratios had on stable mAb expression. The final vector we designed and 
optimized was the first IRES tricistronic vector for expressing high levels of 
mAb in CHO cells and a patent has been awarded based on this work (US 
patent no. 8,809,01). We first established in chapter 3 that the benefits of using 
IRES to link the genes on a single vector compared to the other traditional 
vector designs include: 1) improved proportion of isolated clones expressing 
full mAb with the tighter coupling of the genes on one transcript, 2) increased 
stringency during drug selection by linking the selection marker to an 
attenuated IRES leads to higher titers, 3) control of relative LC and HC 
amounts.  
We next evaluated another way of linking the multiple genes together 
by comparing the use of F2A elements with IRES in chapter 4. MAb produced 
using F2A had poor product quality due to incorrect protein cleavage and 
could not be used for any further mAb production or studies. The ability to use 
IRES to express multiple genes correctly without much optimization would be 
a major benefit and allow easier vector design. In the fifth chapter, the ability 
to control LC:HC ratio at consistent levels in stably transfected cells using 
IRES was used to determine the best arrangement of genes on the vector and 
to study how the ratio affects mAb production. We observed that expression 
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levels and product quality were the best at the controlled LC:HC ratio of 3.4 
when placing LC in the first cistron. There was significant product aggregation 
due to hydrophobic interactions and disulfide bonding between incompletely 
formed IgG when ratio was at 0.3. This aggregation could be reduced by 
increasing BiP chaperone expression or re-transfecting the cells with more LC. 
Using IRES to link LC and HC and placing LC as the first cistron 
directly downstream of the promoter, similar to the vector design of LIHID in 
figure 5.1, is an effective way to ensure LC is expressed in excess of HC. This 
design has shown to be beneficial for obtaining high mAb producing cells with 
low aggregation. The design was also flexible and worked with both antibiotic 
(NPT, chapter 3) and amplifiable selection markers (DHFR, chapter 4 and 5). 
The IRES tricistronic design provides a novel vector for generation of mAb 
producing CHO cells with greater efficiency and better quality. The IRES 
tricistronic vector could be part of a QbD system, helping to control LC:HC 
ratio for better mAb expression and consistent product quality. The excess LC 
could also aid in producing difficult to express mAbs. Finally, the solutions 
tested to reduce mAb aggregates that arise due to excess HC should also be 
effective for cell lines generated with other vector systems.                     
 
7.2 Future work 
In this thesis, we focused only on IgG1 mAb production in CHO cells 
as they are the best-selling biologics and most commonly used mammalian 
cell line respectively. The IRES vector design could be extended to other 
forms of immunoglobulins which are also assembled from multiple different 
proteins to determine how the relative amounts of each protein would affect 
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product expression. The study should also be replicated using other novel cell 
types like the Per.C6 human cell lines. 
The vector still holds much potential for improvements to increase the 
final mAb titer. Firstly, the hCMV promoter used can be replaced with other 
strong promoters like the murine CMV promoter and promoter from the CHO 
elongation factor. The promoter can also be replaced by synthetic promoters 
generated by screening large libraries of randomly evolved mutations or 
constructed based on bioinformatics data of known promoters to maximize 
transcription factor binding and optimize for tissue specificity (Ho and Yang 
2014). Another possible area of improvement would be to use the codon 
optimization tools discussed in section 2.5.1 to create expression cassettes 
optimized for CHO cells. While chromatin modifying elements introduced in 
section 2.5.4 can also be included, there exists possible issues of intellectual 
property rights for many of these elements. The vector could also be combined 
with targeted integration techniques discussed in 2.4.5 to increase the rate of 
integration into an active site for higher productivity. Another benefit of 
targeted integration is the minimizing of gene copies within the host cell to 
reduce the occurrence of tandem induced gene silencing. The site and gene 
copies integrated into the host cell are parameters required for authority 
approval of the cell line for biologics production, this information would be 
more easily obtained using a gene targeted cell line. The site of targeted can be 
chosen based on the CHO genome database obtained to avoid unwanted gene 
mutations.        
Despite not working well during our evaluation, F2A elements are still 
interesting for multi-gene expression studies as it allows for a 1:1 balanced 
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ratio of the genes. F2A has been successfully reported for use previously and 
could still work for our vector design with some optimization like testing 
different signal peptides and increasing the expression of furin endoprotease. 
Another area of this thesis which could be further explored is an expanded 
range of LC:HC ratios spread over smaller intervals. Either IRES from other 
sources could be tested or synthetic IRES sequences can be generated to alter 
the expression of the gene downstream of IRES and create a wider range of 
LC:HC ratios. The effect of BiP on product aggregation has yet to be reported 
and further work could be done to identify how the increased BiP aided in 
lowering the fragments and aggregates. 
As mentioned in the literature review, the growing biosimilar market is 
creating a rising demand for mAb producing cell lines. In this study, the 
materials used were influenced largely by in-house availability and 
experience. An optimized cell generation kit comprising hydrolysate- and 
protein-free chemically defined culture media with optimized feed systems 
and vectors that work with other selection systems like the glutamine 
synthetase (GS) marker could be developed. Scale-up studies of mAb 
producing cell lines in bioreactors could also be conducted to more closely 
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